Generic Name,Brand,FUKKM System/Group,MDC,NEML,Method of Purchase,Category,Indications,Prescribing Restrictions,Dosage,Adverse Reaction,Contraindications,Interactions,Precautions,is_quota
Sulphamethoxazole 200mg & Trimethoprim 40mg/5ml Suspension,,Antiinfectives for Systemic Use > Antibacterials for Systemic Use,J01EE01-961-L80-01-XXX,Yes,LP,B,Infections caused by susceptible pathogens, 6 months - 5 years: 240 mg,Mild to moderate infections: more than 2months: 8 - 12mg Trimethoprim/kg/day divided every 12hours. Serious Infections: 15-20mg Trimethoprim/kg/day divided every 6hours.,"Gastrointestinal upsets, stomatitis, glossitis and skin rashes, tinnitus, erythema multiforme, Stevens-Johnson syndrome, Lyell's syndrome, leucopenia, neutropenia, thrombocytopenia, agranulocytosis, megaloblastic anaemia, pancytopenia or purpura, hyperkalaemia. High dose might cause hyperkalemia & hyponatremia.","Marked liver parenchymal damage, blood dyscrasias, severe renal impairment, pregnancy, hypersensitivity. Use with caution in premature babies or full-term infants in the neonatal period",Increased risk of thrombocytopenia with thiazide diuretics in elderly. May require dosage reduction of warfarin and phenytoin. May displace methotrexate from plasma protein binding sites. Increased risk of venticular arrhythmias with amiodarone,"Haematological disorders, elderly, pregnancy, lactation, G6PD deficiency, folate deficiency, impaired renal function NPRA Safety Alert 1. 30.12.2021 Risk of Acute Respiratory Distress Syndrome (ARDS)",False
Enalapril 20mg Tablet,Invoril Tablets 20mg,Cardiovascular System > Agents Acting on the Renin-angiotensin System,C09AA02-253-T10-03-XX,Yes,Government Contract,B,i) Hypertension ii) Heart failure iii) Prevention of coronary ischemic events in patients with left ventricular dysfunction,None,i) Initial: 5mg once daily. Maintenance: 10-20mg once daily Max. 40mg daily in 1-2 divided doses ii) & iii) Initial: 2.5mg once daily Maintenance: 20mg in 1-2 divided doses Max. 40mg daily in 2 divided doses Dosing is individualised and according to product insert / protocol.,"Dizziness, headache, diarrhoea, fatigue, asthenia, cough, orthostatic hypotension, hyperkalaemia, angioneurotic oedema (discontinue therapy)",Angioedema induced by other angiotensin converting enzyme (ACE) inhibitors. hypersensitivity to this or any other angiotensin converting enzyme inhibitor. Pregnancy (second and third trimesters particularly),"May have additive effects with other antihypertensives, potassium supplement, potassium-sparing diuretics or potassium-containing salt substitutes. Increased lithium level","Symptomatic hypotension likely to occur in volume depleted patients eg. by diuretic therapy, dietary salt restriction, dialysis, diarrhoea or vomiting, patients with heart failure with or without associated renal insufficiency. Caution in severe heart failure, especially ischemic heart or cerebrovascular disease. Patients with obstruction in the outflow tract of the left ventricle. Renal impairment patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney. Dosage reduction and or discontinuation of the diuretic and or enalapril may be required. Serum potassium should be monitored. Not recommended during pregnancy. Lactation. Children",False
Acyclovir (Aciclovir) 5% Cream,,Dermatologicals > Antibiotics and Chemotherapeutics for Dermatological Use,D06BB03-000-G10-01-XXX,No,LP,A*,"Herpes simplex infections of the skin, including initial and recurrent labial and genital herpes simplex infections",None,Apply every 4 hours for 5 - 10 days,"Transient burning or stinging or erythema, mild drying or flaking of the skin",Hypersensitivity to acyclovir or valacyclovir,Not known,"Application to mucous membranes, pregnancy, lactation. Should not be used in the eyes",True
Dexamethasone Sodium Phosphate 0.1% Eye Drops,Maxidex,Sensory Organs > Ophthalmologicals,S01BA01-162-D20-01-XXX,No,LP,A,Acute steroid responsive inflammatory and allergic conditions,None,1 - 2 drops 4 - 6 times a day,"Red eye, steroid glaucoma, steroid cataract, thinning of the cornea and sclera. Burning, dry eyes, photophobia, glaucoma, elevated intraocular pressure, optic nerve damage, cataract","Viral, fungal, tuberculosis and other infections of the eye. Hypersensitivity to dexamethasone",Not known,"- Discontinue use if fungal infection occurs. - Predisposed patients eg, diabetes & patients treated w/ CYP3A4 inhibitors. - Cushing's syndrome &/or adrenal suppression. - Patients w/ persistent corneal ulceration. - Diseases causing thinning of the cornea or sclera, perforation. - Avoid contact w/ soft contact lenses. • Remove contact lens prior to application & wait 15 min before reinsertion. - Avoid abrupt discontinuation. - Prolonged use. - Concomitant use w/ topical NSAIDs. - May affect ability to drive & use machines. - Not to be used in children.",True
Dextrose 10% Injection,-,Blood and Blood Forming Organs > Blood Substitutes and Perfusion Solutions,B05BA03000P6002XX,Yes,APPL,B,For parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patient,None,According to the needs of the patient,"Thrombophlebitis, rebound hypoglycaemia, hypokalaemia, pulmonary embolism, right atrial thrombosis, extravasation","Do not use concentrated solutions of dextrose in patients with anuria, diabetic coma, hyperglycaemia, intracranial or intraspinal haemorrhage, delirium tremens in dehydrated patients and glucose-galactose malabsorption syndrome. Do not administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur",Not known,"Diabetes mellitus or carbohydrate intolerance and hyperglycaemia may accentuate neurologic damage for an ischaemic insult. Patients at risk for cerebral ischaemia, acute stroke, impending cardiac arrest or severe hypotension unless hypoglycaemia is suggested or until glucose is determined",False
Diazepam 5mg/ml Injection,Valium,Nervous System > Psycholeptics,N05BA01-000-P30-01-XXX,Yes,APPL,B,i) Status epilepticus ii) Skeletal muscle spasm iii) Anxiety disorders,None,"i) ADULT: initial dose 10-20mg IV, in the following hours 20mg IM or by intravenous drip infusion as necessary. CHILD 2 to 5 years of age: slow IV 0.2 - 0.5mg every two to five minutes up to a maximum of 5mg. If necessary, dose can be repeated in two to four hours. CHILD 5 years and older: slow IV 1mg every two to five minutes up to a maximum of 10mg. If necessary, dose can be repeated in two to four hours. ii) ADULT: 10mg once or twice IV. CHILD 2 to 5 years of age: IM or IV, 1 to 2mg the dosage being repeated every three to four hours as needed. CHILD 5 years and older: IM or IV, 5 to 10mg, the dosage being repeated every three to four hours as needed. iii) ADULT: 10-20mg three times daily IM or IV until acute symptoms subside.","Drowsiness, dizziness, vertigo, hallucinations, blurred vision, confusion, muscle weakness, fatigue, incontinence or urinary retention, constipation, rashes, changes in libido, leukopenia and gastrointestinal, hypotension, ataxia, respiratory depression, sedation, depression, headache, nausea, tremor, withdrawal syndrome, neutropenia, hepatotoxicity, pancytopenia, thrombocytopenia, blood dyscrasias, bradycardia, dependence/abuse. Paradoxical reactions in children and elderly.","Respiratory depression, acute pulmonary insufficiency, severe hepatic impairment, acute narrow angle glaucoma, myasthenia gravis, hypersensitivity to diazepam products, children less than 2 years old due to benzyl alcohol content in formulation, alcohol intoxication, central nervous system depression","Central nervous system depressants, barbiturates, alcohol, isoniazid, rifampicin, phenytoin, ritonavir, omeprazole, cimetidine, theophylline, digoxin, erythromycin, itraconazole","Respiratory disease, history of drug or alcohol abuse, drug dependence, pregnancy, breast feeding, renal and hepatic impairment and avoid operating vehicles or machinery",False
Adenosine 3 mg/ml Injection,Adenocor,Cardiovascular System > Cardiac Therapy,C01EB10-000-P30-01-XXX,Yes,LP,B,Rapid conversion of paroxysmal supraventricular tachycardia to sinus rhythm,None,"ADULT: Initially: 3 mg given as a rapid IV bolus (over 2 seconds). Second dose: If the first dose does not result in elimination of the supraventricular tachycardia with in 1 or 2 minutes, 6 mg should be given also as a rapid IV bolus. Third dose: If the second dose does not result in elimination of the supraventicular tachycardia with in 1-2 minutes, 12 mg should be given also as a rapid IV bolus","Facial flush, dyspnoea, a feeling of thorasic constriction, nausea, lightheadedness, feeling of discomfort, sweating, palpitations, hyperventilation, head pressure, apprehension, blurred vision, burning sensation, bradycardia, chest pains, headache, dizziness, heaviness in arms, arm, back and neck pains; metallic taste","Bradycardia, bronchoconstrictive or bronchospastic lung disease (eg. asthma). Hypersensitivity to adenosine, second-degree or third-degree AV block (unless pacemaker fitted), sinus node disease (eg. sick sinus syndrome)",Actions may be potentiated by dipyridamole and carbamazepine. Theophylline & caffeine inhibit its action,"Avoid concomitant use of dipyridamole and methylxanthines (eg: caffeine, theophylline). Cardiac arrest, heart block, heart transplant patients, hypertension, hypotension, myocardial infarction. Proarrhythmic events; new rhythms, particularly at time of conversion and unstable angina",False
Diazepam 5mg Rectal Solution,,Nervous System > Psycholeptics,N05BA01-000-G20-01-XXX,Yes,LP,B,i) Status epilepticus ii) Skeletal muscle spasm,None,"Status epilepticus - ADULT: 0.5 mg/kg repeated after 12 hours if necessary. CHILD (febrile convulsions, prolonged or recurrent): 0.5 mg/kg (maximum 10 mg), repeated if necessary. Not recommended for children below 2 years","Drowsiness, dizziness, vertigo, hallucinations, blurred vision, confusion, muscle weakness, fatigue, incontinence or urinary retention, constipation, rashes, changes in libido, leukopenia and gastrointestinal disturbances. Paradoxical reactions in children and elderly","Respiratory depression, acute pulmonary insufficiency, severe hepatic impairment, acute narrow angle glaucoma, myasthenia gravis","Central nervous system depressants, alcohol, barbiturates, antibacterials, antivirals, omeprazole","Respiratory disease, history of drug or alcohol abuse, drug dependence, pregnancy, breast feeding, renal and hepatic impairment and avoid operating vehicles or machinery",False
Diclofenac 50mg Tablet,Voltaren,Musculo-skeletal System > Antiinflammatory and Antirheumatic Products,M01AB05-520-T10-01-XXX,No,LP,B,Pain and inflammation in rheumatic disease and of non-rheumatic origin,None,ADULTS: Initial dose of 150 mg daily. Mild or long term: 75 - 150 mg daily in 2 to 3 divided doses after food. Maximum: 200mg/day. CHILD more than 6 months : 1 - 3 mg/kg body weight daily in divided doses. Maximum: 3mg/kg/day (150mg/day).,"Epigastric pain, GI disturbances, slight dizziness, hypersensitivity, oedema, nephrotoxicity, abnormal liver function, headache, neurological, haematological and dermatological side effects. NPRA Safety Alert 1. 26 Aug 2019 Risk of: (i) Anastomotic leakage and (ii) Kounis syndrome 2. 11 Apr 2023 Off-Label Use of Diclofenac Suppositories to Treat Fever in Children: Potential Risk of Acute Necrotising Encephalopathy of Childhood (ANEC)","Patients with: - history of hypersensitivity to diclofenac or aspirin/other NSAIDs. - Peptic or intestinal ulcer. - History of asthma, urticaria or acute rhinitis precipitated by aspirin or other NSAIDs. - Recent rectal bleeding.","- Increases plasma concentration of warfarin, lithium, & methotrexate. - May reduce effects of diuretics & beta blockers. - May alter plasma concentration of sulfonylureas. - Caution with concomitant use of diuretics and antihypertensives (eg beta-blockers, ACEI ), methotrexate, other NSAIDs and corticosteroids, SSRIs. - Monitoring recommended for patients receiving anticoagulants, antiplatelets agents as well as blood glucose level if used concomitantly with antidiabetics. - Digoxin, ciclosporin, quinolones","- Patient with history of gastrointestinal bleeding or peptic ulceration, coagulopathy, current or risk factors for CV disease (e.g. CHF, ischaemic heart disease, CVA, hypertension, oedema, hyperlipidaemia, diabetes mellitus), dehydration, hypovolemia, asthma, rhinitis, COPD, respiratory tract infections, SLE, mixed connective tissue disorders, porphyria, ocular disease including infections (ophthalmic). - Hepatic and renal impairment. - Children. - Pregnancy (1st-2nd trimester) and lactation. - Smokers. - Avoid prolonged use for migraine (powder for oral solution).",False
Digoxin 0.25mg Tablet,Lanoxin,Cardiovascular System > Cardiac Therapy,C01AA05-000-T10-01-XX,Yes,APPL,B,"Heart failure , with atrial fibrillation, supraventricular arrhythmias (particularly, atrial fibrillation)",None,"Rapid digitalisation: 0.75 -1.5 mg in divided doses over 24 hours; less urgent digitalisation, 250 mcg-500 mcg daily (higher dose may be divided). Maintenance : 62.5mg -500 mcg daily (higher dose may be divided) according to renal function and , in atrial fibrillation, on heart rate response; usual range, 125-250 mcg daily (lower dose may be appropriate in elderly)","Nausea, vomiting, anorexia, diarrhoea, abdominal pains, salivation, sweating; headache, facial pain, malaise, fatigue, drowsiness, depression, disorientation, mental confusion, delirium, hallucination, visual disturbance.Hypokalaemia. Ventricular premature contractions, atrial or ventricular arrhythmias and conduction defects","Digoxin is contraindicated in intermittent complete heart block or second degree atrioventcular block,especially if there is a history of Stokes-Adams attacks. Contraindicated in arrhythmias caused by cardiac glycoside intoxication,supraventricular arrhythmias as in the Wolff-Parkinson-White syndrome,ventriculartachycardia,hypertrophic cardiomyopathy, and hypersensitivity to digoxin.","Plasma concentration increased by quinidine, verapamil, nifedipine, amiodarone. Hypokalaemia may be associated with diuretics, lithium, carbenoxolone, corticosteroids. Antacids, neomycin may reduce serum level of digoxin","Acute myocardial infarction, acute myocarditis, amyloid cardiomyopathy, AV block. Chronic constrictive pericarditis, electrolyte imbalance (eg. hypokalaemia, hypocalcaemia or hypercalcaemia, hypomagnesaemia), hypothyroidism, hypoxia, idiopathic hypertrophic subaortic stenosis. Renal disease, severe bradycardia, severe heart failure and pulmonary disease, ventricular tachycardia and Wolff-Parkinson-White syndrome",False
Adrenaline Acid Tartrate (Epinephrine) 1 mg/ml Injection,-,Cardiovascular System > Cardiac Therapy,C01CA24-123-P30-01-XXX,Yes,APPL,B,Cardiopulmonary resuscitation,None,1 mg by intravenous injection repeated every 3-5 minutes according to response,"Hypertension, arrhythmias, nausea, vomiting, headache, shortness of breath, sneezing","Cardiac dilatation, coronary insufficiency. Within 2 weeks of MAOI use.Organic brain damage, narrow-angle glaucoma. Shock. Concurrent use with local anesthetics for injection of certain areas (eg; fingers, toes, ears); increased risk of vasoconstriction and sloughing of tissue. oncurrent use with cyclopropane or halogenated hydrocarbon anaesthetics; may produce fatal ventricular arrhythmias. Labor; may delay the second stage","Beta-blocking,alpha-adrenergic blockers agents,antihistamines,tricyclic antidepressants carvedilol, chlorpromazine, halothane, moclobemide, rocuronium, selegiline, timolol,methyldopa, diuretics, oxytoxic drugs","Elderly patients, patients with; CV disease, pulmonary oedema, hypertension, hyperthyroidism, diabetes, psychoneurotic illness, asthma, prefibrillatory rhythm, or anesthetic cardiac acidents. Bronchial asthma/emphysema,cerebrovascular hemorrhage, pregnancy, lactation, children",False
Acriflavine 0.1% Lotion,-,Dermatologicals > Antiseptics and Disinfectants,D08AA03-000-L60-01-XXX,Yes,APPL,C+,"Infected skin, lesions, cuts, abrasions, wounds and burns.",None,Apply undiluted three times daily to the affected part .,Hypersensitivity to acriflavine compound,Hypersensitivity to acriflavine compound.,Not known,"Prolonged application, may stain skin, hair & fabric.",False
Diltiazem HCl 30 mg Tablet,,Cardiovascular System > Calcium Channel Blockers,C08DB01-110-T10-01-XX,Yes,APPL,B,i) Treatment of angina ii) Hypertension,None,"Initially 30mg tds, may increase to 60mg tds (elderly initially twice daily; increased if necessary to 360 mg daily.","Headache, dizziness, peripheral oedema, gingival hyperplasia, AV block, bradycardia","Acute myocardial infarction with pulmonary congestion, atrial fibrillation or flutter (IV dose forms): i) Accessory bypass tract (Wolff-Parkinson-White, Lown-Ganong-Levine) ii) Short PR syndromes. Hypersensitivity to this or other calcium channel blocker, patients with sick sinus syndrome , 2nd- or 3rd-degree AV block; pregnancy, lactation","Aspirin, beta-adrenergic blockers, carbamazepine, cimetidine, cisapride, cyclosporin, digitoxin, digoxin, enflurane, lithium, lovastatin, methylprednisolone, midazolam, nifedipine, oral anticoagulants, phenytoin, quinidine, rifampin, saquinavir, simvastatin, clonidine, CYP3A4 inducer","AV block (first degree), combination therapy with beta-blockers (with left ventricular dysfunction), congestive heart failure, gastrointestinal hypermotility (extended release dose forms), gastrointestinal obstruction (extended release dose forms), hypotension, impaired liver function (reduced metabolism, enhanced response). Impaired renal function. Paroxysmal supraventricular tachycardia conversion, persistent dermatologic reactions induced by calcium antagonists have progressed to erythema multiforme or exfoliative dermatitis",False
Albendazole 200mg Tablet,Zentel,"Antiparasitic Products, Insecticides and Repellents > Anthelmintics",P02CA03-000-T10-01-XXX,Yes,APPL,C+,i) Single or mixed infestations of intestinal parasites ii) Strongyloides infection,C+,i)Child 12-24months: 200mg as a single dose ii) Adult & Child above 2 years: 400mg as a single dose for 3 consecutive days; Child 12 - 24months: 200mg as a single dose for 3 consecutive days,"Gastrointestinal discomfort, dizziness, headache, erythema multiforme, Stevens-Johnson syndrome, agranulocytosis, aplastic anemia, leukopenia, pancytopenia, thrombocytopenia, hepatotoxicity","Patients with hypersensitivity to albendazole or to the benzimidazole drug class, pregnancy (avoid pregnancy for at least one month following therapy)",Concurrent use with dexamethasone may result in an increased risk of albendazole adverse effects.,"Discontinue therapy if liver function test elevations are significant, retinal lesions, cerebral hypertensive episodes, pregnancy, hepatic disease, retinal lesions",False
Diosmin 450mg and Hesperidin 50mg Tablet,,Cardiovascular System > Vasoprotectives,C05CA533-931-T10-01-XX,No,LP,B,i) Haemorrhoids ii) Chronic venous insufficiency,None,"i) Acute attack: 6 tablets daily for the first 4 days, then 4 tablets daily in 2 divided doses for 3 days and 2 tablets thereafter. Chronic: 2 tablets daily ii) 2 tab daily with meals","Minor gastrointestinal disturbances, neurovegetative disorders",Hypersensitivity to any component of preparation,Not known,Lactation,False
Diphenoxylate HCl 2.5mg with Atropine Sulphate 0.025mg Tablet,,"Alimentary Tract and Metabolism > Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents",A07DA01-922-T10-01-XXX,Yes,APPL,B,Symptomatic treatment of acute and chronic diarrhoea,None,"ADULT: 2 tablets 4 times daily, later reduced when diarrhoea is controlled. Maintenance: 2 tablets once daily as needed (Max: 8 tablets daily)","Euphoria, paraesthesia, central nervous system effects, anoneurotic oedema and other allergic reactions, toxic megacolon, paralytic ileus, gastrointestinal disturbance. Atropine effects: Hyperthermia, tachycardia, urinary retention, flushing, dry skin and mucous membranes. At therapeutic dose- dryness of the mouth, difficulty in swallowing, thirst, reduce bronchial secretion, mydriasis with cycloplegia","Hypersensitivity to diphenoxylate hydrochloride or atropine, jaundice, acute diarrhoeal conditions like antibiotic associated diarrhoea, pseudomembranous enterocolitis, acute ulcerative colitis and infective diarrhoeas. Paralytic ileus and a ganglionosis. Not recommended for use in children","Barbiturates, tranquilizers, alcohol, MAOIs","Advanced hepatorenal disease, abnormal liver function, Down Syndrome",False
Alfacalcidol 1mcg Capsule,one-alpha,Alimentary Tract and Metabolism > Vitamins,A11CC03-000-C10-02-XXX,No,LP,A/KK,i) Chronic kidney disease mineral bone disorder ii) Osteoporosis iii) Hypoparathyroidism and pseudohypoparathyroidism iv) Rickets and osteomalacia,A/KK; A/KK,Initial dose ADULT and CHILD above 20kg body weight : 1 mcg daily; CHILD under 20kg body weight : 0.05 mcg/kg/day. Maintenance dose : 0.25 mcg to 2 mcg daily Dosing is individualised based on serum calcium level and according to product insert/protocol,"Hypercalcaemia-stop immediately until serum calcium levels return to normal (in about one week) and then resumed at half the previous dose. Anorexia, nausea, vomiting, diarrhoea, lassitude, polyuria, sweating, headache, thirst, vertigo, pruritus, rash, urticaria,hypercalciuria and ectopic calcification. In case of renal impairment, hyperphosphataemia. In hypercalcaemic dialysis patients, possibility of calcium influx from the dialysate should be considered","Hypercalcaemia, metastatic calcification, hyperphosphataemia (except when occurring with hypoparathyroidism), hypermagnesaemia, vitamin D overdose,known hypersensitivity to alfacalcidol, vitamin D or any of its analogues and derivatives.","Thiazide diuretics, calcium, phosphates, carbamazepine, phenobarbitone,","Pregnancy, lactation, renal impairment, infants, elderly. Serum levels of calcium should be monitor regularly (weekly to monthly, depending in the progress of the patient) especially in children, renal impairment and patients receiving high doses. Caution in hypercalciuria esp in those with history of renal calculi and patients being treated with cardioactive glycosides or digitalis.",True
Diphtheria and Tetanus Vaccine Injection,Double antigen,Antiinfectives for Systemic Use > Vaccines,J07AM51963P3001XX,Yes,LP,C+,Immunisation against diphtheria and tetanus.,None,0.5ml by deep SC or IM injection. Dosing is according to Immunisation Schedule under NIP.,"Pain, erythema or nodule at the injection site, fever, malaise, irritability,",Hypersensitivity to any component of the vaccine,Chloramphenicol may inhibit immunologic response of tetanus toxoid,Thrombocytopenia or other coagulation disorders. Adrenaline injection must be immediately available should acute anaphylactic reaction occur due to any component of the vaccine.,False
Calamine Lotion,-,"Dermatologicals > Antipruritics, incl. Antihistamines, Anesthetics, etc.",D04AX00000L8001XX,Yes,APPL,C+,"Soothes and relieves nappy rashes, prickly heat, minor skin irritations, insect bites and sunburn, Pruritic skin conditions.",None,"Apply to the skin as required and allow to dry, 1-3 times daily",Rash or irritation,Not known.,Not known,Avoid contact with eyes and other mucous membranes. Not to be used on open wounds or burns.,False
Morphine Sulphate 10mg/ml Injection,-,Nervous System > Analgesics,N02AA01-183-P30-01-XXX,Yes,APPL,B,i) For moderate to severe pain especially that associated with neoplastic disease ii) As an analgesic adjunct in general anaesthesia., 1 - 5 years: 2.5 - 5 mg ,"ADULT: 5 to 20 mg every 4 hours, intravenously (IV or IM), 2.5 to 15mg should be given by slow injection. CHILD: - Adjusted according to body weight, 0.1 – 0.2 mg /kg every 4 hours. No dose should exceed 15 mg. - Analgesic Indication (i) subcutaneous, 100 mcg to 200 mcg (0.1 to 0.2 mg) per kg of body weight every four hours as needed, not to exceed 15mg per dose. Indication (ii) Intravenous, 50 to 100 mcg (0.05 mg to 0.1 mg) per kg of body weight, administered very slowly.","Constipation, nausea, vomiting, drowsiness, dry mouth, psychomimetic effect (dysphoria, hallucination, nightmare), urinary retention, respiratory depression (rare). Convulsions; dry mouth, headache, vertigo; palpitations; hypothermia; pruritus, urticaria; tachycardia, bradycardia; blurred vision; miosis; dependency","Acute bronchial asthma, respiratory insufficiency, severe CNS depression, GI obstruction, biliary colic (these conditions are not contra-indications in patients who are terminally ill), hypersensitivity to morphine, MAOIs","MAOIs: hypotension and exaggeration of CNS and respiratory depressant effects. Naltrexone: precipitation of opioid withdrawal symptoms. Cimetidine : morphine toxicity (CNS depression, respiratory depression)","Children less then 1 year, neonates, premature infants, elderly, chronic obstructive airway disease, pregnancy, lactation, renal and hepatic impairment, hypothyroidism",False
Doxycycline 100mg Capsule,,Antiinfectives for Systemic Use > Antibacterials for Systemic Use,J01AA02-000-C10-01-XXX,Yes,APPL,B,Prophylaxis and treatment for infections due to susceptible organisms.,None,Prophylaxis 100-200mg daily or weekly Treatment 100-300mg daily Dosing is individualised based on type of infections and according to product insert/protocol,"GI distress, anorexia, maculopapular and erythematous rash, tooth discolouration in children","Hypersensitivity to tetracyclines/doxycycline, porphyria, pregnancy, lactation, children less than 12 years","Anticoagulants, penicillin, antacids, ferum, acitretin, isotretinoin, methotrexate","Lactation, myasthenia gravis, hepatic or renal impairment",False
Benzyl Benzoate 25 % Emulsion (Adult),-,"Antiparasitic Products, Insecticides and Repellents > Antiprotozoals",P03AX01000L2002XX,Yes,APPL,C+,Scabies for adult and children more than 12 years old.,None,"After bath, apply over the whole body, neck down and leave on for 24 hours then wash off. Reapply for another 24 hours, the first repeat application should be within 5 days of the initial application, a third application may be required in some cases.","May be irritant to the skin of some patients, burning sensation especially on genitalia and excoriations occasionally rashes, stinging and contact dermatitis, local irritation, particularly in children, splash contact with benzyl benzoate may produce irritation to the eyes and mucous membranes",Hypersensitivity to benzyl benzoate,Not known,"Contact with mucous membranes, head, face, broken or inflammed skin, avoid contact with eyes. Not recommended for children, lactation (withhold during treatment)",False
Ticlopidine HCl 250 mg Tablet,,Blood and Blood Forming Organs > Antithrombotic Agents,B01AC05110T1001XX,No,Government Contract,A/KK,i) Prevention of thrombotic stroke for patients who are sensitive /intolerant to Acetysalicylic Acid ii) Maintenance of coronary bypass surgery or angioplasty iii) Maintenance of patency of access in patients on chronic haemodialysis,None,250 mg twice daily taken with food,"Minor gastrointestinal disorders. Rarely cutaneous allergic manifestations, thrombocytopenia, cholestatic icterus and or rise in transaminases. Neutropenia and thrombocytopenia (monitor full blood count weekly initially)","Hypersensitivity to ticlopidine or its components, patients with active bleeding disorders. Neutropenia or thrombocytopenia, severe liver impairment",Any drugs likely to produce coagulation,"Predisposition to bleeding, including gastric or duodenal ulcers. Underlying haematologic disorders. Concomitant oral anticoagulant therapy or nonsteroidal antiinflammatory agents (including aspirin). Liver disease, patients undergoing lumbar puncture or surgical procedure. Ticlopidine should be discontinued if the absolute neutrophil count falls below 1200/mm3 or if the platelet count falls below 80,000/mm3. If possible, ticlopidine should be discontinued 10 to 14 days prior to surgery",True
Efavirenz 100mg Capsule,Stocrin,Antiinfectives for Systemic Use > Antivirals for Systemic Use,J05AG03-000-C10-02-XXX,Yes,LP,A*,Combination therapy for HIV infections with a protease inhibitor and or Nucleoside Reverse Transcriptase Inhibitors (NRTIs),None,"ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17 years, more than 40 kg: 600 mg once daily, 32.5 - less than 40 kg: 400 mg once daily, 25 - less than 32.5 kg: 350 mg once daily, 20 - less than 25 kg: 300 mg once daily, 15 - less than 20 kg: 250 mg once daily, 13 - less than 15 kg: 200 mg once daily. No studies in children less than 3 years or less than 13 kg. Formulation unsuitable for children less than 40 kg","Dizziness, nausea, headache, fatigue, rash including erythema multiforme & Stevens-Johnson Syndrome, allergic reaction, abnormal coordination, ataxia, confusion, stupor, vertigo, vomiting, diarrhoea, hepatitis, impaired concentration, insomnia, anxiety, abnormal dreams, somnolence, depression, abnormal thinking, agitation, amnesia, delirium, emotional liability, euphoria, hallucination and psychosis Direktif NPRA.600-1/9/13 (14) - Encephalopathy","Hypersensitivity, concomitant terfenadine, cisapride, midazolam, triazolam ergot derivatives and voriconazole (adjusted dose for both voriconazole and efavirenz are needed)","Amprenavir, indinavir, ritonavir, saquinavir, rifamycins, clarithromycin, oral contraceptives, anticonvulsants, methadone, St. John's wort, sertraline, cetirizine, lorazepam. Other compounds that are substrates of CYP3A4 may have decreased plasma concentration when coadministered with efavirenz","- Must not be used as a single agent to treat HIV or added on as a sole agent to a failing regimen. - Monitor psychiatric adverse experiences, nervous system symptoms and cholesterol. - Caution use in patient with liver disease, history of seizures, known or suspected history of hepatitis B or C infections and in patients with other medications associated with liver toxicity. - May affect ability to drive or operate machinery. - Pregnancy should be avoided in women receiving efavirenz. NPRA Safety Alert (29 Jan 2021) - Risk of late onset neurotoxicity",True
Alprazolam 0.25mg Tablet,Xanax,Nervous System > Psycholeptics,N05BA12-000-T10-01-XXX,No,LP,A/KK,Anxiety disorders,None,"0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.25 mg 2-3 times daily), increased if necessary to a total dose of 3 mg/day. Not recommended for children","Drowsiness, blurred vision, coordination disorder, gastrointestinal disturbance, agitation, lightheadedness, dry mouth, depression, headache, confusion, hypotension, syncope, tachycardia, seizures, respiratory depression, coma, constipation, diarrhoea, nausea, vomiting, insomnia, nasal congestion, rigidity, increased salivation, dermatitis, sedation","Hypersensitivity to benzodiazepines, acute narrow angle glaucoma, concomitant use of ketoconazole/ itraconazole, CNS depression","Ketoconazole, fluconazole, itraconazole, contraceptives; increased alprazolam serum concentrations and potential alprazolam toxicity. Omeprazole, erythromycin, clarithromycin, cimetidine; benzodiazepine toxicity. Sertraline; increased risk of psychomotor impairment and sedation. Fluoxetine; increased risk of alprazolam toxicity. Fluvoxamine; increased risk of CNS side effects. Ritonavir; increased plasma concentrations of alprazolam and enhanced alprazolam effects. Antihistamine/decongestant combinations, antipsychotic, ethanol, mirtazapine, phenothiazines, venlafaxine;increased risk of CNS depression, psychomotor impairment. Sedative/hypnotics, tricyclic antidepressants; CNS depression. Potentiates action of alcohol. Reduced concentration by 50% with cigarette smoking.","Avoid operating vehicles or machinery, abuse prone patient, pregnancy and breastfeeding, renal or hepatic dysfunction, elderly patients, obesity, untreated open angle glaucoma, impaired pulmonary function. Prolonged use can lead to dependence",True
Erythromycin Ethylsuccinate 200 mg/5 ml Suspension,Erythrocin,Antiinfectives for Systemic Use > Antibacterials for Systemic Use,J01FA01-238-F21-01-XXX,Yes,APPL,B,Treatment of susceptible bacterial infections,None,"Child: 30-50 mg/kg daily, increased to twice the usual dose in severe cases. 2-8 yr: 1 g daily in divided doses; <2 yr: 500 mg daily in divided doses.","Rash, urticaria; nausea, vomiting, GI discomfort; ototoxicity; central neurotoxicity; agranulocytosis; arrhythmias; pancreatitis. Potentially Fatal: Hepatotoxicity, cholestatic jaundice; raised serum transaminases; eosinophilia.",Hypersensitivity; porphyria; hepatic impairment; pregnancy.,"May antagonise therapeutic effects lincomycin and clindamycin. Concurrent usage may lead to increased absorption of alcohol. Potentially Fatal: May potentiate actions of neuromuscular blockers, oral anticoagulants, ciclosporin, theophylline. Terfenadine, astemizole, cisapride toxicity increased.","Hepatic& renal impairment, myasthenia gravis",False
Ethambutol HCl 200 mg Tablet,,Antiinfectives for Systemic Use > Antimycobacterials,J04AK02-110-T10-01-XXX,Yes,LP,B,Tuberculosis,None,Adult: 15-25mg/kg daily (max 1200mg) or 50mg/kg biweekly (max2000mg). Children: 15-25mg/kg daily or 50 mg/kg twice weekly.,"Generally well tolerated but may provoke reversible retrobulbar neuritis with a reduction of visual acuity, central scotoma& green-red colour blindness, allergic rashes, GI disturbances, jaundice, peripheral neuritis, confusion, hallucinations, joint pain, fever, malaise, headache, dizziness, anorexia& abdominal pain NPRA Safety Alert 1. 9 Jan 2025 Risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)",Optic neuritis; history of previous adverse effects with ethambutol. Lactation.,"Aluminium hydroxide, ethionamide",Reduced visual acuity. Reduced dosage in impaired renal function. May precipitate attack of gout. Ocular examination is recommended,False
Ethyl Chloride 100ml Spray,-,Nervous System > Anesthetics,N01BX01000A4001XX,Yes,APPL,C,"For minor surgical procedures including lancing boils, incision and drainage of small abscesses, pain due to athletic injuries and pain due to injection administration",None,Spray to affected area at a distance of about 30cm until a fine white film is produced,"Transient hypertension, narcosis, vomiting and coma. Thawing of frozen tissue after surgery may be painful. Chemical frostbite may occur following prolonged spraying onto the skin. Nephrotoxicity or hepatotoxicity (long-term exposure)",Hypersensitivity to ethyl chloride products and vascular impairment of the extremities. Porphyria. Application on broken skin or mucous membranes,"Cisatracurium, St John's Wort","Ethyl chloride is highly flammable and mixtures of the gas with 5% to 15% of air are explosive; never use it in the presence of an open flame or near electric cautery equipment. Caution should be taken to avoid frostbite; when used for cryotherapy, protect adjacent skin with petrolatum. Inhalation of ETHYL CHLORIDE can produce narcosis or even fatal coma with respiratory or cardiac arrest. Cover eyes, nose and mouth if spraying near the face.To protect against tissue sloughing, cover the skin adjacent to the area being treated with petrolatum. Avoid spilling the liqd on the skin. Freezing may also distort the histological structure of biopsy specimens. Highly flammable. Avoid inhalation when used as local anaesthesia",False
Pizotifen 0.5 mg Tablet,Sandomigran,Nervous System > Analgesics,N02CX01253T1001XX,No,LP,B,Prophylactic treatment of vascular headache,None,"Starting with 0.5mg daily, the dosage should be progressively increased. The average maintenance dosage is 1.5mg daily in divided doses or as a single dose at night. Max dose: 4.5 mg/day and 3 mg/dose. Child: >2 yr: Up to 1.5 mg daily in divided doses. Max dose: 1 mg/dose.","Sedation, dizziness, dry mouth and constipation. Increased appetite, sedation, nausea, fatigue. Rarely, hypersensitivity reactions, face oedema, rash, central nervous system stimulation, hallucinations, seizures, depression, drowsiness, headache, palpitation, arrhythmias, gastrointestinal disturbance, palpitations, blood disorders, convulsions, sweating, myalgia, paraesthesias, extrapyramidal effects, sleep disturbances, confusion, tinnitus, tremor, hypotension, hair loss",Hypersensitivity to the drug. Children less than 2 years. Postural giddiness,"Central effects of sedatives, hypnotics, antihistamines, including certain common cold preparations and alcohol may be enhanced. Antagonised hypotensive effect of adrenergic neuron blockers. May mask warning signs of damage caused by ototoxic drugs eg. aminoglycosides","Narrow-angle glaucoma, obesity, urinary retention. May affect ability to drive and operate machinery. Pregnancy, breast feeding. Dosage reduction may be necessary in renal impairment, prostatic hyperplasia, pyloroduodenal obstruction, epilepsy, hepatic impairment, elderly, young children. Pregnancy, lactation",False
Betamethasone 17-Valerate 0.01-0.05% Ointment,Betnovate,"Dermatologicals > Corticosteroids, Dermatological Preparations",D07AC01-256-G50-01-XXX,Yes,LP,B,"Eczema, prurigo nodularis, limited psoriasis in appropriate in sites",None,Apply sparingly to affected area 2 - 3 times daily then reduced to once daily when improvement occurs,"Local skin atrophy, striae, systemic hypercorticism, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, prioral and allergic contact dermatitis","Viral diseases, bacteria and fungal infection, acne, rosacea and perioral dermatitis. Hypersensitivity to betamethasone products",Not known,"Extensive or prolonged use, pregnancy, infant and children less than 4 year. Avoid contact with eyes. Use in patients 12 years of age younger",False
Simvastatin 10 mg Tablet,"Zocor, Simvor",Cardiovascular System > Lipid Modifying Agents,C10AA01000T1001XX,Yes,Government Contract,B,i) Hypercholesterolaemia ii) Prevention of cardiovascular disease,None,i) & ii) 10 - 40 mg once daily. Maximum: 80 mg daily,"Abdominal pain, flatulence, constipation, asthenia and headache, rarely hepatitis, hypersensitivity syndrome, upper respiratory infection. Cognitive impairment (e.g. memory loss, forgetfulness, amnesia, memory impairment, confusion), increase in HbA1c and fasting blood glucose. NPRA Safety Alert 1. 27 May 2025 Myasthenia Gravis / Ocular Myasthenia","Hypersensitivity to simvastatin products, active liver disease, pregnancy and lactation",May cause slight elevation of serum digoxin. Cholestyramine and colestipol increase bioavailability of simvastatin. Increased concentrations with mibefradil NPRA Safety Alert 1. 19 Feb 2024 Interaction with Ticagrelor Leading to Increased Risk of Rhabdomyolysis,"Heavy alcohol use, history of liver disease. Discontinue therapy if serum transaminase levels rise to 3 times upper limit of normal and are persistent. May cause myopathy and renal failure due to rhabdomyolysis. Concomitant administration of fibrates, nicotinic acid, immunosuppressives including ciclosporin, macrolide antibiotics (erythromycin, clarithromycin), itraconazole and ketoconazole or nefazodone may increase the risk of myopathy NPRA Safety Alert 1. 18 Jul 2023 Risk of Inducing or Aggravating Myasthenia Gravis 2. 27 May 2025 Myasthenia Gravis / Ocular Myasthenia",False
Felodipine 10mg Extended Release Tablet,Plendil ER Tabs 10mg,Cardiovascular System > Calcium Channel Blockers,C08CA02-000-T10-02-XX,No,APPL,A/KK,Hypertension,None,"Initiate at 5 mg once daily. Usual dose, 5 - 10 mg once daily in the morning","Peripheral oedema, asthenia, headache, dizziness, fatigue, tachycardia, palpitation, flushing, rash, nausea, dyspepsia, constipation, upper resp infection, ankle swelling, gingival hyperplasia.","Unstable angina pectoris, cardiogenic shock, aortic stenosis","Plasma levels increased by CYP3A4 inhibitors (e.g. cimetidine, azole antifungals, erythromycin, ritonavir) and reduced CYP3A4 by inducers (e.g. phenytoin, carbamazepine, barbiturates). May increase concentration of tacrolimus.","Patients with heart failure, hypertrophic cardiomyopathy with outflow tract obstruction. Hepatic impairment. Elderly. Pregnancy and lactation.",True
Prazosin HCl 5 mg Tablet,,Cardiovascular System > Antihypertensives,C02CA01110T1003XX,No,APPL,B,Hypertension,None,"Initially 0.5 mg 2 - 3 times daily, the initial dose on retiring to bed at night; increased to 1 mg 2 - 3 times daily after 3 - 7 days: further increased if necessary to maximum 20 mg daily","Dizziness, orthostatic hypotension, oedema, palpitations, urinary incontinence, dyspnoea, priapism, headache, lack of energy, nausea",Hypersensitivity to prazosin products or other quinazolines,Additive hypotensive effect with diuretics or other antihypertensives,"Dizziness, lightheadedness, orthostatic hypotension, syncope, fainting and sudden loss of consciousness due to first-dose effect",False
Propylthiouracil 50 mg Tablet,-,"Systemic Hormonal Preparations, excl. Sex Hormones and Insulins > Thyroid Therapy",H03BA02000T1001XX,Yes,LP,B,Hyperthyroidism,None,"ADULT Initially 300-600mg daily in divided doses, at 8 hourly intervals (can be given up to 600-1,200mg/daily in divided doses). Maintenance 50-200mg daily when the condition is controlled, probably within 1 to 3 months. CHILDREN 6-10 years: 50-150mg daily in divided doses. CHILDREN > 10 years: 150-300mg or 150mg/m2 daily Maintenance 50-100mg daily, according to patient's response. Taken with food.","GI disturbances, headache, arthralgia, myalgia, oedema, alopecia, pruritus and rashes. Potentially fatal: agranulocytosis, aplastic anaemia, liver injury and liver failure",Hypersensitivity,"Anticoagulants, beta blockers, digitalis glycosides, theophylline","Reserve use for patients who are unable to tolerate carbimazole, radioactive iodine therapy and surgery. Severe liver injury and acute liver failure, hepatic or renal impairment. Monitor for liver injury and agranulocytosis especially in the first 6 months of therapy. Pregnancy and lactation.",False
Prednisolone 2.5mg/5 ml Syrup,,"Systemic Hormonal Preparations, excl. Sex Hormones and Insulins > Corticosteroids for Systemic Use",H02AB06-000-L90-02-XX,Yes,LP,B,i) Replacement therapy for primary and secondary adrenocortical insufficiency ii) Adrenogenital syndrome iii) Other therapy,None,i) 5 - 25 mg daily in divided doses ii) 10 - 20 mg/m2 body surface daily in divided doses iii) ADULT: 5 - 60 mg daily. CHILD: 0.5 - 2 mg/kg/day in divided doses every 6 - 8 hours or as a single daily,"Fluid and electrolyte disturbances, muscle weakness and peptic ulcer, osteoporosis, abdominal distention, nausea and vomiting",Hypersensitivity and systemic fungal infection,"Phenytoin, phenobarbital, rifampin increase clearance of methylprednisolone. Potassium depleting diuretics enhance potassium depletion. Skin test antigens and immunizations decrease response. Increase circulating glucose level and may need adjustment of insulin or oral hypoglycaemics","Discontinue treatment by reducing the dosage gradually NPRA Safety Alert 1. 19 July 2022 Pheochromocytoma crisis, which may be fatal, has been reported after administration of systemic corticosteroids. Corticosteroids should only be administered to patients with suspected or identified pheochromocytoma after an appropriate risk/benefit evaluation.",False
Nifedipine 10 mg Tablet,,Cardiovascular System > Calcium Channel Blockers,C08CA05000T1001XX,No,APPL,B,Hypertension,None,Initial dose of 10 mg twice daily. Usual range 10 - 30 mg 3 times daily. Maximum: 120 - 180 mg per day. Elderly: Dose reduction may be necessary.,"Dizziness, flushing, headache, hypotension, peripheral oedema, tachycardia, palpitations, nausea, constipation, other gastrointestinal disturbances, increased micturition frequency, lethargy, eye pain, visual disturbances, syncope, vertigo, migraine, mood disturbances, rashes (including erythema multiforme), liver function abnormalities (including cholestasis), pruritus, gingival hyperplasia, myalgia, gynaecomastia, tremor, impotence, fever. Paradoxical increase in ischaemic chest pain during initiation of treatment.","Cardiogenic shock, acute unstable angina, use wthin one month of myocardial infarction. Treatment of angina attack in chronic stable angina or acute reduction of blood pressure in adults. Concomitant use with strong CYP3A4 inducers.","Other antihypertensives, aldesleukin, and antipsychotics, fentanyl, insulin, benazerpril, coumarin anticoagulants, CYP3A4 inhibitors .","Patients with hypotension, poor cardiac reserve, heart failure, severe aortic stenosis, diabetes melitus, underlying severe gastrointestinal narrowing (extended-release tablet). Avoid abrupt withdrawal as it may casue rebound angina. Hepatic impairment. Elderly. Pregnancy and lactation.",False
Hydrocortisone 1% Cream,-,"Dermatologicals > Corticosteroids, Dermatological Preparations",D07AA02-000-G10-01-XXX,Yes,APPL,B,Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses,None,Apply sparingly to the affected area. Adult: 3-4 times daily. Children: 1-2 times daily,"Local atrophic skin changes, impaired skin healing","Fungal and bacterial infections, tuberculosis of the skin, viral disease of the skin, acne vulgaris, rosacea, perioral dermatitis. Hypersensitivity to hydrocortisone",Not known,"Prolonged use in infants and children, ulceration at infection site, diabetes mellitus. Should not be used on pregnant patients in large amounts or for prolonged period of time. Lactation.",False
Metformin HCl 500 mg Tablet,,Alimentary Tract and Metabolism > Drugs Used In Diabetes,A10BA02110T1001XX,Yes,APPL,B,Diabetes mellitus,None,"Initial: 500mg orally twice daily with food. Maintenance: Titrate in 500mg increments weekly, doses up to 2000 mg daily may be divided into 2 equal doses.","Gastrointestinal disorders, taste disturbance/metallic taste. Rarely, decreased vitamin B12 absorption, lactic acidosis, skin reactions, liver function tests abnormalities NPRA Safety Alert 1. 27 Sept 2022 2. 4 Mac 2024 (updated) Vitamin B12 Deficiency","Hypersensitivity, diabetic ketoacidosis, diabetic precoma, renal failure (CrCl < 60ml/min), acute conditions with potential to alter renal function (e.g. dehydration, severe infection, shock), acute or chronic disease which may cause tissue hypoxia (e.g. cardiac or respiratory failure, recent myocardial infarction), hepatic insufficiency, alcohol, lactation.","Alcohol, iodinated contrast agents, glucocorticoids, beta-2 agonists, diuretics, ACEIs.","Renal failure (risk of lactic acidosis), administration of iodinated contrast agent (discontinue prior to radiologic exam and restart 48 hours afterwards). May need to discontinue treatment in patients with stress-related states e.g. fever, trauma, infection or surgery. Elderly; monitor renal function regularly. May impair ability to drive or operate machinery. NPRA Safety Alert 1. 4 Mac 2024 May reduce vitamin B 12 serum levels. (For full info, please refer package insert/related NPRA Safety Alert)",False
Methyldopa 250 mg Tablet,,Cardiovascular System > Antihypertensives,C02AB01110T1001XX,Yes,APPL,B,Hypertension,None,"Adult: 250 mg 2 - 3 times daily, gradually increased at intervals of 2 or more days, maximum; 3 g/day. Elderly: initially 125 mg twice daily, increased gradually, maximum; 2 g daily. Child: Initially, 10 mg/kg or 300 mg/m2 daily in 2-4 divided doses; increase as necessary. Max: 65 mg/kg, 2 g/m2 or 3 g daily, whichever is least.","Sedation, headache, weakness, dizziness, parkinsonism, bradycardia, orthostatic hypotension, GI symptoms, hepatic impairment, impotence","Hypersensitivity to methyldopa, history of hepatitis, autonomic dysfunction, bilateral cardiovascular disease","Antihypertensive drugs, lithium, monoamine oxidase inhibitors (MAOIs)","Avoid abrupt withdrawal, congestive heart failure, dialysis patients (risk of hypertension following procedure), oedema, haemolytic anaemia, hypotension, liver disease, severe bilateral cerebrovascular disease (risk of choreoathetotic movements)",False
Levothyroxine Sodium 100 mcg Tablet,Oroxine,"Systemic Hormonal Preparations, excl. Sex Hormones and Insulins > Thyroid Therapy",H03AA01520T1001XX,Yes,APPL,B,Hypothyroidism,None,"Start at low dose and increase at 2-4 weeks interval. Adult: Initially, 50-100 mcg/day may increase by 25-50 mcg at approximately 3 to 4 weeks intervals until the thyroid deficiency is corrected. Maintenance: 100-200 mcg/day. CHILD; 0 - 3 months: 10 - 15 mcg/kg/day; 3 - 6 months: 8 - 10 mcg/kg/day; 6 - 12 months: 6 - 8 mcg/kg/day; 1 - 5 years: 5 - 6 mcg/kg/day; 6 - 12 years: 4 - 5 mcg/kg/day; more than 12 years: 2 -3 mcg/kg/day","Nervousness, excitability, tremor, muscle weakness, cramps, sweating, flushing, heat intolerance, headache, insomnia, tachycardia, palpitations, angina pectoris, excessive weight loss, menstrual irregularities, diarrhoea, vomiting, convulsions, cardiac arrhythmia, heart failure, coma, myocardial infarction, osteopenia, pseudotumor cerebri, seizure","Hypersensitivity, untreated adrenal insufficiency, acute myocardial infarction, acute myocarditis, acute pancarditis.","Reduced absorption with iron, cholestyramine, colestipol, aluminium- and magnesium-containing antacids, calcium carbonate, simethicone, sucralfate. May alter requirements of antidiabetic drugs. Reduced efficacy of thyroid replacement therapy with imatinib. Reduced tri-iodothyronine serum levels with amiodarone. Reduced serum levels of thyroxine with carbamazepine, phenytoin, phenobarbital, rifampicin, oestrogens. May change hypoprothrombinaemic response to warfarin and other oral anticoagulants. Increased risk of significant hypertension and tachycardia with ketamine","Elderly, CHD, severe or long existing hypothyroidism. Coronary failure, angina pectoris, arteriosclerosis, hypertension, pituitary or adrenal insufficiency, cardiac insufficiency or tachycardic arrhythmias. Not suitable for weight reduction. Galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption, pregnancy and lactation.",False
Potassium Chloride 600 mg SR Tablet,Slow-K,Alimentary Tract and Metabolism > Mineral Supplements,A12BA01-100-T50-01-XXX,Yes,APPL,B,For the treatment and specific prevention of hypokalaemia,None,ADULT: 2 - 3 tablets daily. Severe deficiency: 9 - 12 tablets daily or according to the needs of the patient,"Nausea, vomiting, gastrointestinal ulceration, ECG changes","Acute dehydration, heat cramps, hyperkalaemia, renal failure and in conditions in which potassium retention is present or where additives of potassium and chloride could be clinically detrimental","Potassium sparing diuretics, salt substitutes, ACE inhibitors, angiotensin-II receptor antagonists, methenamine, ciclosporin, tacrolimus","Severe renal impairment, cardiac disease, hyperkalaemia. Initial potassium replacement therapy, should not involve glucose infusions, because glucose may cause a further decrease in the plasma potassium concentration",False
Potassium Chloride 1 g/10 ml Injection,-,Blood and Blood Forming Organs > Blood Substitutes and Perfusion Solutions,B05XA01-100-P30-01-XXX,No,APPL,B,For the correction of severe hypokalaemia and when sufficient potassium cannot be taken by mouth,None,By slow IV infusion depending on the deficit or the daily maintenance requirements. 1 g diluted in 500 ml normal saline or glucose and given slowly over 2 - 3 hours,"Nausea, vomiting, gastrointestinal ulceration, electrocardiogram changes","Acute dehydration, heat cramps, hyperkalaemia, renal failure and in conditions in which potassium retention is present or where additives of potassium and chloride could be clinically detrimental","Potassium sparing diuretics, salt substitutes, ACE inhibitors, angiotensin-II receptor antagonists, methenamine, ciclosporin, tacrolimus","Dilute before use, not for IV bolus. Severe renal impairment, cardiac disease, hyperkalaemia. Initial potassium replacement therapy, should not involve glucose infusions, because glucose may cause a further decrease in the plasma potassium concentration.",False
Potassium Citrate 3 g/10 ml and Citric Acid Mixture,,Alimentary Tract and Metabolism > Mineral Supplements,A12BA02-955-L21-01-XXX,No,APPL,C,For systemic or urinary alkalinization,None,"ADULT: 10-20 ml 3 times daily, well diluted with water. CHILD up to 1 year: 2.5 ml 3 times daily; 1 - 5 years: 5 ml 3 times daily; 6 - 12 years: 10 ml 3 times daily. To be taken well diluted with water, after meals and at bedtime.","Hyperkalaemia, metabolic alkalosis, nausea, vomiting, diarrhoea, mild diuresis","Severe renal impairment with oliguria, azotemia or anuria, Addison's disease, adynamic episodica hereditaria, acute dehydration, heat cramps, severe myocardial damage, potassium citrate in patients with hyperkalemia, sodium citrate for patients on sodium restriction","Concurrent administration of potassium citrate with potassium- containing medications, angiotensin-converting enzyme inhibitors or cardiac glycosides, concurrent administration with aluminum-based gels","Congestive heart failure, hypertension, pulmonary or peripheral oedema, toxaemia of pregnancy, monitor serum electrolytes especially bicarbonate in patients with renal disease, decreased urinary output, especially in the presence of hypocalcaemia",False
Captopril 25 mg Tablet,Apuzin Tablet 25 mg,Cardiovascular System > Agents Acting on the Renin-angiotensin System,C09AA01000T1002XX,Yes,APPL,B,i) Hypertension ii) Congestive heart failure iii) Post-myocardial infarction iv) Diabetic kidney disease,10 TAB/KK (EMERGENCY TROLLEY ITEM),i) Initial: 25-75mg in 2-3 divided doses Maintenance: 100-150mg in 2-3 divided doses ii) Initial: 6.25-12.5mg 2-3 times daily Maintenance: 75-150mg daily in divided doses iii) Initial: 6.25mg followed by 12.5mg and then 25mg Maintenance: 75-150mg daily in 2-3 divided doses iv) 75-100 mg in divided doses Dosing is individualised and according to product insert / protocol.,"Rash, pruritus, flushing, angioedema, loss of taste perception, stomatitis, gastrointestinal irritation and abdominal pain, leucopenia, persistent dry (non-productive) cough, hypotension, tachycardia, chest pain, palpitations, pruritus, hyperkalaemia. Proteinuria; Potentially Fatal: Neutropenia, usually occurs within 3 mth of starting therapy especially in patients with renal dysfunction or collagen diseases. Hyperkalaemia. Anaphylactic reactions.",Angioedema induced by other angiotensin converting enzyme (ACE) inhibitors during prior exposure. Anuric renal failure during prior exposure to ACE inhibitors. Hypersensitivity to this or any other ACE inhibitor. Pregnancy (second and third trimester pregnancy),"May increase serum K with Kalium K-sparing diuretics. Hypotensive effects enhanced by diuretics. Antihypertensive effect diminished by indomethacin, salicylates, NSAIDs","Anaphylaxis during lipid apheresis with dextran sulfate membranes and during hymenoptera desensitization, angioedema; discontinue if laryngeal stridor or angioedema of the face, tongue, or glottis is observed, aortic stenosis, breast feeding period, cough, impaired renal function",False
Carbamazepine 100 mg/5 ml (2% w/v) Syrup,Tegretol,Nervous System > Antiepileptics,N03AF01-000-L90-01-XXX,Yes,LP,A,Epilepsy,None,"ADULT: Initially, 100-200 mg once or twice daily gradually increased by increments of 100-200 mg every 2 week. Maintenance: 0.8-1.2 g daily in divided doses. Max: Adult: 1.6 g daily CHILD: 10-15 years: 0.6-1 g daily 5-10 years: 400-600 mg daily 1-5 years: 200-400 mg daily less than or equal to 1 year: 100-200 mg daily. Alternatively, 10-20 mg/kg body weight daily in divided doses.","Rash, Stevens-Johnson Syndrome, nausea, drowsiness, dizziness, ataxia, blood dyscrasias, confusion, agitation, visual disturbance, constipation or diarrhoea, anorexia, leukopenia, blood disorders, Syndrome of inappropriate ADH (SIADH), cardiac conduction abnormalities, gynaecomastia, allergic skin reactions, vomiting, accommodation disorders, diplopia, raised liver enzymes, thrombocytopenia and hyponatraemia, exfoliative dermatitis.","Hypersensitivity to carbamazepine products or tricyclic compounds, bone marrow suppression, porphyria, concomitant MAOIs.","Plasma level is increased by erythromycin, diltiazem, isoniazid, verapamil, fluoxetine, cimetidine and decreased by other antiepileptics and theophylline. May reduce alcohol tolerance and antagonise the effects of non-depolarising muscle relaxants. Cytochrome P450 3A4 inducers or inhibitors, oral contraceptive","Breast feeding, pregnancy, liver or kidney dysfunction, increased intraocular pressure, history of cardiac damage, elderly patients, glaucoma, may exacerbate certain types of idiopathic epilepsy. Avoid abrupt discontinuation. Neonatal withdrawal syndrome. Potential for an increase in risk of suicidal thoughts or behaviours",True
Verapamil HCl 40 mg Tablet,,Cardiovascular System > Calcium Channel Blockers,C08DA01-110-T10-01-XXX,Yes,APPL,B,i) Supraventricular tachyarrhythmias (SVT) prophylaxis ii) Angina iii) Hypertension,None,i) 120-480mg in 2-3 divided doses ii) 80mg – 120mg 3 times daily iii) Initial: 240 mg daily in 2-3 divided doses. Max: 480 mg daily,"Constipation, dizziness, nausea or vertigo, headache, hypotension, ankle oedema, flushing, fatigue, nervousness, paraesthesia, bradycardiac arrhythmias, dyspnoea, raised prolactin levels, single cases of galactorrhoea, myalgia, arthralgia, allergic skin reactions, purpura, photosensitisation dermatitis, gynaecomastia, reversible increase in transaminases and or alkaline phosphatase, gingival hyperplasia, tachycardia, palpitations, impotence, tinnitus, tremor, heart failure","Cardiovascular shock, complicated acute myocardial shock, severe conduction disorders (2nd and 3rd degree AV block, SA block), sick sinus syndrome, heart failure, atrial fibrillation/flutter and simultaneous preexcitation syndrome, myasthenia gravis, pregnancy, not recommended in lactation.",Increased risk of myocardial depression with beta-blockers or inhalation anaesthetic. May increase plasma digoxin concentration and plasma cyclosporin concentration,"- First degree AV block, bradycardia, hypotension. - May impair ability to drive or operate machinery. - Pregnancy, lactation. - Severe hepatic impairment. - Slows down markedly the elimination of alcohol and prolongs the duration of alcohol",False
Aminophylline 25mg/ml Injection,-,Respiratory System > Drugs for Obstructive Airway Diseases,R03DA05-000-P30-01-XXX,Yes,APPL,B,"Reversible airways obstruction, acute severe brochospasm",None,Adult: Loading dose: 6 mg/kg (ideal body weight) or 250-500 mg (25 mg/ml) by slow inj or infusion over 20-30 min. Maintenance infusion dose: 0.5 mg/kg/hr. Max rate: 25 mg/min. Children: 6 months and over (if not previously on theophylline): Loading dose: 6mg/kg. Maintenance dose: 6 mth-9 yr: 1 mg/kg/hr and 10-16 yr: 0.8 mg/kg/hr. Dosing is individualised and according to product insert/protocol.,"Tachycardia, palpitations, nausea and other gastrointestinal disturbances, headache, CNS stimulation, insomnia, arrythmias, also allergy to ethylenediamine which can cause urticaria, erythema, and exfoliative dermatitis","Hypersensitivity to theophylline or derivatives, hypersensitivity to ethylenediamine","Azole antifungals, ciprofloxacin, clarithromycin, erythromycin : increased risk of theophylline toxicity. Caffeine : increased caffeine level. Halothane : increased risk of arrthmia","Should not be administered concurrently with ephedrine or with other xanthine medications. Use with caution paediatrics, elderly patients, smokers ,patients undergoing influenza immunisation, patient with reduced hepatic clearance.Patients with ischaemic heart disease, hypertension,hyperthyroidism, epilepsy, history of peptic ulcer disease, glaucoma, diabetis mellitus, severe hypoxemia, angina pectoris, acute mycardial injury or pre-existing arrythmias.",False
Amitriptyline HCl 25 mg Tablet,Laroxyl,Nervous System > Psychoanaleptics,N06AA09-110-T10-01-XXX,Yes,LP,B,i) Depression ii) Nocturnal enuresis where organic pathology has been excluded,None,i) Initial: 25mg 3 times a day in the evening Increase gradually in the late evening or at bedtime if necessary up to a maximum of 150mg per day Hospitalised patient: 100mg per day Increase gradually to 200-300mg per day ii) CHILD 6 YEARS AND UNDER: 10mg at bedtime CHILD OVER 6 YEARS Initial: 10mg at bedtime Increase gradually if necessary up to a maximum of 25mg at bedtime Not recommended for treatment of depression in children under 12 years of age. Dosing is individualised and according to product insert/ protocol.,"Dry mouth, constipation, nausea, vomiting, urinary retention, blurred vision, drowsiness, dizziness, tachycardia, increased appetite, confusion, seizures, myocardial infarction, stroke, agranulocytosis, thrombocytopenia, rash and hypersensitivity reactions, blood sugar changes, endocrine side effects, impotence, menstrual irregularities, bone marrow depression","Hypersensitivity to drug/class. Immediate recovery phase after myocardial infarction, heart block, mania. MAOI use within the last 14 days","Barbiturate, phenytoin, carbamazepine, cimetidine, amphetamines, antiarrhythmics, class Ia and III, anticholinergics, antihistamines, beta 2 agonists, benzodiazepines, systemic carbonic anhydrase inhibitors, central alpha 2 agonists, cholinergic agents, clozapine, intranasal decongestants, flumazenil, halothane, lithium, MAOIs, methylphenidate, metoclopramide, muscle relaxants, nitrates, opiates, antipsychotics, phenytoin, protease inhibitors, sedatives/hypnotics, SSRIs, indirect/mixed sympathomimetics, cimetidine, fluoxetine, clonidine","Cardiac disease, hyperthyroidism, impaired hepatic and renal function, urinary retention, history of seizures, glaucoma, suicide risk, pregnancy, lactation, elderly, phaeochromocytoma, history of mania, phychoses, angle-closure glaucoma, concurrent anticonvulsive therapy, anaesthesia",False
Amlodipine 10 mg Tablet,Hovasc 10 mg Tablet,Cardiovascular System > Calcium Channel Blockers,C08CA01-000-T10-02-XXX,Yes,APPL,B,Hypertension,None,5 mg once daily. Max: 10 mg once daily,"Headache, dizziness, gingival hyperplasia, tachycardia, peripheral oedema","Hypersensitivity to amlodipine, symptomatic hypotension, persistent dermatologic reactions, congestive heart failure","Cyclosporin, sildenafil, vardenafil, CYP3A4 inducers, CYP3A4 inducers(fluconazole, itraconazole, ketoconazole)","Angina (exacerbation) during initiation of treatment; with dosage increases; during beta-blocker withdrawal; taper slowly prior to calcium channel blocker therapy. Aortic stenosis (reduced myocardial oxygenation with drug-induced hypotension), congestive heart failure, pregnancy, hepatic impairment, lactation.",False
Fluphenazine Decanoate 25mg/ml Injection,Modecate,Nervous System > Psycholeptics,N05AB02135P3001XX,Yes,APPL,B,Long term management of psychotic disorders,None,"By deep IM : Test dose 12.5 mg (6.25 mg in ELDERLY), then after 4-7 days 12.5 mg-100 mg repeated at intervals of 14-35 days, adjusted according to response. CHILD not recommended","Weight gain, agranulocytosis, akathisia, extrapyramidal effects, hepatotoxicity, neuroleptic malignant syndrome, hyperprolactinaemia, sedation, orthostatic hypotension, anticholinergic effects, seizures, aplastic anaemia, cholestatic jaundice, drowsiness, dependence, antimuscarinic effects, insomnia, depression, convulsions, agitation, tachycardia, postural hypotension, allergic reactions, agranulocytosis, tardive dyskinesia, depressive reactions","Comatose or severely depressed patients, blood dyscrasias, liver damage, hypersensitivity to fluphenazine products, subcortical brain damage, phaeochromocytoma, severe hypotension, bone marrow depression","Tramadol, increased risk of seizures. Cisapride, levofloxacin, increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest). Pethidine, increase in central nervous system and respiratory depression. Levodopa, loss of levodopa efficacy. Procyclidine, decreased phenothiazine serum concentrations, decreased phenothiazines effectiveness, enhance anticholinergic effects (ileus, hyperpyrexia, sedation, dry mouth). Sertraline, fluoxetine; increased risk of developing acute parkinsonism. Class Ia and III antiarrhytmics, beta2 agonists, carbamazepine, central alpha2 agonists, systemic corticosteroids, diuretics, lithium tricyclic antidepressants, alcohol, CNS depressants, clonidine","Patients exposed to extreme heat or phosphorous insecticides, history of convulsive disorder, mitral insufficiency or other cardiovascular diseases and phaeochromocytoma; history of neuroleptic malignant syndrome, history of cholestatic jaundice, hypersensitivity reaction to other phenothiazines, patients undergoing surgery may require lower doses of anaesthetics or depressants, history of dermatoses, myasthenia gravis, Parkinson's disease, seizure disorder, elderly, debilitated, liver or kidney impairment, CV or respiratory disorders, diabetes, pheochromocytoma, epilepsy, glaucoma. May impair temperature regulatory mechanism",False
Fusidic Acid 50 mg/ml Suspension,Fucidin,Antiinfectives for Systemic Use > Antibacterials for Systemic Use,J01XC01000L8001XX,No,LP,A*,Treatment of infections caused by staphylococcal especially Methicillin Resistant Staphylococcus aureus (MRSA),None,ADULT : 15 ml 3 times daily. CHILD 1 - 5 years: 5 ml 3 times daily; 5 - 12 years: 10 ml 3 times daily. INFANT : 1 ml/kg body weight daily in 3 - 4 divided doses,"Gastrointestinal disturbances (dyspepsia, nausea, vomiting)",Hypersensitivity to fusidic acid and or its salts,"Oral anticoagulants (e.g. Warfarin), statins, cyclosporin, Protease inhibitors (e.g. Ritonavir)",Hepatic insufficiency. Pregnancy and lactation,True
Ibuprofen 200 mg Tablet,Brufen,Musculo-skeletal System > Antiinflammatory and Antirheumatic Products,M01AE01000T1001XX,Yes,APPL,B,Pain and inflammation in rheumatic disease,None,"Dosage: ADULT : 200 - 400 mg 3 times daily after food, maximum 3.2 g daily. CHILD : 30-50 mg/kg body weight daily in divided doses, maximum 2.4g daily. Lowest effective dose for the shortest possible duration.","Peptic ulceration, GI bleeding, headache, dizziness, nervousness, skin rash, pruritus, tinnitus, oedema depression, drowsiness, insomnia, blurred vision, hypersensitivity, impairment of renal function, dyspepsia, thrombocytopaenia, visual disturbances, nausea, vomiting, epigastric pain, heartburn, jaundice, hepatitis, depression","Hypersensitivity. Treatment of perioperative pain in the setting of CABG surgery. Patient whom asthma, urticaria or other allergic-type reaction are precipitated by aspirin or other NSAIDs. Active or history of peptic ulcer; history of GI bleeding. Neonates with congenital heart disease, suspected necrotising enterocolitis, and impaired renal function. 3rd trimester of pregnancy, and lactation.","Coumarin-type anticoagulants, aspirin or NSAIDs, digitalis glycosides, lithium, methotrexate, diuretics, cefoperazone, valproic acid, ciclosporin, gold compound, other nephrotic medications, probenecid. Moclobemide enhances effects of ibuprofen. Increased risk of gastrointestinal bleeding with warfarin. Lost of BP response with ACEI","Bleeding disorders, CV disease. Infants with increased total bilirubin. Premature neonates with existing or at risk of infection. Hepatic and renal impairment. Elderly (avoid chronic use).",False
Crotamiton 10 % Cream,Eurax,"Antiparasitic Products, Insecticides and Repellents > Ectoparasiticides, incl. Scabicides, Insecticides and Repellents",P03A000000G1001XX,Yes,LP,B,i) Pruritus ii) Scabies iii) Insect bite reactions,None,i) and iii) Massage into affected area until the medication is completely absorbed. Repeat as needed. Apply 2 or 3 times daily ii) Apply to the whole body from below the chin. 2nd application is applied 24 hr later. May need to use once daily for up to 5 days.,"Nausea, vomiting and abdominal pain. Topical: Pruritus, contact dermatitis, rash, irritation, warm sensation.","Hypersensitivity; acute exudative dermatitis. Application to the eye, mouth, other mucous membranes or on excoriated skin. Do not apply on nipples when breastfeeding.",Not known,For external use only. Pregnancy.,False
Metoclopramide HCl 10mg Tablet,,Alimentary Tract and Metabolism > Drugs for Functional Gastrointestinal Disorders,A03FA01-110-T10-01XXX,Yes,LP,B,"Use in adults for: i) Prevention of delayed chemotherapy induced nausea and vomiting (CINV) ii) Prevention of radiotherapy induced nausea and vomiting (RINV) iii) Symptomatic treatment of nausea and vomiting, including acute migraine induced nausea and vomiting Use in children aged 1-18 years for: i) Prevention of delayed chemotherapy induced nausea and vomiting (CINV) as a second line option",None,"Adult: The recommended single dose is 10mg, repeated up to three times daily. The maximum recommended daily dose is 30mg or 0.5mg/kg body weight. The maximum recommended treatment duration is 5 days. Prevention of delayed CINV (children aged 1-18 years): The recommended dose is 0.1-0.5mg/kg body weight, repeated up to three times daily by oral route. The maximum dose in 24 hours is 0.5mg/kg body weight. Dosing table CHILD age 1-3 years old (body weight 10-14kg): 1mg TDS, 3-5 years old (body weight 15-19kg): 2mg TDS, 5-9 years old (body weight 20-29kg): 2.5mg TDS, 9-18 years old (body weight 30-60kg): 5mg TDS, 15-18 years old (body weight > 60kg): 10mg TDS. Tablets are not suitable for use in children weighing less than 30kg. Other pharmaceutical forms may be more appropriate for administration to this population.","Extrapyramidal effects (especially in children and young adults), hyperprolactinaemia, tardive dyskinesia, drowsiness, restlessness, anxiety, drowsiness, fatigue, akathisia, insomnia, depression, neuroleptic malignant syndrome, diarrhoea, bronchospasm and cardiac conduction abnormalities, galactorrhea, gynaecomastia","Concomitant therapy with drugs which are likely to cause extrapyramidal reactions, epileptics, gastrointestinal haemorrhage, obstruction (mechanical), or perforation, hypersensitivity to metoclopramide, pheochromocytoma. Immediately after GI surgery where stimulation of GI tract motility might be dangerous.","Increased absorption of aspirin and paracetamol; opioid analgesics and antimuscarinics antagonise effect on gastro-intestinal activity, antipsychotics (increased risk of extrapyramidal effects). Decrease absorption of digoxin","Hepatic and renal impairment, elderly, young adults and children; may mask underlying disorders such as cerebral irritation; avoid for 3 - 4 days following gastro-intestinal surgery, may cause acute hypertensive response in phaeochromocytoma; pregnancy and breast feeding; porphyria. Use cautiously in patients with depression, Parkinson's disease or hypertension",False
Metronidazole 200mg Tablet,Flagyl,"Antiparasitic Products, Insecticides and Repellents > Antiprotozoals",P01AB01-000-T10-01-XXX,Yes,APPL,B,Anaerobic infection,None,"Anaerobic bacterial infections Adult: Initially, 800 mg followed by 400 mg 8 hly for about 7 days. Other recommended doses: 500 mg 8 hrly or 7.5 mg/kg 6 hrly (max: 4 g in 24 hr). Child: 7.5 mg/kg 8 hrly. Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. Prophylaxis of postoperative anaerobic bacterial infections Adult: 400 mg by mouth 8 hrly in the 24 hr prior to surgery followed postoperatively by IV or rectal admin until oral therapy is possible. Other sources recommend that oral doses be initiated only 2 hr prior to surgery and that number of doses for all admin routes be limited to a total of 4. Elderly: Dose reduction may be necessary. Tab: Should be taken with food.","GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV). Potentially Fatal: Anaphylaxis.",History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.,"Acute psychoses or confusion with disulfiram. Additive/synergistic effect with other antimicrobials. Effects reduced with phenobarbital or phenytoin. Potentially Fatal: Disulfiram-like reaction with alcohol. Increased risk of adverse effects of coumarin anticoagulants, phenytoin, lithium, ciclosporin, fluorouracil. Increased risk of neurological effects with cimetidine.",Patients with CNS diseases; History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Prolonged use may result in fungal or bacterial superinfection.,False
Ipratropium Bromide 0.5mg and Salbutamol 2.5mg per UDV,Combineb,Respiratory System > Drugs for Obstructive Airway Diseases,R03AK04-320-A30-01-XXX,No,Government Contract,B,Management of reversible bronchospasm associated with obstructive airway diseases,None,"Acute attacks : 1 unit dose vial. In severe cases not relieved by 1 unit dose vial, 2 unit dose vials may require. Maintenance : 1 unit dose vial 3 - 4 times daily","Headache, dizziness, nervousness, tachycardia, fine tremor, palpitations. Potentially serious hypokalaemia may result from beta2-agonist therapy, dryness of mouth, dysphonia, ocular complications, allergic type reactions",Hypersensitivity to atropine or its derivatives or to any other component. Hypertrophic obstructive cardiomyopathy or tachyarrythmia,"Xanthine derivatives, other anticholinergics, beta2-agonists, beta-blockers, tricyclic anti depressants, MAOIs, glucocorticoids - increased risk of tachycardia, agitation, hypomania, hypokalaemia","Patients predisposed to glaucoma, insufficiently controlled diabetes mellitus, recent myocardial infarction, severe organic heart or vascular disorders, hyperthyroidism, phaechromocytoma, risk of narrow-angle glaucoma, prostatic hypertrophy or bladder-neck obstruction, hypoxia, cystic fibrosis, pregnancy and lactation, uriticaria, angioedema, rash, broncospasm, oropharyngeal oedema",False
Iron Dextran 50mg Fe/ml Injection,,Blood and Blood Forming Organs > Antianemic Preparations,B03AC06000P3001XX,No,APPL,B,Severe iron deficiency anaemia,None,"An initial test dose of 0.5 ml should be given over the desired route. For severe iron deficiency anaemia, 1-2 ml daily given by deep IM. Dosage is individualized according to total iron deficit","Adverse effects may be delayed 24-48 hr after IV admin or 3-4 days after IM admin. Flushing, dizziness, fever, chills, nausea, headache, diaphoresis. Chest pain or tightness, shock, MI, hypertension, tachycardia, bradycardia and arrhythmias. Local reactions, pain and staining may occur at the site of inj after IM inj.",Anaemia that are not due to iron deficiency; haemochromatosis; haemolytic anemia. Severe liver damage or acute kidney infection. Lactation.,ACE inhibitors may increase potential anaphylatic reactions. Parenteral chromphenicol may delay response of anaemia to iron therapy. Bone scans performed with pertechnetate-labelled disphosphonates have shown dense areas of increased activity after intramuscular injection,"History of allergies or asthma. Pre-existing CV disease, hepatic impairment. May worsen rheumatoid arthritis. Not recommended in children <4 mth. Admin of oral iron salts should be ceased before giving parenteral iron. Rapid IV admin may cause vascular flushing and hypotension. Pregnancy.",False
Isosorbide Dinitrate 1mg/ml Injection,,Cardiovascular System > Cardiac Therapy,C01DA08-221-P30-01-XX,No,LP,A,Treatment for angina pectoris and left ventricular failure,None,2-12mg IV per hour after dilution. Dosing is according to product insert or protocol.,"GI disturbances, headache, hypotension, tachycardia","Hypersensitivity to organic nitrates, anaemia, symptomatic hypotension","Hypotensive effects may be enhanced by alcohol, beta-blocker, calcium channel blocker, antihypertensive, sildenafil and tricyclic antidepressant","Acute myocardial infarction,cerebral hemorrhage,congestive heart failure, glaucoma, hyperthyroidism, hypertrophic, cardiomyopathy, hypotension,methemoglobinemia, recent head trauma, severe anemia, volume depletion",True
Bromhexine HCl 8mg Tablet,Bisolvon,Respiratory System > Cough and Cold Preparations,R05CB02-110-T10-01-XXX,Yes,LP,C,Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucous secretion and impaired mucous transport.,Medical Assistant in health settings without Medical Officer is allowed to prescribe this medicine for adult use only.,"Adult: 8-16 mg three times daily. Children: By body weight: 0.3 mg/kg/day 8 hourly for 7 days, then 0.15 mg/kg/day 8 hourly; or Based on age: 6-12 years – 4 mg three times daily; 2-6 years – 2 mg three times daily",Gastrointestinal ulceration,Hypersensitivity to bomhexine,May lead to higher antibiotic concentration in lung tissue. Oral anticoagulants,"Gastrointestinal ulceration, pregnancy and lactation",False
Budesonide 200mcg/dose Inhalation,Pulmicort,Respiratory System > Drugs for Obstructive Airway Diseases,R03BA02-000-A21-02-XXX,Yes,APPL,B,Maintenance treatment of asthma as prophylactic therapy especially if not fully controlled by bronchodilators,None,"ADULT: 200-1600 mcg daily in 2-4 divided doses. Maintenance with twice daily dosing. CHILD more than 7 years: 200-800 mcg, 2 - 7 years: 200-400 mcg. To be inhaled in 2-4 divided doses.","Mild irritation of the throat, coughing, and generally reversible hoarseness of the voice. Bad taste, dryness of the throat. Candidiasis of the mouth and throat, paradoxical bronchoconstriction, headache, nausea, tiredness, thirst, diarrhoea, skin reaction",Hypersensitivity to budesonide. Moderate to severe bronchiectasis,"Oral or parenteral corticosteroids: effects enhanced by the concomitant use. Amiodarone: increased risk of developing Cushing's syndrome. Ketoconazole, erytromycin, ritonavir : increased budesonide plasma concentrations","Acute exacerbations, accompanied by increased mucous viscosity and mucous plugging. Caution in viral infections such as varicella, in untreated fungal and bacterial infections of the respiratory system. Pregnancy and lactation",False
Chlorpheniramine Maleate 10mg/ml Injection,,Respiratory System > Antihistamines for Systemic Use,R06AB04-253-P30-01-XX,Yes,APPL,B,Allergic conditions,None,"10 - 20 mg IM or SC, repeated if required. Not to exceed 40 mg in 24 hours. 10 - 20 mg over 1 minute by slow IV","Drowsiness, dizziness, stinging or burning sensation at injection site, hypotension, CNS stimulation, tinnitus, blurred vision, irritability, lassitude","Hypersensitivity to chlorpheniramine, not to be used in children less than 2 years of age.","Alcohol pontentiate CNS depressants, actions prolonged by MOAIs, anticholinergic drugs","Porphyria, pregnancy, asthma, glaucoma, avoid operating vehicles or machinery. Parenteral injection have to be protected from light to prevent discolouration. To be used with caution and doctor's advice in children 2 to 6 years of age.",False
Chlorpromazine HCl 100mg Tablet,Largactil,Nervous System > Psycholeptics,N05AA01-110-T10-02-XXX,Yes,APPL,B,i) Psychotic conditions ii) Anti-emetic,None,ADULT: Initial: 25-50mg two- three times daily Maintenance: 25-100mg two- three times daily CHILD: Not recommended Dosing is according to product insert / protocol.,"Postural hypotension, akathisia, tardive dyskinesia, arrhythmias, constipation, haematologic effects, agranulocytosis, aplastic anaemia, thrombocytopenia, neuroleptic malignant syndrome, jaundice, agitation, insomnia, parkinsonism symptoms, drowsiness, convulsion and tachycardia, acute dystonia, leukopenia, angioedema, bronchospasm, urticaria, hyperprolactinemia, eye, cardiac, skin & subcutanoues tissue disorders, dry mouth, respiratory depression, neuroleptic malignant syndrome. Rarely agranulocytosis, priapism","Hypersensitivity to chlorpromazine products, phenothiazines, myelosuppression, coma, severe CNS depression, bone marrow depression","Alcohol, CNS depressant, anticholinergic, tramadol, phenobarbitone, beta-blockers (metoprolol, atenolol, propranolol), captopril,norepinephrine, procyclidine, warfarin, epinephrine, cimetidine, ethanol, adrenaline, antacids, amphetamine, amiodarone, bumetamide, chlorothiazides, clarithromycin, erythromycin, frusemide, phenytoin, antiarrhythmics, antidepressants & other antipsychotics, carbamazepine","Pregnancy and lactation, elderly, epilepsy or history of seizure, impaired kidney and liver function, Parkinson's disease, severe hypotension, hypothyroidism, cardiac failure, phaeochromocytoma, myasthenia gravis & prostate hypertrophy. Avoid in patient hypersensitive to phenothiazines, history of narrow-angle glaucoma or agranulocytosis. Monitor BP & complete blood count. Avoid exposure to sunlight",False
Paracetamol 250 mg Suppository,Panadol,Nervous System > Psychoanaleptics,N02BE01000S2001XX,Yes,LP,B,Symptomatic relief of fever and post operative pain whom cannot tolerate oral preparations.,None,"ADULT & CHILDREN more than 12 years old: 500mg - 1g every 4-6 hours CHILD 6 - 12 years : 250 - 500 mg; 1 - 5 years : 125 - 250 mg; 3 - 11 months : 80 mg inserted every 4 - 6 hours if necessary, maximum 4 doses in 24 hours. INFANTS under 3 months should not be given Paracetamol unless advised by doctor; a dose of 10 mg/kg (5 mg/kg if jaundiced) is suitable.","Allergic reactions, skin rash NPRA Safety Alert 1. 10 Oct 2024 Paracetamol and Fixed Drug Eruption (FDE): Upward Trend of Reports Involving Paediatric Patients",Nephropathy,"Anticoagulants, alcohol, liver enzyme inducers, aspirin, chloramphenicol and phenobarbitone",Renal and hepatic failure. Avoid chronic use,False
Paracetamol 500 mg Tablet,Panadol,Nervous System > Analgesics,N02BE01000T1001XX,Yes,APPL,C+,Mild to moderate pain and pyrexia,None,"ADULT: 500 - 1000 mg every 4 - 6 hours, maximum of 4 g daily","Allergic reactions, skin rash NPRA Safety Alert 1. 10 Oct 2024 Paracetamol and Fixed Drug Eruption (FDE): Upward Trend of Reports Involving Paediatric Patients",Nephropathy,"Anticoagulants, alcohol, liver enzyme inducers, aspirin, chloramphenicol and phenobarbitone",Renal and hepatic failure. Avoid chronic use,False
Fluvoxamine 100mg Tablet,Luvox,Nervous System > Psychoanaleptics,N06AB08-253-T10-02-XXX,Yes,Government Contract,B,i) Depression ii) Obsessive Compulsive Disorder (OCD),None,"i) Initial: 50 – 100 mg per day in the evening Increase gradually if necessary up to a maximum of 300mg per day Dose over 150mg per day given in 2 – 3 divided doses Recommended dose to prevent recurrence: 100mg per day ii) ADULT Initial: 50mg per day for 3 – 4 days Increase gradually if necessary up to a maximum of 300mg per day Dose over 150mg per day given in 2 – 3 divided doses CHILD (8 years on and adolescents) Initial: 25mg per day, preferably at bedtime Increase in 25mg increments every 4 – 7 days if necessary up to a maximum of 200mg per day Dose over 50mg per day given in 2 divided doses Dosing is individualised and according to product insert/ protocol. Should not be used in patients under 18 years old except for the treatment of OCD. If, based on clinical need, a decision to treat is nevertheless taken; the patient should be carefully monitored for appearance of suicidal symptoms.","Blurred vision, dry mouth, tremor, gastrointestinal disturbances, somnolence, constipation, headache, insomnia, vomiting, dizziness, agitation, extrapyramidal effects, bradycardia, seizures, hepatotoxicity, withdrawal syndrome, Steven Johnson Syndrome, anphylactic reaction, abnormal ejaculation, hepatitis, asthenia, abnormal bleeding, hyponatremia, seizure, serotonin syndrome, worsening depression, hypomania, mania (rare), suicidal thoughts","Use of MAOI within 14 days, coadministration of terfenadine, astemizole or cisapride, may cause increased plasma concentrations of these drugs and an increased incidence of side effects, hypersensitivity to fluvoxamine","Warfarin, phenytoin, theophyline, propanolol, lithium, benzodiazepines, caffeine, ergotamine, MAOIs, sildenafil, statins, heparin, NSAIDs, aspirin, carbamazepin, clozapin, haloperidol, proton pump inhibitor, tricyclic antidepressants, grapefruit, St. John wort, dilatiazem, metoclopramide, serotonergic drugs, linezolid, tramadol, celecoxib","Concomitant use with MAOIs, hepatic insufficiency, children, epilepticus, geriatric, pregnancy, lactation, cardiovascular disease, avoid abrupt withdrawal, elderly, abnormal bleeding, hyponatremia, may activate mania or hypomania, history of seizure, suicidal ideation, worsening depression.",False
Folic Acid 5 mg Tablet,-,Blood and Blood Forming Organs > Antianemic Preparations,B03BB01000T1001XX,Yes,APPL,C+,i) For the prevention and treatment of folate deficiency states ii) For the prevention of neural tube defect in the foetus,6-12 years: 5mg/day ii) 5 mg daily starting before pregnancy and continued through the first trimester,i) ADULT initially 10-20mg mg daily for 14 days or until haematopoietic response obtained. Daily maintenance: 2.5 mg-10mg .CHILD up to 1 year:250 mcg/kg daily; 1 to 5 years:2.5mg/day;6-12 years: 5mg/day ii) 5 mg daily starting before pregnancy and continued through the first trimester,"GI disturbances, hypersensitivity reactions; bronchospasm.","Undiagnosed megaloblastic anaemia; pernicious, aplastic or normocytic anaemias.","Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.","Treatment resistance may occur in patients with depressed haematopoiesis, alcoholism, deficiencies of other vitamins. Large doses of folic acid may lower the blood concentration of vitamin B12.Folate dependent tumours, those with phenytoin,neonates.Should not be given until the diagnosis of pernicious anaemia has been ruled out.",False
Frusemide 10mg/ml Injection,Pharmaniaga Furosemide 20mg/2ml Injection,Cardiovascular System > Diuretics,C03CA01-000-P30-01-XXX,Yes,APPL,B,Oedema,None,Initial: 20-50mg once via slow IV or IM Maintenance: Increase by 20mg every 2 hours and titrate to an effective dose if necessary. CHILD: 0.5 - 1.5 mg/kg 6-24hourly. Dosing is individualised and according to product insert / protocol.,"Hypokalaemia, hyperuricaemia, hypotension, hyperglycaemia, hyponatremia","Anuria, hypersensitivity to furosemide, hepatic coma and pre-coma. Severe hypokalaemia, severe hyponatraemia, hypovolaemia with or without concomitant hypotension","Activated charcoal, amikacin, gentamicin, kanamycin, angiotensin converting enzyme inhibitors, aspirin, chloral hydrate, digoxin steroids, NSAIDs","Alterations in blood glucose and glucose tolerance tests. Diabetes mellitus, electrolyte imbalance (eg: hypokalaemia, hyponatraemia), fluid imbalance, dehydration, blood volume reduction with circulatory collapse and possible vascular thrombosis and emboli may occur with excessive diuresis, especially in elderly patients. Gout or hyperuricaemia. Hepatic disease (cirrhosis and ascites). Hypersensitivity to sulfonamides. Ototoxicity (hearing loss, tinnitus), avoid rapid injection, high doses or concurrent administration of other ototoxic agents. If high-dose therapy is used, controlled intravenous infusion is recommended at a rate not to exceed 4 mg/min. Severe progressive renal disease (azotemia, oliguria). Systemic lupus erythematosus",False
Perindopril 4 mg Tablet,,Cardiovascular System > Agents Acting on the Renin-angiotensin System,C09AA04000T1001XX,Yes,APPL,B,i) Hypertension ii) Stable coronary artery disease iii) Heart failure,None,i) & ii) Initial: 4mg once daily Max. 8mg daily iii) Initial: 2mg once daily Maintenance: 4mg once daily Dosing is individualised and according to product insert / protocol.,"Gastrointestinal disorders, dizziness, headaches, mood and or sleep disorders, asthenia, taste disorder, cramps, localized skin rashes, dry cough, angioneurotic oedema","Angioedema induced by other angiotensin converting enzyme (ACE) inhibitors. Hypersensitivity to this or any other angiotensin converting enzyme inhibitor. Pregnancy (second and third trimesters particularly), lactation.",Potassium supplements or potassium-sparing diuretics may induce hyperkalaemia especially in renal failure. Neuroleptics or imipramine-like antidepressants increase risk of postural hypotension. Serum lithium concentrations may rise during lithium therapy,"Arterial hypotension, renal failure, water and sodium depletion, renovascular hypertension, surgery or anaesthesia, elderly. Haemodialysis, avoid combination with highly permeable membranes (polyacrylonitrile). Measure plasma creatinine at baseline and during the month following institution of treatment. May precipitate excessive hypotension in severe chronic heart failure with or without associated renal insufficiency. Patients with ischaemic heart disease or cerebrovascular disease in whom excessive fall in blood pressure may result in myocardial infarction or cerebrovascular accident, hepatic impairment",False
Phenobarbitone (Phenobarbital) 30mg Tablet,Luminal,Nervous System > Antiepileptics,N03AA02-000-T10-02-XX,Yes,APPL,B,Epilepsy,None,ADULT: 60 - 180 mg daily on. CHILD: Up to 8 mg/kg daily,"Hypersensitivity, rash, hypotension, drowsiness, ataxia, respiratory depression, dyskinesias","Hypersensitivity to phenobarbital products, porphyria","Alcohol, antibacterial, warfarin, antidepressants, other antiepileptics, antipsychotics, antiviral, cyclosporin","Depression, renal impairment, pulmonary insufficiency, elderly, avoid abrupt discontinuation, pregnancy, breast feeding, porphyria, hyperactivity in children",False
Aqueous Cream,-,Dermatologicals > Emollients and Protectives,D02AX00-000-G10-01-XXX,Yes,APPL,C+,As an emollient for dry skin. Can be used as soap substitute for bathing.,None,As a soap or apply to the skin as an emollient cream,Not known,Not known,Not known,It should not be used before phototherapy or in phototesting procedures,False
Phenytoin Sodium 100mg Capsule,Dilantin,Nervous System > Antiepileptics,N03AB02-520-C10-02-XX,Yes,APPL,B,Control of tonic-clonic (grand mal) and psychomotor seizures,None,ADULT Initial: 300mg daily in 3 equally divided doses Maintenance: 300-400 daily in 3-4 equally divided doses Max. dose: 600mg daily CHILD Initial: 5mg/kg/day in 2-3 equally divided doses Maintenance: 4-8mg/kg/day Max. dose: 300mg daily Dosing is according to product insert.,"Nystagmus, ataxia, lethargy, blood dyscrasias, cardiovascular toxicity, nausea, vomiting, headache, tremor, insomnia, gingival hypertrophy, acne, lupus erythematosus, Stevens-Johnson syndrome, leukopenia, megaloblastic anaemia, hirsutism, hepatitis. Slurred speech, decreased coordination, mental confusion, constipation, toxic hepatitis, liver damage, hematopoietic complications, dermatological manifestations, agranulocytosis, bullous dermatosis, granulocytopenic disorder, liver damage, nephrotoxicity, pancytopenia, purpuric rash, scaling eczema, thrombocytopenia, toxic epidermal necrolysis","Hypersensitivity to phenytoin or hydantoin products, sinus bradycardia, SA block, second and third degree AV block and Adams-Stokes syndrome (intravenous phenytoin only)","Various drugs may increase phenytoin serum levels either by decreasing its rate of metabolism by the hepatic CYP450 2C9 and 2C19 enzymatic system (eg.disulfiram, omeprazole, ticlopidine), by competing for the protein binding sites (eg. salicylates, sulfisoxazole, tolbutamine), or by a combination of both processes (eg. phenylbutazone, valproate sodium). Some drugs may decrease phenytoin serum levels (eg. ciprofloxacin, theophylline, sucralfate).","Avoid abrupt withdrawal, liver insufficiency, porphyria, discontinue if skin rash occurs, diabetes, elderly, pregnancy, breast feeding. Severe myocardial insufficiency. Potential for an increase in risk of suicidal thoughts or behaviours.",False
Atenolol 100 mg Tablet,Pharmaniaga Atenolol Tablet 100 mg,Cardiovascular System > Beta Blocking Agents,C07AB03-000-T10-02-XXX,Yes,APPL,B,i) Hypertension ii) Arrhythmias iii) Angina pectoris iii) Myocardial infarction,None,"i), ii) & iii) 50 - 100 mg daily iv) Dosing is individualised and according to product insert / protocol.","Chronic heart failure, AV block, bradycardia, bronchospasm, dizziness, vertigo, nausea, fatigue, diarrhoea","Hypersensitivity to atenolol products, bradycardia, 2nd and 3rd degree AV block overt cardiac failure, cardiogenic shock, metabolic acidosis, severe peripheral circulatory disturbances, sick sinus syndrome","Clonidine, catecholamine-depleting agents, beta-blockers","Avoid abrupt withdrawal; gradual withdrawal over a period of 1 to 2 weeks is recommended. Bronchospastic disease, congestive heart failure, diabetes mellitus, hyperthyroidism/thyrotoxicosis. Patients receiving clonidine - discontinue atenolol several days prior to withdrawal of clonidine. Peripheral vascular and renal disease",False
Povidone Iodine 10% (equivalent to 1% iodine) Solution,-,Dermatologicals > Antiseptics and Disinfectants,D08AG02000L9902XX,Yes,LP,B,"Skin operation prior to surgery, in cleansing open wounds, as an antiseptic for operative wounds infections",None,To be applied undiluted in pre-operative skin disinfection and general antisepsis.,"Rash, pruritus, local oedema",Hypersensitivity to iodine or any component of the formulation,Not known,"Highly toxic if ingested, sodium thiosulfate is the most effective chemical antidote, avoid contact with eyes, use with caution in infants and nursing women",False
Atropine Sulphate 1mg/ml Injection,-,Alimentary Tract and Metabolism > Drugs for Functional Gastrointestinal Disorders,A03BA01-183-P30-01-XXX,Yes,APPL,B,"i) Reduce vagal inhibition,salivary and bronchiol secretion in anaesthesia ii) Reversal of excessive bradycardia iii) Reversal of effect of competitive muscle relaxants iv) Overdosage with other compounds having muscarinic action v) Organophosphate poisoning",None,"i) Adult: 300-600 mcg IM/SC 30-60 minutes before anaesthesia. Alternatively, 300-600 mcg IV immediately before induction of anaesthesia. Child: >20 kg: 300-600 mcg; 12-16 kg: 300 mcg; 7-9 kg: 200 mcg; >3 kg: 100 mcg. Doses to be given via IM/SC admin 30-60 minutes before anaesthesia. ii) Adult: 500 mcg every 3-5 minutes. Total: 3 mg. Max Dosage: 0.04 mg/kg body weight. iii) Adult 0.6-1.2 mg before or with anticholinesterase iv) Adult: 0.6-1 mg IV/IM/SC, repeated every 2 hr. v) Adult: 2 mg IV/IM, every 10-30 minutes until muscarinic effects disappear or atropine toxicity appears. In severe cases, dose can be given as often as every 5 minutes. In moderate to severe poisoning, a state of atropinisation is maintained for at least 2 days and continued for as long as symptoms are present. Child: 20 mcg/kg given every 5-10 minutes.","Dry mouth, dysphagia, constipation, flushing and dryness of skin, tachycardia, palpitations, arrhythmias, mydriasis, photophobia, cycloplegia, raised intraocular pressure. Toxic doses cause tachycardia, hyperpyrexia, restlessness, confusion, excitement, hallucinations, delirium and may progress to circulatory failure and resp depression. Potentially Fatal: Atrial arrhythmias, AV dissociation, multiple ventricular ectopi.","Glaucoma, chronic respiratory disease, sick sinus syndrome, thyrotoxicosis, cardiac failure, pyloric stenosis, prostatic hypertrophy.","Additive anticholinergic effects with quinidine, antidepressants and some antihistamines.","Reflux oesophagitis, elderly, infants and children. Pregnancy.",False
Prochlorperazine Mesylate 12.5 mg/ml Injection,,Nervous System > Psycholeptics,N05AB04253P3001XX,No,APPL,B,i) Severe nausea and vomiting ii) Vertigo/labyrinthine disorders,None,"Deep IM injection, 12.5 mg repeated if necessary after 6 hours and then followed by an oral dose. Not recommended in children","Extrapyramidal symptoms, drowsiness, postural hypotension, coma, neuroleptic malignant syndrome, cholestatic jaundice, leucopenia and agranulocytosis, constipation, dry mouth, urinary retention, liver damage and insomnia","CNS depression or coma, bone marrow depression, phaeochromocytoma, hypersensitivity to phenothiazines, comatose states, cardiovascular collapse","Tramadol, increased risk of seizures. Procyclidine, decreased phenothiazine serum concentrations, decreased phenothiazine effectiveness, enhanced anticholinergic effects (ileus, hyperpyrexia, sedation, dry mouth). Levodopa, loss of levodopa efficacy. Ethanol, increased central nervous system depression and an increased risk of extrapyramidal reactions","Hypotension, pregnancy and lactation, glaucoma, prostatic hypertrophy, stenosing peptic ulcer, children with acute illnesses, dehydration or electrolyte imbalance, signs and symptoms suggestive of Reye's syndrome in children and adolescents, patients with tardive dyskinesia or a history of neuroleptic malignant syndrome, epilepsy, acute narrow angle glaucoma, liver damage, insomnia, renal dysfunction, parkinson's disease, myasthenia gravis. May lower convulsive threshold thus dosage adjustments of anticonvulsants may be neccessary.",False
Prochlorperazine Maleate 5mg Tablet,,Nervous System > Psycholeptics,N05AB04253T1002XX,No,APPL,B,i) Severe nausea and vomiting ii) Vertigo/labyrinthine disorders,None,"Nausea and vomiting Adult: As maleate or mesilate: 20 mg, further doses are given if needed. Recommended buccal dose: As maleate: 3-6 mg bid. Vertigo Adult: As maleate or mesilate: 15-30 mg daily, given in divided doses. May reduce gradually to 5-10 mg daily. Recommended buccal dose: 3-6 mg bid. May be taken with or without food.","Cholestatic jaundice, cardiac arrhythmias, orthostatic hypotension, leucopaenia, thrombocytopaenia, dry mouth, blurring of vision, glaucoma, urinary retention, constipation, galactorrhoea, gynaecomastia, amenorrhoea and impotence. Buccal: Transient numbness of gum and tongue. Potentially Fatal: Bone-marrow suppression. Cardiac arrhythmias or aspiration.","CNS depression, comatose patients. Bone marrow depression, phaechromocytoma, prolactin-dependent tumours, hypersensitivity. Childn <2 yr. Pregnancy and lactation.","Additive anticholinergic effects with antihistamines, tricyclic antidepressants and drugs used in parkinsonism. May reduce the antihypertensive effect of guanethidine and other adrenergic neurone blockers. May also increase risk of arrhythmias when used with drugs that prolong QT interval. Potentially Fatal: Potentiation of other CNS depressants including alcohol, sedatives, hypnotics, barbiturates, opioids, antihistamines and general anaesthetics.","Extrapyramidal syndrome, hypotension, epilepsy, impaired hepatic, renal, CV, cerebrovascular or respiratory function, glaucoma. May impair ability to drive or perform tasks requiring mental alertness or physical coordination. Parenteral use in children is not recommended. History of jaundice, parkinsonism, diabetes mellitus, hypothyroidism, myasthenia gravis, paralytic ileus, prostatic hyperplasia or urinary retention. Regular eye examinations are recommended in patients on long-term treatment.",False
Promethazine HCl 25 mg/ml Injection,Phenergan,Respiratory System > Antihistamines for Systemic Use,R06AD02-110-P30-01-XXX,No,APPL,B,i) Allergic conditions ii) Treatment and prevention of vomiting including: - motion sickness - drug induced nausea - prevention and control of nausea and vomiting associated with certain types of anaesthesia and surgery,None,"i) Allergic Conditions Adult and adolescent dose: 25mg intramuscular or intravenous. May be repeated within 2 hours if required. Children 2 years and older: intramuscularly-0.125mg/kg body weight every 4 to 6 hours OR 0,5mg/kg bodyweight at bedtime as needed OR 6.25-12.5mg three times a day as needed OR 25mg at bedtime as needed. ii. Treatment and prevention of vomiting: - Motion Sickness Adult and adolescent dose: 25mg twice a day as needed. Children: 0.5mg/kg every 12 hours as needed OR 10 - 25mg twice a day as needed. - Anti Emetic Therapy Adult and adolescent dose: 25mg initially and then 10 -25mg every 4 - 6 hours as needed. Children: 0.25-0.5mg/kg every 4 to 6 hours as needed OR 10 - 25mg every 4 to 6 hours as needed. Dosing is individualised and according to product insert/protocol","Sedation, gastrointestinal disturbances, antimuscarinic effects, muscular weakness, tinnitus, allergic reactions, blood disorders, respiratory depression","Hypersensitivity to promethazine. Comatose patients, acute attack of asthma, children under 2 years, SC and intra- or peri-arterial injection","Antihypertensives, phenothiazines, alcohol, anticholinergics, tricyclic antidepressants, MAOIs, evening primrose oil","Pregnancy, lactation, cardiovascular or hepatic diseases, narrow angle glaucoma, asthma, COPD, pediatric patient, peptic ulcer, pyloduodenal obstruction, prostatic hypertrophy, to be used with caution and doctor's advice in children 2 to 6 years of age.",False
Azithromycin 250 mg Tablet,,Antiinfectives for Systemic Use > Antibacterials for Systemic Use,J01FA10-011-T10-01-XX,Yes,LP,"A*, A/KK",PRESCRIBER CATEGORY A*: (i) Treatment of complicated respiratory tract infections; (ii) Prophylaxis against Mycobacterium avium complex in patients with advanced HIV PRESCRIBER CATEGORY A/KK: (iii) Adult treatment of uncomplicated genital infections due to Chlamydia trichomatis or susceptible Neisseria gonorrhoea. (iv) Treatment of pertussis,A/KK,i) 500 mg daily for 3 days; ii) 1 g weekly iii) 1 g as a single dose; iv) 500mg in a single dose on day 1 then 250mg per day on days 2-5,"Nausea, abdominal discomfort, vomiting, flatulence, diarrhoea & loose stools. Hearing impairment, interstitial nephritis, acute renal failure, abnormal liver function, dizziness & vertigo, convulsions, headache, somnolence. Cardiac disorders: palpitations, arrhythmia, supraventricular tachycardia, QT prolongation, torsades de pointes. Skin and subcutaneous tissue disorders: allergic reactions, erythema multiforme, Steven-Johnson Syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), Severe cutaneous adverse reactions (SCARs). NPRA Safety Alert 1. 24 April 2025 Rare Risk of Cardiovascular Death",Known hypersensitivity to azithromycin or any of the macrolides,"Antacids, ergot derivatives. Monitor patients on concurrent warfarin, digoxin or cIclosporin","Moderate or severe renal impairment, liver impairment, pregnancy & lactation",True
Pyrazinamide 500mg Tablet,-,Antiinfectives for Systemic Use > Antimycobacterials,J04AK01-000-T10-01-XXX,Yes,APPL,B,Tuberculosis,None,Adult: 20-40mg/kg daily (max 1500mg) or 50mg/kg biweekly (max 2000mg). Children: 20-30mg/kg daily or 30-40mg/kg thrice weekly.,"Liver toxicity depending on treatment duration & concomitant therapy. Transient increase in serum transminase levels, acute atrophy of the liver. Nausea, vomiting, anorexia, diarrhoea, abdominal pain. Hyperuricaemia may occur with dosages more than 2 g/day","Porphyria, severe liver damage, acute liver disease, pregnancy, lactation","Concurrent use of pyrazinamide and zidovudine may result in decreased efficacy of pyrazinamide. Cyclosporin, ethionamide","Slightly impaired liver function, hyperuricaemia, arthralgia, renal insufficiency, diabetes mellitus",False
Pyridoxine HCl 10mg Tablet,,Alimentary Tract and Metabolism > Vitamins,A11HA02-110-T10-01-XXX,Yes,LP,C+,i)Pyridoxine-dependent convulsions in infant ii)Sideroblastic anaemia iii)B6-deficient anaemia in adult iv) Prophylaxis to peripheral neuritis in isoniazid therapy v) Nausea and vomiting of pregnancy and irradiation sickness,None,"i) INFANT 4 mg/kg daily for short periods ii) 100 - 400 mg daily in divided doses iii) ADULT 20 - 50 mg up to 3 times daily iv) Prophylaxis 10 mg daily, therapeutic 50 mg 3 times daily v) 20 - 100 mg daily","Peripheral sensory neuropathy, hypotonia, respiratory difficulties, nausea and other gastrointestinal complaints, photosensitivity, vesicular lesions and bullous lesions",Hypersensitivity to pyridoxine or any component of preparation,"Levodopa, penicillamine, selegiline, phenytoin","Pregnancy, lactation, neonatal seizures, concurrent treatment with levodopa. Long term use in a dose of 200 mg or more daily has been associated with neuropathy",False
Baclofen 10mg Tablet,Lioresal,Musculo-skeletal System > Muscle Relaxants,M03BX01-000-T10-01-XXX,No,APPL,B,Spasticity of the skeletal muscle,None,"ADULT:5 mg 3 times daily. Max: 80 mg daily (20mg 4 times a day). CHILD: starting dose: 0.3mg/kg/day in divided dose, titrate up cautiously in 1 -2 weeks interval. Usual maintenance dose: 0.75 - 2 mg/kg daily (age more than 10 years, maximum: 2.5 mg/kg daily). The dose should not exceed 40 mg/day in children below 8 years of age, but a maximum dose of 60 mg/day may be given in children over 8 years of age. Dosing is individualised and according to product insert/protocol","Daytime sedation, drowsiness, nausea and other central nervous system disorders, gastrointestinal disturbances, dysuria, frequency of micturition, enuresis or retention of urine, respiratory depression","Epilepsy and other convulsive conditions, corticol or subcorticol brain damage, peptic ulceration, known hypersensitivity to baclofen","Tricyclics and lithium enhance muscle relaxant effect, ACE inhibitor, diuretics and antihypertensives enhance hypotensive effect. Sedative effect enhanced with alcohol, anxiolytics and hypnotics. Excretion reduced by ibuprofen and possibly other NSAIDs","Pregnancy, patients suffering not only from spasticity but also from psychotic disorders, schizophrenia or confusional states, epilepsy, cerebrovascular or respiratory insufficiency. Central nervous system depressants, antihypertensives, levodopa. Caution in road users. Avoid abrupt discontinuation",False
Tranexamic Acid 250 mg Capsule,,Blood and Blood Forming Organs > Antihemorrhagics,B02AA02000C1001XX,Yes,LP,B,Haemorrhage associated with excessive fibrinolysis,None,"ADULT: 1-1.5 g (15-25 mg/kg) 2-4 times daily. CHILD: 25 mg/kg/day 2-3 times daily. Menorrhagia (initiated when menstruation has started), 1 g 3 times daily for up to 4 days; maximum 4 g daily","Nausea, vomiting, diarrhoea, hypotension, thrombosis, disturbances in colour vision","Severe renal impairment, thromboembolic disease, intravascular clotting process, disturbance of colour vision and subarachnoid haemorrhage","Anti-inhibitor coagulant complex, oral contraceptive, oestrogen, tretinoin","Cardiovascular disease, cerebrovascular disease, concomitant antifibrinolytic therapy. Concomitant therapy with oestrogens or thrombolytics. Renal impairment and transurethral prostatectomy (potential for intravesicular clotting)",False
Ranitidine 150 mg/10 ml Syrup,Zantac,Alimentary Tract and Metabolism > Drugs for Acid Related Disorders,A02BA02110L9001XX,No,LP,B,Peptic ulcer disease,None,CHILD 2-4 mg/kg 2 times daily. Maximum 300 mg daily,"Gastrointestinal disturbances, diarrhoea, altered liver function tests (rarely liver damage), headache, dizziness, rash and tiredness. Rare side-effects include acute pancreatitis, bradycardia, AV block, confusion, depression and hallucinations particularly in the elderly or the very ill, hypersensitivity reactions (including fever, arthralgia, myalgia, anaphylaxis), blood disorders (including agranulocytosis, leucopenia, pancytopenia, thrombocytopenia) and skin reactions (including erythema multiforme and toxic epidermal necrolysis). There have been occasional reports of gynaecomastia and impotence",Hypersensitivity to ranitidine,Absorption may be reduced by concomitant administration with high doses (2 g) of sucralfate,"H2-receptor antagonists should be used with caution in hepatic impairment, in renal impairment, pregnancy and in breast-feeding. H2-receptor antagonists might mask symptoms of gastric cancer. Avoid in porphyrias. Ranitidine and phenytoin is not recommended. If no alternatives exist, clinical monitoring of patient response, tolerance and serum phenytoin concentrations is recommended, especially during the first month of therapy",False
BCG Vaccine Freeze-Dried Injection,-,Antiinfectives for Systemic Use > Vaccines,J07AN01-000-P40-01-XXX,Yes,APPL,C+,For the prevention of tuberculosis.,None,0.05 to 0.1 ml by intradermal. Dosing is according to Immunisation Schedule under NIP.,"Superficial, self healing ulceration, injection site reaction, lymphadenopathy","Congenital or acquired cell-mediated immune deficiencies (including HIV), patients with systemic corticosteroid/ immunosuppressive treatment, malignant condition, pyrexia, generalised infected dermatoses, organ abnormalities, pregnancy.",Not known,"Children born to HIV positive mothers, pregnancy",False
Rifampicin 300mg Capsule,,Antiinfectives for Systemic Use > Antimycobacterials,J04AB02-000-C10-02-XXX,Yes,APPL,B,i) Tuberculosis ii) Leprosy iii) Prophylaxis for meningococcal meningitis iv)Staphylococcus biofilm related prosthetic joint infection or any biofilm sensitive to rifampicin in combination therapy with another antibiotic,None,i) ADULT: 450 - 600 mg as a single morning dose. CHILD: 10 - 20 mg/kg body weight daily in 1 - 2 doses. Directly observed therapy (DOT): 10 mg/kg twice weekly or 3 times/week. Maximum: 600 mg ii) ADULT: 600 mg/day CHILD: 10mg/kg iii) ADULT: 600 mg twice daily for 2 days CHILD: 10mg/kg twice daily for 2 days INFANT: 5mg/kg twice daily for 2 days iv) ADULT: 600mg OD CHILD: 10-20mg/kg/day in 1-2 divided doses Dosing is individualised and according to product insert/protocol.,"Flushing, itching, gastrointestinal reactions, pseudomembranous colitis, hepatitis, thrombocytopenia, muscle weakness. Flu syndrome may occur with intermittent dosage regimens. May produce a reddish brown discoloration of body fluids",Hypersensitivity and jaundice patient,"May reduce the activity of anticoagulant, corticosteroids, cyclosporin, digitalis, oral contraceptives, oral hypoglycaemics","Alcoholism, patients with impaired liver function, pregnancy, lactation",False
Benzhexol 2 mg Tablet,Artane,Nervous System > Anti-parkinson Drugs,N04AA01110T1001XX,Yes,APPL,B,"i) Symptomatic treatment of paralysis agitans and of parkinsonism, arteriosclerotic, idiopathic, or post-encephalitic origin ii) Alleviate extrapyramidal syndrome induced by phenothiazine derivatives or reserpine iii) Spasmodic torticollis, facial spasms and other dyskinesia",None,i) & iii) Initial: 1-2mg daily Maintenance: Gradual increment to 6-10mg daily according to response ii) 5-15mg daily Dosing is individualised and according to product insert / protocol.,"Severe mental disturbances, confusion, drowsiness, restlessness, hallucinations, excitement, nausea and vomiting, dry mouth, blurring of vision, constipation, urinary retention, glaucoma","Children under 3 years, narrow-angle glaucoma, closed-angle glaucoma, tardive dyskinesias, prostatic enlargement, paralytic ileus, chronic pulmonary disease, sick sinus syndrome, thyrotoxicosis, cardiac failure with tachycardia.",Alcohol and central nervous system depressants may increase the sedative effect of benzhexol. Delayed absorption of other oral drugs,"Autonomic neuropathy, heart disease, hepatic or renal disease, hyperthyroidism, paediatric, elderly, potential for abuse, prostatic hypertrophy, glaucoma, obstructive disease of gastrointestinal or genitourinary, pregnancy and lactation. Use with caution in patients with ileostomy or colostomy. Avoid driving or hazardous activities. Monitor intraocular pressure",False
Benzoyl Peroxide 5% Gel,Panoxyl,Dermatologicals > Anti-acne Preparations,D10AE01241G3001XX,Yes,LP,B,Mild to moderate acne vulgaris,None,Apply 1-2 times daily preferably after washing with soap and water,"Burning or stinging contact dermatitis, redness, Excessive drying of skin. Skin discoloration; skin rash, peeling, transient local oedema.",Hypersensitivity to benzoyl peroxide products,Not known,"Avoid contact with eyes, mouth and other mucous membranes. May bleach dyed clothing and fabrics. Avoid unnecessary sun exposure",False
Theophylline 250mg Long Acting Tablet,Nuelin SR,Respiratory System > Drugs for Obstructive Airway Diseases,R03DA04-000-T50-01-XXX,Yes,Government Contract,B,Reversible airways obstruction and acute severe asthma,None,ADULT: 250 mg 2 times daily. CHILD under 12 years : Up to 10 mg/kg body weight 2 times daily,"Gastric irritation,nausea, vomiting, anorexia, epigastric pain,reactivation of peptic ulcer, gasro esophageal reflux, haematemesis, tachycardia, palpiation, headache, CNS stimulation, reflex hyperexcitability, insomnia and tremor. Other possible reactions include diarrhea, extrasystoles, flushing, hypotension, tachypnoea, potentiation of diuresis, albuminuria, haematuria, rash, hyperglycemia, hypokalaemia, alopecia, inappropriate ADH secretion(high dose), more serious signs of high serum levels(usually above 30 microgram/mL) such as cardiac arrythmias and convulsions, may appear without prior warning",Hypersensitivity to theophylline,"Azole antifungals,macrolides, quinolones, oral contraceptives, disulfiram, interfereon alpha and verapamil, cimetidine, high dose allopurinol","Patients with reduced thyroid function, congestive heart failure, acute pulmonary oedema,chronic obstructive pulmonary disease, severe hypoxia, pneumonia, acute febrile episodes, viral infection, impaired liver function: reduced theophylline clearance. Patients with cardiac arrythmias, coronary artery disease, unstable angina, cardiomyopathy and severe hypertension.Patients with peptic ulcer disease or gastro esophageal reflux. Concomitant medication use which results in reduced theophylline clearance.",False
Thiamine Mononitrate 10mg Tablet,-,Alimentary Tract and Metabolism > Vitamins,A11DA01-221-T10-02-XXX,Yes,APPL,C,Prevention and treatment of thiamine deficiency state,-,Mild chronic deficiency: 5mg to 30mg daily Severe deficiency: up to 300mg daily,"Contact dermatitis, chronic pigmented purpura, skin rash, itching",Hypersensitivity to thiamine or any component,"Alkaline solutions, bicarbonates, carbonates, citrates, erythromycin lactobionate, iron salts, methohexital, neutral solutions, alkaline barbiturate solutions (eg phenobarbital, thiopental)",Not known,False
Prolase Tablet,Papase,Musculo-skeletal System > Other Drugs for Disorders of the Musculo-skeletal System,M09AB00000T1001XX,No,APPL,B,Oedema and inflammation in conjunction with other physical or chemotherapeutic measures,None,"2 tablet 4 times daily for the first day, then 1 tablet 4 times daily for at least 5 days.","Skin rash, vertigo and gastrointesinal upsets",Blood clotting disease,No known,Renal or hepatic dysfunction and pregnancy,False
"Zinc oxide, benzyl benzoate and balsam peru suppository",,Cardiovascular System > Vasoprotectives,C05AX04931S1001XX,No,APPL,C,"For relief of pruritus, burning and soreness in patients with haemorrhoids and perianal conditions",C,Insert 1 suppository night and morning after bowel movements; do not use for longer than 7 days OR please refer to the product insert.,Local irritation,Hypersensitivity to any component of preparation,Not known,Not for prolonged use. Use in children is not recommended,False
Cephalexin Monohydrate 500mg Capsule,Ceporex,Antiinfectives for Systemic Use > Antibacterials for Systemic Use,J01DB01-010-C10-02-XXX,Yes,LP,B,"i) Respiratory tract infection, urinary tract infection ii) Complicated, recurrent or chronic infections, bronchitis iii) Pneumonia",None,i) 250 mg 6 hourly ii) 250 - 500 mg 6 hourly iii) 1 - 1.5 g 3 times daily or 4 times daily. Maximum: 6 g/day,"GI disturbances, overgrowth of non-susceptible organisms, hypersensitivity reactions, reversible neutropenia",Hypersensitivity to cephalosporins,Concurrent treatment with high doses of cephalosporins& aminoglycosides or potent diuretics may adversely affect renal function. Probenecid may increase or prolong plasma level& toxicity of cephalosporins,"Hypersensitivity to penicillins, renal impairment, superinfection",False
Cetirizine HCl 10mg Tablet,,Respiratory System > Antihistamines for Systemic Use,R06AE07-110-T10-01-XXX,Yes,LP,B,"Urticaria, allergic dermatoses (insect bites, atopic eczema), perennial rhinitis, allergic rhinitis",None,ADULT and CHILD over 6 years:10 mg daily or 5 mg twice daily. Child 2-6 years: 5 mg once daily or 2.5 mg twice daily,"Somnolence, fatigue, headache and dry mouth, pharyngitis, abdominal pain, coughing, diarrhoea, epistaxis, bronchospasm, nausea, vomiting,","Hypersensitivity to cetirizine or hydroxyzine, not to be used in children less than 2 years of age.",Decreased cetirizine clearance resulting in elevated cetirizine serum concentrations and possibly cetirizine toxicity with theophylline,"Activities requiring mental alertness. Concurrent use of central nervous system depressants. Renal insufficiency or hepatic dysfunction, elderly. To be used with caution and doctor's advice in children 2 to 6 years of age.",False
Cetrimide 1-2% Lotion.,Cetavlon,Dermatologicals > Antiseptics and Disinfectants,D08AJ04000L6001XX,No,APPL,C+,As shampoo and cleansing agent,None,Apply to affected area,Cutaneous irritation and local effects,Hypersensitivity to cetrimide,Not known,"Contact with the eyes, brain, meninges, and middle ear should be avoided. Cetrimide should not be used in body cavities or as an enema",False
"Charcoal, Activated 250mg Tablet",-,"Alimentary Tract and Metabolism > Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents",A07BA01-000-T10-01-XXX,Yes,LP,C,"i) Diarrhoea and food poisoning; ii) Reduce absorption of drugs, plant, inorganic poison and chemicals in poisoning cases.",None,i) ADULT: 500mg -1000mg given 3-4 times daily. CHILD (up to 12 years): 250-500mg 3-4 times daily. ii) ADULT and CHILD over 12 years: initial 25-100 g or 1-2g/kg; repeat initial dose as soon as possible or 25-50 g every 4-6 hours. CHILD (up to 12 years): 0.5 to 1 g/kg/dose (Maximum: 50 g/dose). Dose may be repeated every 2-6 hours as needed.,Black stools and gastrointestinal disturbances,"An unprotected airway, gastrointestinal tract not anatomically intact","Acarbose, carbamazepine, digoxin, frusemide, olanzapine, phenytoin; decreased effectiveness of these drugs, reduce absorption of oral therapy and render their effectiveness, simultaneous oral therapy should be avoided. Clear activated charcoal from stomach /avoid its usage if methionine (specific oral antidote) is to be used","Aspiration of charcoal, hydrocarbons, corrosive, imaging of gastroesophageal. Caution in patient at risk of gastrointestinal obstruction",False
Chloramphenicol 0.5% Eye Drops,Nicol Eye Drops 0.5% W/V,Sensory Organs > Ophthalmologicals,S01AA01-000-D20-01-XXX,Yes,Government Contract,C,Ophthalmic infections,None,Instill 1 drop of a 0.5% solution every 2 hr. Increase dosage interval upon improvement.,"Allergic reactions, superinfection, bone marrow hypoplasia including aplastic anaemia",Hypersensitivity to chloramphenicol products,Not known,Overgrowth of non-susceptible organisms in prolonged use,False
Chloramphenicol 1% Eye Ointment,Chloromycetin,Sensory Organs > Ophthalmologicals,S01AA01-000-G51-01-XXX,Yes,APPL,C,Treatment of ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol susceptible organisms,None,"ADULT and CHILD : Apply to the conjunctiva, a thin strip (approximately 1 cm) of ointment every 3 hours or more frequently","Allergic reactions, superinfection, bone marrow hypoplasia including aplastic anaemia",Hypersensitivity to chloramphenicol products,Not known,Overgrowth of non-susceptible organisms in prolonged use,False
Chloramphenicol 5% w/v Ear Drops,Chloromycetin,Sensory Organs > Otologicals,S02AA01-000-D10-01-XXX,Yes,APPL,C,"Acute otitis media, otitis externa with perforation",None,Apply 2 - 3 drops into the ear 2 - 3 times daily. Not to be used for long term,"Sensitivity to the vehicle propylene glycol, local irritation with symptoms of burning, itching, urticaria, transient stinging","Hypersensitivity to chloramphenicol products, perforated tympanic membrane, chronic otitis media with perforation","With other antibacterials, antiepileptics, anticoagulants, cyclosporin",Use with caution in the presence of perforated tymphanic membrane. Overgrowth of non-susceptible infection over prolonged use,False
Chlorhexidine Gluconate 5% Solution,,Dermatologicals > Antiseptics and Disinfectants,D08AC02-137-L99-01-XXX,Yes,APPL,C+,Use as antiseptic and disinfectant in: i) Preoperative skin disinfection; ii) Emergency disinfection of instruments; iii) Wounds or burns.,None,To be used as diluted solution: (i) 0.5 % w/v Aqueous solution : Dilute 10 ml of solution with 70% alcohol up to 100ml. (ii) 0.5 % w/v Aqueous solution : Dilute 10 ml of solution with 70% alcohol up to 100ml. Immerse for 2 minutes (iii) 0.05 % w/v aqueous solution : Dilute 1 ml of solution with 100 ml of sterile water.,"Mucosal irritation (discontinue if desquamation), parotid gland swelling, irritation and gastrointestinal disturbances. Inhalation of solvent vapours may give rise to nausea, headaches and dizziness",Hypersensitivity to any of its components,Avoid cemented glass components,"Avoid contact with meninges, application into hairy areas and not use as a preoperative skin preparation for the face or head. Keep disinfectant solution out of the eyes, ears and mouth",False
Clonazepam 0.5mg Tablet,Rivotril,Nervous System > Antiepileptics,N03AE01-000-T10-01-XX,Yes,LP,B,i) Epilepsy ii) Non-epileptic myoclonus,None,"i) & ii) ADULT: Initial dose should not exceed 1.5mg/day divided into 3 doses, may be increased in increments of 0.5mg every 3 days until seizures are controlled. Maintenance dose: 3-6mg/day. Maximum: 20mg/day. CHILD up to 10 years: initial dose 0.01-0.03 mg/kg/day in 2-3 divided doses, increased by no more than 0.25-0.5mg every third day, maximum 0.2mg/kg/day. CHILD 10-16 years: initial dose 1-1.5mg/day in 2-3 divided dose, may be increased by 0.25-0.5mg every third day until individual maintenance dose of 3-6mg/day is reached.","Drowsiness, ataxia, aggravation of seizure, fatigue, dizziness. Tiredness, sleepiness, lassitude, muscular hypotonia, muscle weakness, light-headedness, ataxia, slowed reaction, poor concentration, restlessness, confusion, agitation, excitability, irritability, disorientation, anterograde amnesia, depression. Increased production of saliva or bronchial secretions in infants and young children, coordination disturbances, vertigo, anorexia, visual disturbances, libido changes","Hypersensitivity to clonazepam products and benzodiazepines, severe liver disease, narrow angle glaucoma, respiratory depression, acute pulmonary insufficiency","Phenytoin, phenobarbital, carbamazepine and valproate may increase the clearance of clonazepam. Combination with valproate may cause petit mal status epilepticus. Enhanced effects on sedation, respiration and hemodynamics when co-administered with any central acting depressants including alcohol","Avoid abrupt withdrawal, renal insufficiency, respiratory disease, acute intermittent porphyria, uncontrolled open angle glaucoma, elderly, pregnancy, lactation, may exacerbate tonic seizures. Patients with spinal or cerebellar ataxia, acute alcohol or drug intoxification, severe liver damage, sleep apnoea, renal and hepatic diseases. History of depression and or suicide attempts. Simultaneous use of other anti-epileptics. Avoid driving and operating machinery",False
Carbimazole 5 mg Tablet,Neo-mercazole,"Systemic Hormonal Preparations, excl. Sex Hormones and Insulins > Thyroid Therapy",H03BB01000T1001XX,Yes,APPL,B,Hyperthyroidism,None,"ADULT: Initially, 10-60mg daily in divided doses given 8 hourly. Maintenance: 5 to 20mg daily. CHILDREN > 6 years: Initially 15mg daily in divided doses. CHILDREN 1-6 years: Initially 7.5mg daily in divided doses","Skin rashes, nausea, headache, gastrointestinal disturbances, hepatic disorders, neutropenia, agranulocytosis. Rarely, pancytopenia / aplastic anaemia, haemolytic anaemia","Blood dyscrasias, hypersensitivity, tracheal obstruction","Concurrent use of digoxin and carbimazole may result in decreased peak serum levels of digoxin. Antithyroid drugs, by reducing the extent of hyperthyroidism, decrease the metabolism of clotting factors and thus reduce the effects of oral anticoagulants","Liver disorders, pregnancy (discontinue 3-4 weeks before delivery), lactation",False
Ceftriaxone 0.25g Injection,Rocephin,Antiinfectives for Systemic Use > Antibacterials for Systemic Use,J01DD04-520-P40-01-XXX,Yes,LP,A/KK,i) Gonorrhoea ii) Chancroid,None,i) 250 mg by deep IM injection ii) single IM injection 250 mg only. For severe infection up to 100 mg/kg/day,"GI upsets, haematological changes, skin reactions, coagulation disorders, phlebitis, agranulocytosis, renal precipitations NPRA Safety Alert 1. 31 Jan 2019 Disturbed consciousness, convulsions or involuntary movements 2. 20 Apr 2021 Risk of Encephalopathy 3. 5 Sept 2023 Risk of Seizures","Hypersensitivity to cephalosporins. Neonates aged less than or 28 days if they require treatment with calcium-containing intravenous solutions, including calcium-containing infusions such as parenteral nutrition, because of the risk of precipitation of ceftriaxone-calcium","Ciclosporin, typhoid vaccine","Previous hypersensitivity to penicillins, anaphylactic shock, severe renal& hepatic failure, pregnancy. Ceftriaxone and calcium -containing solutions may be administered sequentially to one another if the infusion lines are thoroughly flushed between infusions with compatible fluid. Diluents containing calcium (Ringer's / Hartmann's solution) are not to be used to reconstitute ceftriaxonevials or to further dilute a reconstituted vial for IV administration because a precipitate can form. Ceftriaxone must not be administered simultaneously with calcium- containing intravenous solutions, including continous calcium -containing infusions such as parenteral nutrition via a Y-site, because precipaitation of ceftriaxone-calcium can occur",True
Cefuroxime Axetil 250 mg Tablet,Zinnat,Antiinfectives for Systemic Use > Antibacterials for Systemic Use,J01DC02-233-T10-02-XXX,No,APPL,A/KK,"Upper and lower respiratory tract, genito-urinary tract, skin & soft tissue and urinary tract infections (UTI)",None,"ADULT: Most infections: 250 mg twice daily Severe infections: 500mg twice daily CHILD: Most infections: 125mg twice daily or 30 mg/kg/day in 2 divided doses, up to 500 mg daily Severe infections: 250mg twice daily Dosing is individualised and according to package insert","GI disturbances occasionally pseudomembraneous colitis, hypersensitivity reactions, eosinophilia, headache, superinfection NPRA Safety Alert 1. 31 Jan 2019 Disturbed consciousness, convulsions or involuntary movements 2. 5 Sept 2023 Risk of Seizures",Hypersensitivity to cephalosporins,"Drugs which reduce gastric acidity, such as proton pump inhibitors and H2 antagonists","Anaphylactic reaction to penicillins, Severe renal impairment; pregnancy, lactation",True
Clotrimazole 1% Cream,,Dermatologicals > Antifungals for Dermatological Use,D01AC01-000-G10-01-XXX,Yes,LP,B,"For treatment of fungal infection (eg: cutaneous candidiasis, tinea orporis, tinea cruris, tinea pedis and tinea versicolor).",None,"Apply on affected area twice daily, optimally for 4 weeks including 2 weeks after lesions have cleared.","Skin reactions, contact dermatitis, pruritis",Hypersensitivity to clotrimazole,Not known,Contact with eyes and mucous menbranes should be avoided,False
Cloxacillin Sodium 125mg/5ml Suspension,Orbenin,Antiinfectives for Systemic Use > Antibacterials for Systemic Use,J01CF02-520-L80-01-XXX,Yes,APPL,B,"Treatment of susceptible bacterial infections, notably penicillinase-producing staphylococci",None,Child: 50-100 mg/kg in divided doses every 6 hr,"Neutropenia, agranulocytosis; GI upsets; rash. Sore mouth or tongue. Black hairy tongue.Neuromuscular hypersensitivity; pseudomembranous colitis; anaphylaxis.","Hypersensitivity to cloxacillin products/penicillins, cephalosporins",Probenecid impairs renal excretion. Decreases anticoagulant effect,Renal impairment. Neonates born to mothers hypersensitive to penicillin. Hypersensitivity to cephalosporins. History of ulcerative colitis. Supra-infection with prolonged used.,False
Colchicine 0.5mg Tablet,-,Musculo-skeletal System > Antigout Preparations,M04AC01-000-T10-01-XXX,Yes,LP,B,"i) Acute gout and prophylaxis of recurrent gout. ii) Leucocytoclastic Vasculitis either cutaneous or systemic involvement, Behcet's syndrome, Urticarial vasculitis, Systemic sclerosis, Sweet's syndrome and severe recalcitrant aphthous stomatitis",None,"i) Acute gout: Initial dose, 1 mg, then 0.5 mg after 1 hour. No further tablets should be taken for 12 hours. After 12 hours, treatment can resume if necessary with a maximum dose of 500 micrograms (1 tablet) every 8 hours until symptoms are relieved. The course of treatment should end when symptoms are relieved or when a total of 6 mg (12 tablets) has been taken. No more than 6 mg (12 tablets) should be taken as a course of treatment. After completion of a course, another course should not be started for at least 3 days (72 hours). Prophylaxis of recurrent gout: 0.5 mg bd. ii) 0.5 mg 1-3 times daily depends on disease and severity, up to a maximum of 3 mg/day","Bone marrow depression with aplastic anaemia, peripheral neuritis, myopathy, hair loss, gastrointestinal disturbances, epigastric pain, diarrhoea, nausea, vomiting, myelosuppression, abdominal pain, diarrhoea, gastrointestinal haemorrhage, rashes, renal and hepatic damage in excessive doses. Rarely peripheral neuritis, myopathy, alopecia and with chronic therapy blood disorders like agranulocytosis, aplastic anaemia","Serious GI, renal, hepatic & cardiac disorders and those with blood dyscrasias, hypersensitivity to colchicine, children under 2 years old, pregnancy, debilitated patients, SC/IM administration","Reversible malabsorption of Vit B12, action inhibited by acidifying agents & enhanced by alkalinizing agents, cyclosporin, erythromycin. Response to CNS depressants and sympathomimetics may increase when used concurrently with colchicine. Increased risk of myopathy when used concurrently with simvastatin. Potential risk of severe drug interactions, including death in certain patients treated with colchicine and concomitant P-glycoprotein or strong CYP3A4 inhibitors such as clarithromycin, ciclosporin, erythromycin, calcium channel antagonists (verapamil, diltiazem), telithromycin, ketoconazole, itraconazole, HIV protease inhibitors and nefazodone. P-glycoprotein or strong CYP3A4 inhibitors are not to be used in patients with renal or hepatic impairment who are taking cochicine. A dose reduction or interruption of colchicine treatment should be considered in patients with normal renal and hepatic function if treatment with a P-glycoprotein or a strong CYP3A4 inhibitors required. Avoid consuming grapefruit and grapefruit juice while using colchicine","Pregnancy, lactation, children and elderly, GI disease, cardiac, renal and hepatic impairment. Prolonged therapy not recommended",False
Gabapentin 300 mg Capsule,Neurontin,Nervous System > Antiepileptics,N03AX12-000-C10-01-XX,Yes,Government Contract,"A*, A/KK","PRESCRIBER CATEGORY A*: Add-on therapy for intractable partial epilepsy, refractory to standard anti-epileptic drugs. PRESCRIBER CATEGORY A/KK: Treatment of various types of neuropathic pain, both peripheral (which includes diabetic neuropathy, post-herpetic neuralgia, trigeminal neuralgia) in adult more than 18 years.",PAIN FREE CLINIC ONLY ,"ADULT & CHILD > 12 yrs: 900-3600mg/day. Therapy may be initiated by administered 300mg TDS on day 1, or by titrating the dose as: 300mg once on day 1, 300mg BD on day 2, 300mg TDS on day 3. Thereafter, may be increased in 3 equally divided doses up to max 3600mg/day.CHILD 3-12 yr: Initially 10-15 mg/kg/day in 3 divided dose. Effective dose: CHILD 3 to less than 5 yrs: 40mg/kg/day in 3 divided doses, CHILD 5-12 yrs: 25-35mg/kg/day in 3 divided doses ii) ADULT: 900mg/day in 3 equally divided doses. Max 3600mg/day","Somnolence, dizziness, ataxia, weight gain, fatigue, nystagmus, tremor, diplopia, amnesia, dyspepsia, asthenia, leukopenia, headache, myalgia",Hypersensitivity to gabapentin,Antacid like Maalox reduced the bioavailability of gabapentin,"Renal insufficiency, patients less than 12 years old, diabetes, pregnancy, lactation, elderly, renal impairment, haemodialysis, absence seizures. Avoid abrupt withdrawal. Discontinuation of gabapentin and or addition or substitution of alternative therapy should be gradual, over a minimum of 1 week. May affect ability to drive or operate machinery. Potential for an increase in risk of suicidal thoughts or behaviours",True
Gemfibrozil 300mg Capsule,Pharmaniaga Gemfibrozil Capsule 300mg,Cardiovascular System > Lipid Modifying Agents,C10AB04-000-C10-01-XX,Yes,APPL,A/KK,"Treatment of hyperlipoprotinaemias (TYPES IIA, IIB, III, IV, V)",None,"ADULT: 1200 mg/day in 2 divided doses, 30 minutes before breakfast and dinner. Dose range from 0.9-1.5 g daily","Myositic syndrome, cholelithiasis, GI disturbances, rash, headache, blood dyscrasias, myalgia. Impotence, painful extremities, blurred vision; pruritus, urticaria; impotence; dizziness; cholestatic jaundice. Potentially Fatal: Bone marrow hypoplasia; intracranial haemorrhage; nephrotoxicity; peripheral neuritis.","Hypersensitivity to gemfibrozil, severe hepatic or renal dysfunction, gall stones, neonates, children, pregnancy, lactation",Co-admin with repaglinide may lead to an increase in the serum levels of repaglinide. May enhance the effects of oral anticoagulants. May also increase the plasma concentrations of ciclosporin and associated nephrotoxicity when used concurrently,"Cholelithiasis, concomitant use of anticoagulants and hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) risk of rhabdomyolysis. Diabetes, hypothyroidism, not recommended for patients with type IIa hyperlipidemia (low-density lipoproteins cholesterol elevations only)",True
Glycerin,-,Alimentary Tract and Metabolism > Drugs for Constipation,A06AX01000L5001XX,No,LP,C+,As a lubricant and osmotic dehydrating agent,None,Apply to area when required,"Mainly due to dehydration action, irritation",Not known,Not known,"Cause irritation when given locally, local anesthetic may be used before application",False
Glycerin 25% and Sodium Chloride 15% Enema,,Alimentary Tract and Metabolism > Drugs for Constipation,A06AG20921G2001XX,Yes,APPL,C+,Constipation,None,1 enema as required,"Rectal discomfort, burning sensation",Hypersensitivity to any component in the preparation,Not known,Frequent or prolonged use of laxatives may result in dependence,False
Glyceryl Trinitrate 5mg/ml Injection,Gitrinil Injection 10 ml Amp,Cardiovascular System > Cardiac Therapy,C01DA02-221-P30-01-XXX,No,APPL,A,i) Angina pectoris. ii) Congestive heart failure. ii) Control of hypertensive episodes. iv) Production of controlled hypotension during surgery.,None,Initial: 5-25mcg/min Dosing is individualised and according to product insert or protocol.,"Flushing, dizziness, tachycardia and throbbing headache. Large doses cause vomiting, restlessness, blurred vision, hypotension (which can be severe), syncope and rarely cyanosis and methaemoglobinaemia, impairment of respiration and bradycardia","For IV :Constrictive pericarditis, pericardial tamponade, restrictive cardiomyopathy, symptomatic hypotension, hypersensitivity to organic nitrates","Hypotensive effect enhanced by alcohol, beta blockers, antihypertensives, tricyclic antidepressants, narcotics, sildenafil. May potentiate effects of antihistamines, anticholinergics. Antagonises pressor action of sympathomimetics",Severe renal or hepatic impairment. Need to be diluted for infusion via approved administration sets only. Absorption by plastics & filters. Nitrate-free interval is recommended in patients on continuous treatment with nitrates to reduce the risk of tolerance,True
Griseofulvin 125mg Tablet,Fulcin,Dermatologicals > Antifungals for Dermatological Use,D01BA01-000-T10-01-XXX,Yes,APPL,B,"Dermatophyte infections of the skin, scalp, hair and nails, where topical therapy has failed or inappropriate",None,"Adults: 500mg-1000mg daily, taken as a single dose or in divided; Children: 10mg-20mg/kg daily in divided doses. The dosing is individualized according to product insert / protocol","Significant: Onset or exacerbation of SLE, photosensitivity reaction, rarely, leucopenia, granulocytopenia. Gastrointestinal disorders: Diarrhoea, dry mouth, vomiting, nausea, gastric discomfort, epigastric distress, oral candidiasis. Rarely, gastrointestinal haemorrhage. General disorders and administration site conditions: Fatigue. Nervous system disorders: Headache, dizziness, paraesthesia, impaired coordination, peripheral neuropathy. Psychiatric disorders: Confusion, insomnia. Renal and urinary disorders: Rarely, nephrosis, proteinuria. Skin and subcutaneous tissue disorders: Rash, urticaria, irritation (e.g. stinging, burning). Potentially Fatal: Severe skin reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme), photosensitivity, hepatotoxicity (e.g. jaundice, elevated LFT or bilirubin). NPRA Safety Alert 1. 3 Mei 2023 Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalised exanthematous pustulosis, erythema multiforme.","Established porphyria, hepatocellular failure, SLE and related conditions, pregnancy",Antagonises oral anticoagulants and oral contraceptives. Decreased GI absorption with phenobarbital. Reduced plasma concentrations with enzyme inducers e.g. phenylbutazone and hypnotics. Enhances effects of alcohol and causes disulfiram-like reaction.,"Lactation; ability to drive or operate machinery may be impaired; avoid exposure to intense sunlight or artificial light. May damage sperm cells - male should not father children within 6 month of treatment NPRA Safety Alert 1. 3 Mei 2023 Severe cutaneous adverse reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalised exanthematous pustulosis) and erythema multiforme have been reported with griseofulvin use. These reactions may be serious and may result in hospitalisation or death. If severe skin reactions occur, griseofulvin should be discontinued.",False
Haloperidol 5 mg Tablet,,Nervous System > Psycholeptics,N05AD01-000-T10-02-XXX,Yes,LP,B,"i) Psychotic disorder – management of acute and chronic psychotic disorders including schizophrenia, manic states and drug-induced psychoses ii) Management of aggressive and agitated patients, including patients with chronic brain syndrome or mental retardation. iii) Gilles de la Tourette’s syndrome - for the control of tics and vocalisations of Tourette’s syndrome in children and adults.",None,"ADULT: moderate symptoms: 0.5mg to 2.0mg bid/tid; severe symptoms, chronic or resistant: 3.0mg to 5.0mg bid/ tid Geriatric / dehabilitated : 0.5mg to 2.0mg bid/tid maximum up to 100mg daily CHILD: 3-13 years old (15 to 40 kg): 0.5mg/day increase by 0.5mg at 5 to 7 days in bid/tid, dosing range 0.05mg/kg/day to 0.15mg/kg/day Dosing is according to product insert.","Extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, hypotension, tachycardia, insomnia, anxiety, weight changes, anticholinergic effects, gynaecomastia, galactorrhoea, menstrual irregularities, neuroleptic malignant syndrome, arrhythmias, seizure, jaundice, hyperpyrexia, anxiety, depression, anorexia, leukopaenia","Parkinson's disease, severe CNS depression, bone marrow suppression, severe cardiac or hepatic disease, comatose states, hypersensitivity to haloperidol. Lactation","Tramadol, fluoxetine, fluvoxamine, carbamazepine, cisapride,dicoumarol, procyclidine, methyldopa, olanzapine, rifampicin, lithium, tricyclic antidepressants. May increase the plasma levels of haloperidol when used with clozapine or chlorpromazine","Concomitant anticoagulant use, concomitant CNS depressant use (anaesthetics, opiates, and alcohol), history of convulsive disorders, known allergies or allergic reactions to drugs, manic patients, neuroleptic malignant syndrome, elderly patients, impaired liver function, CV disease, thyrotoxicosis, parkinsonism, angle-closure glaucoma, benign prostatic hyperplasia; severe cardiac or hepatic disease, presence of acute infections or leucopaenia, hyperthyroidism, pregnancy, elderly, children. Patients receiving anticoagulants. Discontinue treatment upon signs of neurological toxicity in patients taking lithium. Temperature regulation: Impaired core body temperature regulation may occur",False
Hyoscine N-Butylbromide 10mg Tablet,,Alimentary Tract and Metabolism > Drugs for Functional Gastrointestinal Disorders,A03BB01-320-T10-01-XXX,Yes,APPL,C,"Gastrointestinal tract and genito-urinary tract spasm, dyskinesia of the biliary system.",Medical Assistant in health settings without Medical Officer is allowed to prescribe this medicine for adult use only.,"ADULT 10-20mg, 3-4 times a day. CHILD 6-12 years old: 10mg 3 times a day.","Xerostomia, dyshidrosis, tachycardia, urinary hesistancy and retention, allergic reactions, skin reactions, confusions, excitement, constipation, paralytic ileus","Obstructive disease of the gastrointestinal or urinary tract, narrow-angle glaucoma, cardiac tachyarrhythmias, myasthenia gravis, prostatic hypertrophy with urinary retention","Intensifies anticholinergic effects of tricyclic antidepressants, antihistamines, quinidine, amantadine and disopyramide. Enhances tachycardic effects of beta-adrenergic agents. Dopamine antagonist eg metoclopramide reduces effects of both drugs on gastrointestinal tract","Geriatric and pediatric patients, pregnancy, breastfeeding, intestinal atony, paralytic ileus and ulcerative colitis, coronary artery diseases, arrhythmias , heart failure, hypertension, xerostomia, hiatal hernia with reflux esophagitis, prostatic hypertrophy.",False
Ketoprofen 2.5% Gel,Orudis,Musculo-skeletal System > Topical Products for Joint and Muscular Pain,M02AA10-000-G30-01-XXX,No,LP,A/KK,"Local treatment of osteoarticular & muscular painful disorders of rheumatic or traumatic origin: Contusions, distortions, muscle strains, stiff neck, lumbago.",-,Apply onto affected areas 2-4 times daily up to 10 days.,Pruritus and localised erythema,"Hypersensitivity. Avoid in patients whom aspirin or other NSAIDs-induced asthma or other allergic-type reactions. Avoid in patient with exudative dermatoses, eczema sores & infected skin or broken skin. Do not apply to the mucous membranes or eyes.",Not known,"Bronchial asthma. Avoid in children less than 5 years. If skin rash occurs after gel application, treatment should be stopped. Severe renal impairment. Avoid direct excessive sunlight during treatment or 2 weeks following treatment discontinuation. Pregnancy and lactation.",True
Labetalol HCl 100mg Tablet,,Cardiovascular System > Beta Blocking Agents,C07AG01-110-T10-01-XX,Yes,APPL,B,"i) Mild, moderate or severe hypertension ii) Hypertension in pregnancy",None,i) & ii) Initial: 100mg twice daily Maintenance: 200-400mg twice daily Max. 2400mg daily in 3 or 4 divided doses Dosing is individualised and according to product insert / protocol.,"Hypotension, bradycardia, nausea, vomiting NPRA Safety Alert 1. 17 Okt 2022 Nipple pain, Raynaud's phenomenon of the nipple","Hypersensitivity to labetalol products, bradycardia, asthma/obstructive airway disease, cardiogenic shock, heart block overt cardiac failure","Alpha-1 adrenergic blockers, amiodarone, cimetidine, clonidine, digoxin, dihydropyridine, calcium channel blockers, diltiazem, enflurane, epinephrine, flunarizine, halothane, hypoglycemic agents, imipramine, isoflurane, lidoflazine, methyldopa, verapamil","Anaesthesia/surgery, including when used in cases to control bleeding (myocardial depression). Avoid abrupt withdrawal; gradual withdrawal over a period of 1 to 2 weeks is recommended. Bronchospastic disease, congestive heart failure, diabetes mellitus. The bioavailability and half-life of labetalol are increased in the elderly. In addition, the hypotensive response is greater in this age group following oral or i.v. administration. Therefore, lower doses of labetalol are likely to be required in elderly patients.",False
Levonorgestrel 150mcg and Ethinyloestradiol 30mcg Tablet,Rigevidon,Genito Urinary System and Sex Hormones > Sex Hormones and Modulators of the Genital System,G03AA07-954-T10-01-XXX,Yes,LP,C+,Contraception,None,"1 tablet daily for 21 days from first day of the cycle, followed by 7 tab free days","Thromboembolic disease, hypertension, gall bladder disease, nausea, vomiting, migraine","Thromboembolic disorders, cardiovascular disease, breast or endometrial cancer, oestrogen dependent neoplasia, undiagnosed abnormal vaginal bleeding, cholestatic jaundice of pregnancy, hepatic adenomas or carcinomas, known or suspected pregnancy","Effectiveness may be reduced by antibiotics, phenytoin, carbamazepine, barbiturates, rifampicin","Age, smoking, gall bladder disease, diabetes, hypertension, epilepsy, migraine, cardiac or renal dysfunction, history of depression, uterine fibroids, lactation. Gastrointestinal disease (impaired absorption of oral contraceptive steroids in the small bowel due to inflammatory disease)",False
Lignocaine (Lidocaine) 20 mg/ml Injection,,Cardiovascular System > Cardiac Therapy,C01BB01110P3001XX,Yes,LP,B,Ventricular tachycardia and ventricular fibrillation. For IV use. To be diluted before use,B,"50-100 mg IV as a bolus, repeated after 5 minutes if necessary. Maintenance : 1-4 mg/min by IV infusion under ECG monitoring","Nervousness, dizziness, paraesthesia, drowsiness, tinnitus, disorientation, blurred vision, tremor, convulsions, respiratory depression, hypotension, bradycardia","Hypersensitivity to amide local anesthetics, Stokes-Adams syndrome, Wolff-Parkinson-White syndrome,severe degrees of sinoatrial, AV or intraventricular block in absence of pacemaker, ophthalmic use","Beta-adrenergic blockers; increased lidocaine levels.Cimetidine;decreased lidocaine level. Class I antiarrhythmic agents (eg, tocainide, mexiletine);toxic effects are additive and potentially synergistic. Procainamide; additive neurological and cardiac effects. Succinylcholine;prolongation of neuromuscular blockade. Incompatibility with; amphotericin B, parenteral cephalosporins, doxycycline, epinephrine, isoprenaline, methohexital, nitroprusside, norepinephrine, phenytoin, sodium bicarbonate, sulfadiazine","Adams-Stokes syndrome, advanced heart failure. EKG monitoring for intravenous administration. Epidural anaesthesia; a test dose is recommended, heart block, hepatic disease, hypovolaemia, renal disease, severe degrees of sinoatrial, atrioventricular or intraventricular block. Shock, sinus bradycardia, spinal anaesthesia, severe haemorrhage, shock, heart block, local infection at injection site, septicaemia. Wolff-Parkinson-White syndrome",False
Lignocaine (Lidocaine) 2% Jelly,,Nervous System > Anesthetics,N01BB02-110-G40-01-XXX,No,APPL,B,"Use for endotracheal tubes and instruments, painful procedures in the ear, nose and throat, burns, wounds, abrasions, lacerations; catheterisation of the male and female urethra and for symptomatic treatment of cystitis and urethritis",None,Apply to affected area 10 mins before catheterization.,"Allergic reactions. Intoxication, cutaneous and hypersensitivity symptoms. Sore throat. Central nervous system excitation followed by depression with drowsiness, respiratory failure and coma, numbness of tongue and perioral region, myocardial depression, peripheral vasodilation, hypotension, bradycardia, arrhythmia, cardiac arrest. Prolonged use in the eye may lead to severe contact keratitis and corneal damage","Hypersensitivity to lidocaine or amide type of local anaesthetics. Hypovolaemia, heart block or other conduction disturbances",Potentiation of cardiac effects antiarrhythmias. Drugs structurally related to local anaesthesia,"Traumatised mucosa and sepsis in the region of application, chronic heart failure, bradycardia or respiratory depression, hepatic insufficiency. Should not be used as ophthalmic drug. Presence of sepsis or severely traumatized mucosa in area of application. When used for endotracheal tube lubrication, avoid introducing into the lumen of the tube. Closely supervise patients being treated with class III antiarrhythmic drugs eg amiodarone and monitor ECG due to the additive effects",False
Meclozine HCl 25mg and Pyridoxine 50mg Tablet,,Respiratory System > Antihistamines for Systemic Use,R06AE55-919-T10-01-XXX,No,LP,B,Nausea and vomiting of pregnancy,20 PT/KK (KUOTA),Optimum dosing: 1 to 2 tablets OD. Maximum dosing: 4 tablets/day.,"Drowsiness, dry mouth, blurred vision, headache, gastrointestinal disturbance",Hypersensitivity to meclozine,May enhanced sedative effect of central depressants including alcohol,"Use with caution in prostatic hyperthrophy, urinary retention, glaucoma and pyloroduodenal obstruction, hepatic disease, severe heart failure, asthma. Avoid operating vehicles and machinery. Meclozine may inhibit lactation",False
Medroxyprogesterone Acetate 500 mg Tablet,Provera/Farlutal,Antineoplastic and Immunomodulating Agents > Endocrine Therapy,L02AB02-122-T10-01-XXX,Yes,LP,A,"Breast carcinoma, endometrial carcinoma, renal carcinoma",-,200-500 mg orally daily,"Vaginal bleeding, cholestatic jaundice, depression, fluid retention, weight gain, hirsutism, acne, visual abnormalities, nausea, fatigue, galactorrhea, amenorrhea and anovulation, decreased glucose tolerance, thromboembolic phenomena, anaphylaxis, corticoid-like activity (high doses)","Hypersensitivity to medroxyprogesterone, thrombophlebitis, undiagnosed vaginal bleeding, impaired liver function, pregnancy, known or suspected malignancy of breast or genital organs, missed abortion","Aminoglutethimide, alprazolam, bexarotane, nevirapine, rifampicin","Examination of breast, pelvis and PAP smear before starting treatment. Diabetes, history of depression, cardiac dysfunction, ocular disorder, prolonged progestin therapy and bone mineral density loss",True
Mefenamic Acid 250mg Capsule,Ponstan,Musculo-skeletal System > Antiinflammatory and Antirheumatic Products,M01AG01-000-C10-01-XX,Yes,APPL,C,Mild to moderate pain,None,ADULT: 250 - 500 mg 3 times daily after meals.,"Diarrhoea, skin rash, allergic, glomerulonephritis, non-oliguric renal failure, thrombocytopenia, reversible haemolytic anaemia, hypertension, oedema, myocardial infarction NPRA Safety Alert 1. 2 Sept 2024 Mefenamic Acid-Associated Generalised Bullous Fixed Drug Eruption (GBFDE)","Gastrointestinal ulceration or inflammatory bowel disease, renal/hepatic impairment","Alendronate, ACEIs, antacids, beta-adrenergic blockers, calcium channel blocker, ciclosporin, diuretics, methotrexate, sulphonylureas, warfarin","Elderly, renal impairment, asthmatic sensitive to NSAIDs or salicylates, pregnancy, increased risk of serious cardivascular thrombotic events, myocardial infarction NPRA Safety Alert 1. 2 Sept 2024 Mefenamic Acid-Associated Generalised Bullous Fixed Drug Eruption (GBFDE)",False
Miconazole 2% Cream,,Dermatologicals > Antifungals for Dermatological Use,D01AC02221G1001XX,Yes,LP,C,"i) Fungal infections: Tinea pedis, Tinea corporis, Tinea capitis and other dermatophyte infections caused by Trichophyton and Epidermophyton species; ii) Antifungal agent that has been in various candida infections including vaginal candidiasis.",To be used as 2nd line treatment at health facilities without medical officer.,Apply sparingly and rub gently onto affected area 1-2 times daily continuing for 14 days after lesions have healed,"Ocassional skin irritation or sensitivity, contact dermatitis, vaginal burning due to cream base",Hypersensitivity to azole products.,Not known,"First trimester of pregnancy, lactation. Local sensitization or irritation, to discontinue use. Do not use in children below 2 years old except under the advice and supervision of a doctor.",False
Midazolam 5mg/5ml Injection,Dormicum,Nervous System > Psycholeptics,N05CD08-110-P30-01-XX,Yes,Government Contract,"A, A/KK","Prescriber Category A: Pre-operative sedation, induction of general anaesthesia, premedication and sedation in ICU and sedation for minor procedures Prescriber Category A/KK: For induction of intubation and sedation post-intubation",5 VIAL/KK (EMERGENCY TROLLEY ITEM ONLY),"Pre-operative sedation, induction of general anaesthesia, premedication and sedation in ICU and sedation for minor procedures : Usual sedative range 2.5 - 7.5 mg (about 70 mcg/kg by IV injection over 30 seconds). Premedication by IM injection 70 - 100 mcg/kg 30 -60 minutes before surgery; ELDERLY: 1 - 1.5 mg/kg. Induction: Induction by slow IV infusion 200 - 300 mcg/kg (ELDERLY 100 - 200 mcg/kg. CHILD over 7 years 150 - 200 mcg/kg); Maximum: 0.35mg/kg. Sedation in ICU 0.03 - 0.2 mg/kg/hour For induction of intubation and sedation post-intubation : Induction: Induction by slow IV infusion 200 - 300 mcg/kg (ELDERLY 100 - 200 mcg/kg. CHILD over 7 years 150 - 200 mcg/kg); Maximum: 0.35mg/kg. Sedation: 0.03 - 0.2 mg/kg/hour","Muscle stiffness, induration of veins, pain, redness, headache, apnoea, nausea, coughing, vomitting, drowsiness, respiratory depression, phlebitis, gastrointestinal disturbances, increased appetite, jaundice, hypotension, bronchospasm, pain at the site of injection","Acute narrow angle glaucoma, hypersensitivity to midazolam products, acute alcohol intoxication, shock, lactation","Neuroleptics, tranquilizer, antidepressant, hypnotics, analgesics, anaesthetics, antipsychotics, anxiolytics, antiepiletics, antihistamines, erythromycin, clarithromycin, cimetidine, omeprazole, diltiazem, efavirenz, indinavir, nelfinavir, ritonavir, saquinavir, fluvoxamine, halothane, sevoflurane, thiopental, itraconazole, theophylline, atorvastatin","Elderly, COPD, congestive heart failure, respiratory failure, severe electrolyte and fluid disturbances, pregnancy and lactation, hepatic and renal impairment, labor and delivery, prolonged use and abrupt withdrawal, moderate lowering of intraocular pressure in ophthalmic. Children under 15 kg not to exceed 1 mg/ml",True
Magnesium Trisilicate Mixture,Rexom Mist Magnesium Trisilicate,Alimentary Tract and Metabolism > Drugs for Acid Related Disorders,A02AA10-912-L21-01-XXX,Yes,Government Contract,C,"Heartburn, dyspepsia",None,ADULT children over 12 years: 10-20ml 3 times daily or as required; CHILD: 5-11 years: 5-10 ml three times a day or as required,"Diarrhoea, systemic alkalosis has been reported when administered orally with cation-exchange resins","Acute surgical abdomen, hypersensitivity to antacids, hypophosphataemia","Major: sodium polystyrene sulfonate (advoid). Moderate: tetracyclines, ketoconazole, itraconazole, dipyridamole, quinolones, captopril, iron and aspirin (adjust frequency interval)","Renal impairment-nonabsorbable calcium, magnesium or aluminum preparations such as antacids or laxatives should not be used in patients receiving oral cation-exchange resins. Alternatively, the interaction may be avoided by administering the resin as an enema",False
Naloxone HCl 0.02mg/ml Injection,,Various > All Other Therapeutic Products,V03AB15-110-P30-01-XX,Yes,APPL,B,For the complete/partial reversal of narcotic depression including respiratory depression induced by opioids such as natural and synthetic narcotics. Diagnosis of suspected acute opioids overdosage,None,"0.005 - 0.01 mg/kg body weight repeated at intervals of 2 - 3 minutes according to the patient's needs by IM, IV or SC","Opiate withdrawal symptoms, nausea, vomiting, tachycardia, tremor, sweating, pulmonary oedema, hyperventilation, cardiac dysrhythmia, biliary colic, dysphagia, memory impairment, seizure, agitation, dyspnea, laryngeal spasm, pulmonary edema, tachyarrhythmia",Hypersensitivity to naloxone,Clonidine: hypertension,"Dependence may precipitate withdrawal symptoms, concurrent cardiotoxic drugs, pre-existing cardiac disease, narcotic dependency, pregnancy, lactation, neonates",False
Norethisterone 0.35 mg Tablet,Noriday,Genito Urinary System and Sex Hormones > Sex Hormones and Modulators of the Genital System,G03AC01000T1001XX,No,Government Contract,C+,Contraception,None,1 tablet daily starting on the first day of the menstrual bleeding,"Gastrointestinal distress, oedema, menstrual disorders, dermatologic effects, nausea, fatique, depression, acne, hirsutism, breast tenderness, thromboembolic phenomena, galactorrhoea, decreased glucose tolerance, anaphylaxis, corticoid like reaction (high doses)","Hypersensitivity, breast carcinoma, liver disease or dysfunction, pregnancy, incomplete abortion, abnormal and undiagnosed vaginal bleeding, active or history of thromboembolic disease, thrombophlebitis, hypercoagulable state. Cerebral vascular or coronary artery diseases","Effectiveness may be reduced by antibiotics, phenytoin, carbamazepine, barbiturates, rifampicin","Gastrointestinal disease (impaired absorption of oral contraceptive steroids in the small bowel due to inflammatory disease, diarrhoea, ileostomy or jejunoileal bypass may result in contraceptive failure)",False
"Nystatin 100,000units/ml Suspension",Mycostatin,"Alimentary Tract and Metabolism > Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents",A07AA02-000-L80-01-XXX,Yes,LP,B,"Prevention and treatment of candidiasis of the skin and mucous membranes, protection against candidas overgrowth during antimicrobial /corticosteroid therapy and as selective decontamination regimens",None,"Treatment: Adult & Children: 100,000 to 600,000 units 6 hourly; Infant: 100,000 – 200,000 units 6 hourly; Neonates: 100,000 units 8 hourly. Prophylaxis: Adult: 1,000,000 units daily; Neonates and Infants: 100,000 units 2-3 times a day; Children: 250,000 – 500,000 units 2-3 times a day.","GI disturbances, rash, urticaria , Steven Johnson Syndrome, oral irritation",Hypersensitivity to nystatin,Not known,"Not intended to treat systemic mycoses. If hypersensitivity develops, discontinue use",False
Oral Rehydration Salt,-,"Alimentary Tract and Metabolism > Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents",A07CA00-905-F21-01-XXX,Yes,Government Contract,C,Replacement of fluid and electrolytes loss in diarrhoea,None,Dissolve 1 sachet in 200 or 250mL of water according to product insert. The amount to give depends on hydration status. ADULT: 200-400mL (1 - 2 sachets) for every loose motion / diarrhoea / vomiting CHILD (2 yrs & above): 100-200mL (1 sachet) for every loose motion / diarrhoea / vomiting. In severe dehydration 100ml/kg for 3-4 hours. INFANT (up to 2 yrs): 1 - 1.5 times their usual feed volume (50-100mL) each diarrhoea/vomiting Dose is according to product insert and dependent on the product / brand used as well as patient comorbidities e.g. heart failure and chronic kidney disease.,"Hypernatremia, nausea and vomiting",Patients with renal failure or hyperkalaemia,Potassium sparing diuretics,"Cardiac failure, hypertension, impaired renal function, peripheral and pulmonary oedema, toxaemia in pregnancy",False
Oxytocin 10units/ml Injection,Pitocin,"Systemic Hormonal Preparations, excl. Sex Hormones and Insulins > Pituitary and Hypothalamic Hormones and Analogues",H01BB02-000-P30-01-XXX,Yes,APPL,B,"i) Induction of labour ii) Inadequate uterine effort iii) Management of third stage of labour iv) Prevention and treatment of post-partum haemorrhage v) As adjunctive therapy for the management of incomplete, inevitable or missed abortion", dose may be decreased after desired frequency of contractions is reached and labor has progressed to 5 - 6 cm dilation,"i & ii) Intiate at 2 milliunits/min, may be increased by 4 miliunits/min gradually at 30 minute intervals. Dose may be decreased once a contraction pattern similar to normal labour is achieved and labor has progressed to 5 - 6 cm dilation. Maximum dose of oxytocin for multiparae - 16 miliunits/min and nulliparae-32 miliunits/min. iii) IV/IM: 5 -10 units iv) IV : 5-10 units followed by IV infusion at 10 units/hour v) Initial: 5 units given via slow inj over 5 minutes, may be followed by an infusion at a rate of 20-40 milliunits/minute as necessary The dosing is individualized based on maternal, fetal response and product insert / protocol","Gastrointestinal upsets, water intoxication resulting from large amounts of solution or too rapid infusion, cardiac arrhythmias","Hypersensitivity to oxytocin, significant cephalopelvic disproportion, unfavorable fetal positions, fetal distress, hypertonic or hyperactive uterus, contraindicated vaginal delivery","Prostaglandins, inhalation anaesthetics, vasoconstrictor agents","For induction or enhancement only as IV infusion, careful monitoring of fetal heart rate and uterine contractions are required",False
Oxytocin 5 units & Ergometrine Maleate 0.5 mg/ml Injection,Syntometrine,Genito Urinary System and Sex Hormones > Other Gynecologicals,G02AC01-900-P30-01-XXX,Yes,APPL,C+,i)Prevention and treatment of postpartum haemorrhage associated with uterine atony. ii)Active management of third stage of labour,None,"i) 1 ml IM, may be repeated after 2 hours. Should not exceed 3 ml within 24 hours ii) For routine management of third stage of labour, 1 ml IM following delivery of the anterior shoulder or immediately after delivery of the child","Gastrointestinal upsets, abdominal pain, headache, dizziness, skin rashes. Rarely hypertension, bradycardia, cardiac arrthymias, chest pain, anaphylactoid reactions","Pregnancy, labour (except second stage following delivery of the anterior shoulder), severe hypertension, pre-eclampsia, eclampsia, severe disorders of cardiac, hepatic or renal function, occlusive vascular disease, sepsis and in patients with a history of hypersensitivity","Vasoconstrictors, prostaglandins, halothane anaesthesia","Hypertension, cardiac, hepatic or renal disease. Should not be given until after delivery of child & in multiple births not until the last child has been delivered",False
Salbutamol 0.5mg/ml Injection,Ventolin,Respiratory System > Drugs for Obstructive Airway Diseases,R03CC02-183-P30-01-XXX,Yes,LP,A,i. Asthma and other conditions associated with reversible airways obstruction ii. For prevention of uncomplicated premature labour,None,"i. 500 mcg by SC/IM injection 4 hourly or 250 mcg by slow IV. If required, by IV infusion, initially 5 mcg/min adjusted according to response and heart rate, usually in the range 3 - 20 mcg/min ii. Infusions containing 5 mg in 500ml (10 mcg/ml) at the rate of 10 - 45 mcg/min increased at intervals of 10 minutes until evidence of patient response as shown by reduction of strength, frequency or duration of contractions; maintain rate for 1 hour after contractions have stopped, then gradually reduce by 50% every 6 hours","Haemorrhage, thrombocytopenia, tachycardia and palpitations, erythema, ventricular ectopic beats, myocardial ischaemia and infarction have been reported following IV administration. Fine tremor (particularly in the hands), nervous tension, headache, peripheral dilatation and palpitations, tachycardia, arrhythmias, disturbances of sleep and behaviour in children. Muscle cramps and hypersensitivity reactions including paradoxical bronchospasm, urticaria, and angioedema","Hypersensitivity, hyperthyroidism or thyrotoxicosis, tachycardia or tachycardiac arrthymias, subvalvular aortic stenosis","Monoamine oxidase inhibitors - increased risk of tachycardia, agitation or hypomania","Thyrotoxicosis, pregnancy and lactation. Potential for paradoxical bronchospasm, patients with cardiovascular disorders, hyperthyroidism, diabetes mellitus, phaeochromocytoma, patients with history of aneursym and patients who are usually responsive to sympathomimetics amines. Labour and delivery may be complicated",True
Salbutamol 0.5% Inhalation Solution,Ventolin,Respiratory System > Drugs for Obstructive Airway Diseases,R03AC02-183-A30-01-XXX,Yes,APPL,B,Indicated for the relief of bronchospasm in patients with reversible obstructive airway disease and acute bronchospasm.,-,"2.5 to 5mg (0.5ml – 1ml), repeat according to response and tolerability. Dosing is individualised and according to product insert/protocol.","Slight tremor (particularly in the hands), nervous tension, headache, peripheral dilatation and palpitations, tachycardia, arrhythmias, disturbances of sleep and behaviour in children, muscle cramps, hypersensitivity reactions including paradoxical bronchospasm, urticaria, angioedema, hypotension, pulmonary oedema, erythema multiforme",Hypersensitivity to any of their components,"Antagonism with beta-blockers. Use with caution with additional adrenergic drugs, MAOI inhibitors or tricyclic antidepressants - increased risk of tachycardia, agitation or hypomania","Thyrotoxicosis, hyperthyroidism, cardiovascular disease, arrhythmias, susceptiility to QT-interval prolongation, hypokalaemia, diabetes mellitus, not appropriate for managing premature labour, pregnancy and lactation",False
Salbutamol 100mcg/dose Inhalation,"Ventolin, Buventol",Respiratory System > Drugs for Obstructive Airway Diseases,R03AC02-183-A10-01-XXX,Yes,APPL,B,Asthma and other conditions associated with reversible airways obstruction,None,ADULT : 100 - 200 mcg up to 3 - 4 times daily. CHILD : 100 mcg increased to 200 mcg if necessary,"Slight tremor (particularly in the hands), nervous tension, headache, peripheral dilatation and palpitations, tachycardia, arrhythmias, disturbances of sleep and behaviour in children, muscle cramps, hypersensitivity reactions including paradoxical bronchospasm, urticaria, angioedema, hypotension, pulmonary oedema, erythema multiforme",Hypersensitivity to any of their components,"Antagonism with beta-blockers. Use with caution with additional adrenergic drugs, MAOI inhibitors or tricyclic antidepressants - increased risk of tachycardia, agitation or hypomania","Thyrotoxicosis, pregnancy and lactation, hyperthyroidism, cardiovascular disease, arrhythmias, susceptiility to QT-interval prolongation, hypokalaemia, diabetes mellitus, not appropriate for managing premature labour, pregnancy and lactation",False
Selegiline HCl 5 mg Tablet,Jumex,Nervous System > Anti-parkinson Drugs,N04BD01110T1001XX,No,APPL,A*,Only for treatment of late stage Parkinsonism with on and off phenomenon,None,5 mg twice daily at breakfast and lunch. Maximum 10 mg/day,"Hypotension, nausea, confusion, agitation, hallucination, dyskinesia, sleep disturbances, psychosis, constipation, dry mouth, headache, tremor, dizziness","Extrapyramidal symptoms not related to dopamine deficiency, thyrotoxicosis, narrow angle glaucoma agitated psychosis, hypersensitivity to selegiline products. Pregnancy","Hyperpyrexia and central nervous system toxicity with pethidine. Hypertension and central nervous system excitation with fluoxetine and sertraline. Hypotension with MAOIs. Carbamazepine, amitriptyline, amphetamine","History of peptic ulcer, pregnancy and lactation, elderly, concurrent use of tricyclic antidepressants, uncontrolled hypertension. Suicidal ideation and behavior or worsening depression, increased risk during the first few months of therapy or following changes in dosage (particularly in children, adolescents and young adults with major depressive disorder)",True
Sodium Bicarbonate 8.4% (1 mmol/ml) Injection,-,Blood and Blood Forming Organs > Blood Substitutes and Perfusion Solutions,B05XA02131P3002XX,Yes,APPL,B,i) For acceleration of excretion in drug intoxication (where excretion of the drug into the urine is accelerated by elevated urine pH) ii) For metabolic acidosis secondary to underlying diseases,None,According to the needs of the patient. In severe shock due to cardiac arrest: 50 ml by IV,"Gastrointestinal cramps, flatulence, alkalosis","Alkalosis, hypernatraemia, hypocalcaemia, hypochloraemia, severe pulmonary oedema, unknown abdominal pain","Amphetamine, aspirin, chlorpropamide, dextroamphetamine, ephedrine, itraconazole, ketoconazole, lithium, pseudoephedrine, flecainide","Renal impairment, peptic ulcer, congestive heart failure, oedema, cirrhosis",False
Sodium Chloride 0.45% Injection,-,Blood and Blood Forming Organs > Blood Substitutes and Perfusion Solutions,B05XA03100P6001XX,Yes,APPL,B,For replenishing fluid and for restoring / maintaining the concentration of sodium and chloride ions,None,100 - 1000 ml by IV or according to the needs of the patient,"Nausea, vomiting, diarrhoea, abdominal cramps, congestive heart failure, hypertension, tachycardia, fluid accumulation, irritability, restlessness, weakness, headache, dizziness, obtundation and convulsions","Hypernatraemia or fluid retention, hypersensitivity (ophthalmic products), sodium chloride solutions with preservatives in newborns, for injection or flushing of intravenous lines or mixing medications, hypertonic saline abortifacient in pregnancies less than 15 weeks",Not known,"Restrict intake in impaired renal function, cardiac failure, hypertension, peripheral and pulmonary oedema, toxaemia of pregnancy",False
Sodium Chloride 0.18% with Dextrose 10% Injection,-,Blood and Blood Forming Organs > Blood Substitutes and Perfusion Solutions,B05XA03904P6001XX,Yes,LP,B,For replenishing fluid and energy and for restoring or maintaining the concentration of sodium and chloride ions,None,According to the needs of the patient,"Thrombophlebitis, rebound hypoglycaemia, hypokalaemia, sodium accumulation and oedema","Hypernatraemia or fluid retention, hypersensitivity (ophthalmic products), sodium chloride solutions with preservatives in newborns, for injection or flushing of intravenous lines or mixing medications, hypertonic saline abortifacient in pregnancies less than 15 weeks",Not known,"Restrict intake in impaired renal function, cardiac failure, hypertension, peripheral and pulmonary oedema, toxaemia of pregnancy. Diabetes mellitus or carbohydrate intolerance and hyperglycaemia may accentuate neurologic damage for an ischaemic insult. Patients at risk for cerebral ischaemia, acute stroke, impending cardiac arrest or severe hypotension unless hypoglycaemia is suggested or until glucose is determined",False
Sodium Valproate 200mg/5ml Syrup,Epilim,Nervous System > Antiepileptics,N03AG01-520-L90-01-XXX,Yes,Government Contract,B,i) Treatment of generalized or partial epilepsy. ii) Treatment and prevention of mania associated with bipolar disorder,None,"i. Epilepsy: ADULT: Initially 600 mg/day in 2 - 3 divided doses, dose may be increased by 200 mg at 3-day intervals to max 2.5 g/day. Usual maintenance dose: 1-2 g/day (20-30 mg/kg/day). CHILD: - More than 20 kg. Initially 400 mg/day with spaced increases until control is achieved (usually 20-30 mg/kg/day), dose may be increased to 35 mg/kg/day. - Less than 20 kg 20 mg/kg/day, in severe cases the dose may be increased provided plasma concentration can be monitored. ii. Treatment and prevention of mania associated with bipolar disorders: ADULT: The recommended initial dose is 1000mg/day. The dose should be increased as rapidly as possible to achieve the lowest therapeutic dose, which produces the desired clinical effects. The recommended maintenance dosage for the treatment of bipolar disorder is between 1000mg and 2000mg daily. In exceptional cases, the dose may be increased to not more than 3000mg daily.","Nausea, vomiting, headache, dizziness, ataxia, tremor, weight gain, transient hair loss, oedema, thrombocytopenia (dose related), leukopenia. Gastrointestinal disorders, liver failure, children under the age of two years are at increased risk, pancreatitis NPRA Safety Alert (21 Jan 2020): - Risk of congenital malformations in neonates, and serious developmental problems among children whose mothers were exposed to sodium valproate during pregnancy.","Hepatic disease or significant hepatic dysfunction, hypersensitivity to valproate sodium, valproic acid or divalproex sodium, porphyria NPRA Safety Alert (31 Jan 2019): • Epilepsy: - valproate is contraindicated in pregnancy unless there is no suitable alternative treatment. - valproate is contraindicated in women of childbearing potential, unless the conditions described in the Direct Healthcare Professional Communication (DHPC) letter are fulfilled. • Bipolar disorder: - valproate is contraindicated in pregnancy. - valproate is contraindicated in women of childbearing potential, unless the conditions described in the DHPC letter are fulfilled.","Increases phenobarbital, primidone and phenytoin plasma concentrations. Potentiates toxic effect of carbamazepine. Risk of rash may be increased by coadministration with lamotrigine. May potentiate the effect of antipsychotics, MAOIs, antidepressants and benzodiazepines. Monitor prothrombin time when used with anticoagulants. Caution when used with newer anti-epileptics whose pharmacodynamics are not well-established. Zidovudine, mefloquine, chloroquine, imipenem, meropenem. NPRA Safety Alert (10 June 2018): - Drug-drug Interaction with Propofol","Avoid sudden withdrawal, certain metabolic disorders, fatigue, loss of appetite, vomiting. Pregnancy and lactation. Avoid concomitant use of salicylates in children less than 3 years due to risk of liver toxicity, use of salicylates in children less than 16 years is also not recommended. Monitor liver function before therapy and during first 6 months. Potential for an increase in risk of suicidal thoughts or behaviours. Pancreatitis, renal insufficiency, SLE, hyperammonaemia, diabetic patients, weight gain. Female children, female adolescents, women of childbearing potential, pregnancy (due to high teratogenic potential and risk of developmental disorders in infants exposed in utero to valproate)",False
Spironolactone 25 mg Tablet,,Cardiovascular System > Diuretics,C03DA01000T1001XX,Yes,APPL,B,"Oedema and ascites in cirrhosis of the liver, congestive heart failure",None,ADULT: 100 - 200 mg daily in divided doses. Increase to 400 mg if required. CHILD: initially 3 mg/kg daily in divided doses,"Headache, drowsiness, gastrointestinal disturbances including cramp and diarrhoea, ataxia, mental confusion, hirsutism, deepening of the voice, menstrual irregularities, impotence, skin rashes, hyponatraemia, hyperkalaemia","Hypersensitivity, hyperkalaemia, renal failure, anuria, patients receiving other potassium-sparing diuretics or potassium supplements","Angiotensin converting enzyme inhibitors, ciclosporin: hyperkalaemia. Aspirin: decreased spironolactone effectiveness. Digoxin: digoxin toxicity (nausea, vomiting, cardiac arrhythmias). NSAIDs: reduced diuretic effectiveness, hyperkalaemia","Hyperkalaemia or progressive renal failure, impaired hepatic or renal function, diabetes mellitus, patients likely to develop acidosis. Pregnancy and lactation",False
Streptomycin Sulphate 1g Injection,-,Antiinfectives for Systemic Use > Antibacterials for Systemic Use,J01GA01-183-P40-01-XXX,Yes,APPL,B,i) Tuberculosis ii) Brucellosis iii) Bacterial endocarditis, max: 1.5 g/dose. Not >120 g over the course of treatment should be given unless there are no other treatment options. Child: 20-40 mg/kg (max: 1 g) daily or 25-30 mg/kg (max: 1.5 g) 2-3 times weekly,15 mg/kg daily (Max: 1 g daily) Dosing is according to product insert.,"Ototoxicity and nephrotoxicity, Giddiness, vertigo, tinnitus, ataxia, hypersensitivity reactions, Anaphylactic shock, aplastic anaemia and agranulocytosis. Stevens-Johnson syndrome and toxic epidermal necrolysis.Vitamin K and vitamin B deficiency.",Hypersensitivity to other aminoglycosides. Pregnancy.,"Used with blood substitutes and diuretics, ciclosporin,cisplatin, vancomycin intensify nephrotoxicity and ototoxicity. H1-receptor blockers may mask early signs of ototoxicity.Possible inhibition of respiration with anaesthetics or muscle relaxants.","Renal and hepatic impairment. Elderly, Pregnancy and lactation, patient with myasthenia gravis.",False
Vitamin K1 1 mg/ml Injection,Konakion,Blood and Blood Forming Organs > Antihemorrhagics,B02BA01000P3001XX,Yes,APPL,C+,Vitamin K deficiency in neonates,None,"Prophylaxis of vitamin K deficiency bleeding in neonates Child: Neonate: 0.5-1 mg, given as a single dose via IM inj. Alternatively, 2 mg may be given orally, followed by a 2nd dose of 2 mg after 4-7 days. Intravenous Vitamin K deficiency bleeding in neonates Child: Infant: 1 mg by IV/IM/SC inj, further doses may be given if necessary.","Anaphylaxis, dyspnoea, cyanosis, pain, swelling, phloebitis at the Inj site, diaphoresis, dizziness, hypotension (rare), allergic reactions after SC and IM inj.","Hypersensitivity to Vitamin K, menadione (K3) administration in glucose-6-phosphate dehydrogenase deficiency","Decreased effect of oral anticoagulants.Requirement for Vitamin K may be increased in patients receiving in patients with broad spectrum antibiotics, quinidine, quinine, high doses of salicylates or antibacterial sulphonamides.",Increased risk of severe haemolytic anaemia in neonates after large doses; severe hepatic impairment; pregnancy. Premature neonates weighing <2.5 kg,False
Water for Injection,-,Various > All Other Non-therapeutic Products,V07AB00000P3001XX,Yes,APPL,C+,As a diluent and vehicle for the administration of medications,None,According to the needs of the patient,Not known,Not known,Not known,The stability of any medicament prepared should be checked,False
Zinc Oxide Cream,-,Dermatologicals > Emollients and Protectives,D02AB00000G1001XX,No,LP,C+,"Skin protective in various skin conditions such as nappy rash, eczema and problem skin",None,Apply 3 times daily or as required,Hypersensitivity to any component,Weeping dermatoses,Not known,"Hypersensitivity to any component. Avoid contact with eyes. Not to be applied over deep or puncture wounds, infections or lacerations",False
Clopidogrel 75 mg Tablet,,Blood and Blood Forming Organs > Antithrombotic Agents,B01AC04192T1001XX,Yes,Government Contract,A/KK,"Secondary prevention of atherothrombotic events in: i) Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. Prescribing restriction: as second/third line treatment in patients who are sensitive or intolerant to acetylsalicylic acid and/or ticlopidine). ii) Adult patients suffering from acute coronary syndrome: • Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention. • ST segment elevation acute myocardial infarction, in combination with acetylsalicylate acid (ASA) in medically treated patients eligible for thrombolytic therapy.",20 TAB/KK (EMERGENCY TROLLEY ITEM ONLY),75 mg once daily,"GI bleeding, purpura, bruising haematoma, epistaxis, haematuria, ocular haemorrhage, intra cranial bleeding, abdominal pain, dyspepsia, gastritis & constipation, rash, pruritus","Active pathological bleeding such as peptic ulcer & intracranial haemorrhage, breast feeding","Cytochrome P450 effect. Amiodarone, cisapride, ciclosporin, diltiazem, irbesartan, losartan, oral hypoglycemics, paclitaxel, phenytoin, quinidine, sildenafil, tamoxifen, verapamil, warfarin, aspirin, heparin, thrombolytics, NSAIDs, atorvastatin, erythromycin, clarithromycin. Concomitant use of the drugs that inhibit CYP2C19 should be discouraged","Avoid for first few days after MI and for 7 days after ischaemic stroke; not recommended in unstable angina, coronary artery bypass grafting and percutaneous transluminal coronary angioplasty; patients at risk of increased bleeding from trauma, surgery or other pathological conditions; discontinue 7 days before elective surgery if antiplatelet effect not desirable, liver impairment, renal impairment, pregnancy. Based on literature data, patients with genetically reduced CYP2C19 function (intermediate or poor metabolisers) have lower systemic exposure to the active metabolite of clopidogrel and diminished antiplatelet responses, and generally exhibit higher cardiovascular events rates following myocardial infarction than do patients with normal CYP2C19 function",True
Etonogestrel 68mg Implant,,Genito Urinary System and Sex Hormones > Sex Hormones and Modulators of the Genital System,G03AC08-000-P10-01-XXX,Yes,LP,A/KK,Contraception,"5 PT (KKB), 8 PT (KKTS), 10 PT (KKS, KKTD, KKBC), 15 PT (KKJ), 20 PT (KKTPG) (KUOTA)",Subdermal insertion: A single implant is effective for 3 years (to be removed 3 years from the date of insertion),"Undesirable effects with a frequency >5%: Acne, headache, increase in body weight, breast tenderness and pain; >2.5%-≤5%: Alopecia, depressive moods, emotional lability, changes in libido, abdominal pain, dysmenorrhoea. A rise in blood pressure has occasionally been seen.","Pregnancy, venous thromboembolic disorder, severe hepatic disease, progestogen-dependent tumours, undiagnosed vaginal bleeding, and hypersensitivity to the active substance or to any of the excipients of etonogestrel implant.","Drug interactions, which result in an increased clearance of sex hormones, can lead to breakthrough bleeding and contraceptive failure. The mechanism of this interaction appears to be based on the hepatic enzyme-inducing properties of these drugs. Interactions may be expected during concomitant use of hydantoins, barbiturates, primidone, carbamazepine or rifampicin; interactions with oxcarbazepine, rifabutin, troglitazone, felbamate and griseofulvin are also suspected. Maximal enzyme induction is generally not seen before 2-3 weeks but may then be sustained for at least 4 weeks after cessation of drug therapy.",Pre-existing or risk of breast cancer. Prolonged immobilisation. Diabetes. Women predisposed to chloasma should avoid sun & UV exposure. Lactation. Concomitant treatment with hepatic enzyme inducers may necessitate the use of additional barrier contraception.,True
Sulpiride 200 mg Tablet,Negatil,Nervous System > Psycholeptics,N05AL01000T1001XX,Yes,Government Contract,B,Acute and chronic psychotic disorders,None,200-1000mg daily,"Extrapyramidal syndrome, drowsiness, dry mouth, urinary retention, tachycardia, postural hypotension, dizziness, galactorrhoea, gynaecomastia, amenorrhoea, sedation, somnolence. Early dyskinesia, tardive dyskinesia, sedation or drowsiness, transient hyperprolactinemia, weight gain, QT interval prolongation, orthostatic hypotension, neuroleptic malignant syndrome","Hypersensitivity to sulpiride, phaeochromocytoma, prolactin dependent tumour, in combination with sultopride and dopamine agonists apart from in patients with Parkinson's disease, lactation, levodopa, class Ia and III antiarrhythmics, certain neuroleptics (thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, amisulpride, tiapride, pimozide, haloperidol, droperidol), bepridil, cisapride, diphemanil, erythromycin, mizolastine, vincamine, halofantrine, pentamidine, sparfloxacin, moxifloxacin","Tramadol, increased risk of seizures. Other central nervous system depressants, alcohol, levodopa. Dopamine agonists, sultopride, halofantrine, pentamidine, sparfloxacin, moxifloxacin, bradycardiac agents, hypokalaemic agents, antihypertensives, if treatment with neuroleptics is necessary in patients with Parkinson's disease receiving treatment with dopamine agonists, the latter must be gradually reduced and then discontinued","Cardiovascular disease, manic or hypomanic patients, renal insufficiency, neuroleptic malignant syndrome, hyperthyroidism, pulmonary disease, urinary retention, previous hypersensitivity to other benzamide derivatives eg. metoclopramide, elderly patients. Pregnancy, lactation, Parkinson's disease. May be exacerbated by the presence of bradycardia, hypokalaemia, a long QT which is either congential or acquired (due to combination with a medicinal product increasing the QT interval). Do not use in the event of congential galactosaemia, glucose/galactose malabsorption syndrome or lactase deficiency and children less than 6 year. Parkinson's disease, renal impairment, epileptic patients. Avoid alcohol",False
Salmeterol 25mcg and Fluticasone Propionate 125mcg Inhalation,Seretide,Respiratory System > Drugs for Obstructive Airway Diseases,R03AK06-989-A21-02-XXX,Yes,LP,A*,Regular treatment of reversible obstructive airway diseases including asthma.,None,ADULT and CHILD more than 12 years : 1 - 2 puff twice daily. CHILD over 4 years : 1 puff twice daily,"Hoarseness and dystonia, throat irritation, headache, oropharyngeal candidiasis and palpitations, tremor, cardiac arrhythmias (atrial fibrillation and supraventricular tachycardia)","Hypersensitivity to any of the ingredients of salmeterol, fluticasone or any component of the product","Beta-blockers, strong CYP3A4 inhibitors e.g. ketoconazole, ritonavir","Not for relief of acute symptoms. Not be initiated in patients with unstable and acutely deteriorating asthma, which may be a life-threatening condition. Should not be used to transfer patients from oral to inhaled steroids. Treatment should not be stopped abruptly in patients with asthma due to risk of exacerbation, therapy should be titrated-down under physician supervision. Caution in patients with active or quiescent pulmonary tuberculosis, thyrotoxicosis, pre-existing cardiovascular disease, patients predisposed to low levels of serum potassium. Height of children receiving prolonged treatment with inhaled corticosteroid is regular monitored. When transferring from systemic to inhaled steroid therapy, monitor adrenocortical function regularly and withdraw systemic corticosteroid therapy gradually. Pregnancy and lactation.",True
Nitrofurantoin 100mg Tablet,,Antiinfectives for Systemic Use > Antibacterials for Systemic Use,J01XE01-000-T10-02-XXX,Yes,LP,B,Uncomplicated lower urinary tract infections,None,Acute uncomplicated urinary tract infections Adult: 50-100 mg 4 times daily for 7 days. Dual-release preparation: 100 mg bid. Child: >3 mth and older children: 3 mg/kg daily in 4 divided doses. Prophylaxis of uncomplicated urinary tract infections Adult: 50-100 mg at bedtime. Child: >3 mth and older children: 1 mg/kg once daily.,"Anorexia, nausea, vomiting, diarhoea, acute and chronic pulmonary reactions, peripheral neuropathy, hypersensitivity reactions, hepatic reaction (hepatic necrosis, hepatic failure, hepatitis, jaundice)","Impaired renal function, infants less than 3 months old, glucose-6-phosphate deficiency (G6PD) including breast-feeding of affected infants, pregnancy at term and porphyria","Concurrent use with norfloxacin may result in antagonism of antibacterial effect of norfloxacin. Fluconazole may increased risk of hepatic or pulmonary toxicity. Probenecid, antacids","Elderly. Monitor hepatic and pulmonary function during prolonged therapy. Pre-existing pulmonary, hepatic, neurological, or allergic disorders, predisposition to peripheral neuropathy e.g. renal impairment, anaemia, DM, electrolyte imbalance, debility, vitamin B deficiency. Withdraw if signs of peripheral neuropathy occur. Lactation.",False
Etoricoxib 90 mg Tablet,Arcoxia,Musculo-skeletal System > Antiinflammatory and Antirheumatic Products,M01AH05000T1001XX,No,Government Contract,A/KK,i)Acute and chronic treatment of signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA) ii)Acute gouty arthritis iii)Acute pain,10 PT/KK,"i) OA: 60 mg once daily. RA: 60mg once daily and may be increased to 90mg once daily if needed.Once the patient is stabilized, down-titration to 60mg once daily may be appropriate. ii & iii) Acute gouty arthritis and acute pain: 120 mg once daily (Given the exposure to COX-2 inhibitors, doctors are advised to use the lowest effective dose for the shortest possible duration of treatment)","Small increase in blood pressure, increased risk of thrombotic complication, headache, dizziness, fatigue, insomnia, nausea, vomiting, diarrhoea, heartburn, taste disturbance, decreased appetite and flatulence","Patients who experienced asthma, urticaria or allergic type of reaction after taking aspirin or NSAIDs, acute peptic ulcer, severe renal or hepatic disease,ischaemic heart disease and stroke, hypertensive patient whose blood pressure is not under control","Warfarin, ACEIs, lithium, methotrexate, oral contraceptives, rifampicin, aspirin, SSRIs","Bleeding disorders, liver disease, renal impairment , hypertension, recent myocardial infarct, cardiovascular disease, hyperlipidaemia, diabetes, smoking, peripheral arterial disease",True
Gamma Benzene Hexachloride 1% Cream/Lotion,,"Antiparasitic Products, Insecticides and Repellents > Ectoparasiticides, incl. Scabicides, Insecticides and Repellents",P03AB02100G1002XX,Yes,LP,A/KK,i) Only for scabies in adult weighing more than 50kg. Use should be restricted to patients who have failed treatment with or cannot tolerate other medications that pose less risk. ii) Treatment of head lice.,None,i) Only for single application. Adult: Apply a thin layer of 1% topical preparation onto all skin areas from the neck to toes. Completely wash off from the body with warm water after 8-12 hr. ii) Apply lotion into the scalp and hair. Leave the lotion for 4 minutes. Remove the lice using comb afterwards.,"Seizures, dermatitis, dizziness, eczema, papular lesions, itching, Henoch- Schonlein purpura, percutaneous absorption, atypical leukaemia, aplastic anemia and abnormal vision on the use of the cream.","Adults weighing less than 50kg. Pregnancy and premature babies, lactation. Avoid in patients with a history of epilepsy (e.g. HIV, history of head trauma or prior seizure, CNS tumor, excessive alcohol consumption) or who have a low body-weight, hypersensitivity to lindane products, Norwegian (crusted) scabies, other skin conditions (e.g. atopic dermatitis, psoriasis) that may increase systemic absorption.",Not known,"Not for oral ingestion and avoid eye contact. Dermatological disorders, excoriated skin, elderly. Simultaneous use of lindane lotion and other creams, ointments or oils. CNS toxicity may be greater in the young; use with extreme caution in infants, children, and pregnant and nursing mothers, conditions which may increase the risk of seizure.",True
Calcium Carbonate 500 mg Capsule,-,Alimentary Tract and Metabolism > Mineral Supplements,A12AA04-121-C10-01-XXX,Yes,Government Contract,B,i) Hyperphosphatemia (phosphate binder) in chronic kidney disease patients ii) Calcium supplementation,None,"i) Total dose of elemental calcium from calcium-based phosphate binder not to exceed 1,500 mg/day. Dosing is individualised based on serum phosphate level and according to product insert/protocol ii) 500 mg to 4g per day as calcium carbonate in 1-3 divided doses (500mg capsule contains 200mg elemental calcium) Dosing is individualised based on serum calcium level and according to product insert/protocol",Gastric hypersecretion and acid rebound (usually after high doses or prolonged use); hypercalcaemia (esp in renal failure patients or after high doses); constipation; flatulence; alkalosis; milk-alkali syndrome; tissue calcification,"Hypercalcaemia, digitalis toxicity,blood hypercoagulability and hypersensitivity to calcium carbonate","Corticosteroid, excessive use of alcohol, caffeine, tobacco, calcitonin, thiazide diuretics, vitamin D, antimuscarinic agents, fluoride, iron, phenothiazines, phosphate, quinidine, bisphosphonates, fluoroquinolones, tetracyclines and antacids. Interaction can be minimised by giving calcium carbonate and any other medications 2 to 3 hours apart.","Renal impairment, hypercalcaemia-associated disease eg, other malignancies, sarcoidosis, patients with renal stones or history of renal stone formation.",False
Acetylsalicylic Acid 100 mg & Glycine 45 mg Tablet,Cardiprin,Blood and Blood Forming Organs > Antithrombotic Agents,B01AC06-259-T10-01-XXX,No,Government Contract,B,"i) Prevention of myocardial infarct, stroke, vascular occlusion and deep vein thrombosis. ii) Transient ischaemic attacks",None,1 tablet daily,"Nausea, vomiting, dyspepsia, GI ulceration, haematemesis, malaena. Occasionally hepatotoxicity",Bleeding disorders. Hypersensitivity to salicylate,"Alcohol, dipyridamole, metoclopramide, metoprolol, carbonic anhydrase inhibitors, corticosteroids, coumarin anticoagulants, sulphonylureas, methotrexate, phenytoin, valproic acid, probenecid, sulphinpyrazone","Dyspepsia, gastric mucosal lesions, haemorrhagic disorders, gout, intolerant to aspirin, renal or hepatic impairment, asthma and G6PD deficiency",False
Tramadol HCl 50mg Capsule,Tramal,Nervous System > Analgesics,N02AX02-110-C10-01-XXX,Yes,Government Contract,A/KK,"Moderate to severe acute or chronic pain (eg. Post-operative pain, chronic cancer pain and analgesia/pain relief for patients with impaired renal function)",None,"ADULT: 50mg initially, can take another 50mg after 30 - 60 min if pain not relieved. Max 400 mg daily. CHILD: 1mg/kg/dose repeated every 6 hours (Max: 2mg/kg/dose and 100mg/dose)","Sweating, dizziness, vomiting, dry mouth, gastrointestinal disturbances, cerebral convulsions especially on co-medication with neuroleptics, physical dependence. Rarely, palpitations, tachycardia, faintness, circulatory collapse, headaches, constipation, skin reactions. Very rarely, muscular weakness, altered appetite, micturition disturbances","Narcotic withdrawal treatment, hypersensitivity, acute alcoholism. Acute intoxication with alcohol, analgesics, sedatives or psychotropic drugs. MAOI therapy (within the 14 days of last discontinuation)","Amitryptiline, chlorpromazine, clozapine, dothiepin, fluoxetine, fluvoxamine, haloperidol, risperidone, sertraline, sulpiride, thioridazine, trifluoperazine: increased risk of seizures. Moclobemide, selegiline: nausea, vomiting, cardiovascular collapse, respiratory depression, seizures. Carbamazepine: decreased tramadol efficacy. Digoxin: increased risk of digoxin toxicity (nausea, vomiting, cardiac arrhythmias). Increased incidence of seizures when used with tricyclic antidepressants eg cyclobenzaprine, MAOI, SSRIs, neuroleptic agents and other drugs that lower the seizure threshold","Reduced level of consciousness, respiratory disorders, increased intracranial pressure, pregnancy, lactation, history of epilepsy. Opiate dependence, hypersensitivity to morphine-like analgesics, children less than 1 year. Myxedema, hypothyroidism or hypoadrenalism. Hepatic or renal function disorders. May impair ability to drive or machinery operation (alcohol).",True
Clotrimazole 500mg Vaginal Tablet,,Genito Urinary System and Sex Hormones > Gynecological Antiinfectives and Antiseptics,G01AF02-000-S10-03-XXX,Yes,LP,B,Vaginal candidiasis,None,500 mg as a single one-time dose,"Local irritation or skin reaction and mild burning, nausea, vomiting, troches, increased liver enzymes",Hypersensitivity to clotrimazole,"Concurrent use with betamethasone may result in increased susceptibility to skin infection or enhanced organism growth. Concurrent use with tacrolimus may increase plasma concentration of tacrolimus and cause toxicity (nephrotoxicity, hyperglycaemia, hyperkalaemia), fentanyl","Monitor hepatic function in patients with pre-existing hepatic impairment, not for ophthalmic use and vaginal use in pregnant patients should be supervised by a physician",False
Risperidone 37.5 mg Injection (Long Acting),Risperdal Consta,Nervous System > Psycholeptics,N05AX08000P3002XX,No,LP,A*,"Treatment of acute and chronic schizophrenic psychosis and other psychotic conditions, in which positive and negative symptoms are prominent. It also alleviates affective symptoms associated with schizophrenia",None,25 mg IM every 2 weeks. Dose increments (if required) to 37.5 mg or 50 mg can be considered after a minimum of 4 weeks on each dosage,"Weight gain, insomnia, depression, fatigue and extra-pyramidal symptoms","Hyperprolactinaemia, hypersensitivity to risperidone products, prolonged QT interval","May antagonize the effects of levodopa and other dopamine-agonists. Carbamazepine and other hepatic enzyme inducers, phenothiazines, tricyclic antidepressants and some beta-blockers, fluoxetine","Neuroleptic malignant syndrome, tardive dyskinesia, QT prolongation, cardiovascular or cerebrovascular disease or conditions that predispose patients to orthostatic hypotension, hypothermia or hyperthermia, previous diagnosis of breast cancer or prolactin-dependent tumours, renal and hepatic insufficiency, Lewy body dementia or Parkinson's disease, seizure history, pathologic changes in blood count, dysphagia, elderly patients, hypovolaemia, dehydration, risk of aspiration pneumonia, epilepsy, pregnancy and lactation. May affect ability to drive or operate machinery NPRA Safety Alert (17 June 2014) - risk of intraoperative floppy iris syndrome (IFIS) during and after cataract surgery",True
Methadone 5mg/ml Syrup,Adecure Syrup 5mg/ml for 100ml,Nervous System > Other Nervous System Drugs,N07BC02-110-L90-01-XXX,Yes,Government Contract,A/KK,Detoxification treatment or maintenance treatment of narcotic addiction.,None,"Initial 10-20mg per day, increasing by 10-20mg per day until there are no signs of withdrawal or intoxication. Usual dose 40-60mg/day","Constipation, nausea, vomiting, asthenia, dizziness, somnolence, cardiac arrest, disease of cardiovascular system, shock, respiratory arrest, respiratory depression, diaphoresis, constipation, sedation NPRA Safety Alert (2 November 2022) 1. Hypoglycaemia","Hypersensitivity to methadone, severe hepatic impairment, respiratory depression, obstructive airways disease, ulcerative colitis, concomitant administration with monoamine oxidase inhibitors (MAOIs) or within 2 weeks of discontinuation","Buprenorphine, didanosine, efavirenz, fluconazole, fluvoxamine, naltrexone, nevirapine, rifampin, risperidone, ritonavir, voriconazole, zidovudine","May cause dependence on prolonged use. Avoid alcoholic beverages, effects on ability to drive or operate machine. Methadone, even in low doses is a special hazard for children, non-dependent adults are also at risk of toxicity and dependent adults are at risk if tolerance is incorrectly asessed during induction",True
Bisacodyl 10mg Suppository,,Alimentary Tract and Metabolism > Drugs for Constipation,A06AB02-000-S20-02-XXX,Yes,APPL,C,i) Constipation ii) Bowel preparation for radiological procedures and surgery,None,i) ADULT and CHILD (over 10 years): 10 mg per rectal; CHILD (4 to 10 years): 5 mg per rectal. ii) ADULT and CHILD (over 10 years: )10 to 20 mg; CHILD (4 to 10 years): 5 mg the following morning before procedures insert rectally,"Rarely,electrolyte and fluid imblances, abdominal discomfort, diarrhoea, rectal burning, vomiting","Ileus, intestinal obstruction, acute abdominal conditions, rectal bleeding, appendicitis","Milk, antacids, warfarin","Prolonged use, abdominal pain, inflammatory bowel disease, sudden, persistent change in bowel habits and ulcerated haemorrhoids of rectal fissures",False
Bisacodyl 5 mg Tablet,,Alimentary Tract and Metabolism > Drugs for Constipation,A06AB02-000-T10-01-XXX,Yes,LP,C,i) Constipation ii) Bowel preparation for radiological procedures and surgery,None,i) ADULT and CHILD (over 10 years): 5 to 10 mg; CHILD (4 to 10 years): 5 mg. To be taken at night for effect on the following morning. ii) ADULT and CHILD (over 10 years): 10 mg in the morning and 10 mg in the evening the day before procedures; CHILD (4 to 10 years): 5 mg the night before procedures.,"Rarely,electrolyte and fluid imblances, abdominal discomfort, diarrhoea, rectal burning, vomiting","Ileus, intestinal obstruction, acute abdominal conditions, rectal bleeding, appendicitis","Milk, antacids, warfarin","Prolonged use, abdominal pain, inflammatory bowel disease, sudden, persistent change in bowel habits",False
Hepatitis B Vaccine Injection,,Antiinfectives for Systemic Use > Vaccines,J07BC01000P4001XX,Yes,APPL,C+,Immunisation against infections caused by Hepatitis B virus.,None,0.5 – 1.0 ml by IM. Dosing is according to Immunisation Schedule under NIP and product insert.,"Fatigue, malaise, nausea, diarrhoea, reactions at injection site",Hypersensitivity to any of the components,Not known,"Pregnancy, immunodeficiency and or receiving immunosuppresant therapy, severely compromised cardiopulmonary status",False
Compound Sodium Lactate (Hartmanns Solution),-,Blood and Blood Forming Organs > Blood Substitutes and Perfusion Solutions,B05XA30125P6001XX,Yes,APPL,C,"Replacement of extracellular losses of fluid and electrolytes, as an alkaliniser agent",None,100-1000 ml by IV or according to the needs of the patient,"Anxiety, panic attacks, apprehension or fear, paraesthesias, tremors, dizziness, metabolic alkalosis, hypokalaemia","Lactic acidosis, severe acidosis, hypernatraemia and conditions where sodium administration would be detrimental",Not known,"Metabolic or respiratory alkalosis, congestive heart failure, other sodium-retaining conditions, concurrent corticosteroids, conditions impairing lactate utilisation (severe hepatic insufficiency, shock, beriberi, hypoxia) and during prolonged therapy",False
Diphenhydramine Hydrochloride 14mg/5ml Expectorant,Benadryl,Respiratory System > Antihistamines for Systemic Use,R06AA52-110-L21-01-XXX,Yes,APPL,C,Cough,None,ADULT : 5 - 10 ml 2 - 3 times daily.,"Cardiovascular: hypotension, headache, palpitations, tachycardia, extrasystoles. Hematological : hemolytic anemia, thrombocytopenia, agranulocytosis. CNS : sedation, sleepiness, dizziness, disturbed coordination, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, praesthesia, vertigo, tinnitus, neuritis, convulsions. Ophthalmic: blurred vision, diplopia v) GI : epigastric distress, anorexia, nausea, vomitting, diarrhoea, constipation. Genitourinary: urinary frequency, difficult urination, urinary retention, early menses. Respiratory : thickening of bronchial secretions, tightness in chest and wheezing, nasal stuffiness. Dermatological : urticaria, rash, photosensitivity ix) others : dry mouth, nose an throats, chills, excessive perspiration","Hypersensitivity to diphenhydramine or other antihistamines of similar chemical structure, lactation, newborns or infants. Not to be used in children less than 2 years of age.","Reduces the absorption of the antituberculous agent para-aminosalicylic acid (PAS) from the gastrointestinal tract. Additive effects if use with hypnotics, sedatives, tranquilizers and alcohol. MAO inhibitors prolong and intensify the anticholinergic (drying)","May cause drowsiness, may impair ability to drive and operate machine or any activities requiring mental alertness. Elderly patients since sedation and hypotension occur frequently in patients over 60 years old. Special risk patients : glaucoma, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, bladder neck obstruction, patients with increased intraocular pressure, hyperthyroidism, cardiovascular disease, hypertension, history of asthma or lower respiratory tract disease iv) children : may prodeuce excitation in young children. To be used with caution and doctor's advice for children 2 to 6 years of age.",False
Terbutaline Sulphate 0.5mg/ml Injection,Bricanyl,Respiratory System > Drugs for Obstructive Airway Diseases,R03CC03-183-P30-01-XXX,Yes,LP,B,"Bronchial asthma, chronic bronchitis, emphysema and other lung diseases where broncoconstriction is a complicating factor",None,"SC, IM or slow IV : 250-500 mcg up to 4 times daily. CHILD 2 - 15 years 10mcg/kg to a maximum of 300 mcg. Continuous IV infusion, as a solution containing 3 - 5 mcg/ml, 1.5 - 5 mcg/minute for 8 - 10 hours; reduce dose for children","Nausea, vomiting and headache, tremor, tonic cramp, palpitation, tachycardia and arrythmias.",Not to be used in neonates,"Beta-blockers - inhibit bronchodilating effect. Monoamine oxidase inhibitors - increased risk of tachycardia, agitation or hypomania. Theophylline - decreased theophylline concentrations","This preparation contains benzyl alcohol, its use should be avoided in children under 2 years of age. This product contains Sodium Metabisulphite that may cause serious allergic type reactions in certain susceptible patients. Caution use in with patients with cardiovascular disease, pregnant patients or women in labor",False
Telmisartan 40 mg Tablet,Micardis,Cardiovascular System > Agents Acting on the Renin-angiotensin System,C09CA07000T1001XX,No,APPL,A/KK,"Patients intolerant to ACE inhibitors in: i) Hypertension ii) Reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors",None,i) 40mg - 80mg once daily. Max: 160mg daily ii) 80mg once daily Dosing is individualised and according to product insert / protocol.,"Headache, dizziness, upper respiratory infection and cough NPRA Safety Alert 1. 28 May 2025 (ARBs) Intestinal Angioedema","Hypersensitivity to telmisartan products, pregnancy and renal artery stenosis, lactation, biliary obstructive disorders, severe hepatic impairment","Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may cause hyperkalaemia (esp digoxin, lithium) May increase hypotensive effect of other antihypertensive","Angioedema (associated with aspirin and or penicillin allergy), discontinue with laryngeal stridor or angioedema of the face, tongue or glottis. Aortic or mitral valve stenosis, biliary cirrhosis or biliary obstruction, coronary artery disease and elderly, biliary obstructive disorders or hepatic insufficiency, Patient with diabetes mellitus & coronary artery disease (CAD). NPRA Safety Alert 1. 28 May 2025 (ARBs) Intestinal Angioedema",True
Losartan 50mg Tablet,,Cardiovascular System > Agents Acting on the Renin-angiotensin System,C09CA01-500-T10-01-XXX,Yes,Government Contract,B,Patients intolerant to ACE inhibitors in: i) Hypertensive patient with left ventricular hypertrophy ii) Type 2 Diabetes Mellitus with chronic kidney disease iii) Hypertension,-,"i), ii) & iii) Initial: 50mg once daily Max: 100mg once daily Dosing is individualised and according to product insert / protocol.","Angioedema, headache, dizziness, cough NPRA Safety Alert 1. 28 May 2025 Intestinal Angioedema","Hypersensitivity to losartan, pregnancy","Fluconazole, lithium, rifampicin","Angioedema: intravascular volume depletion (eg those treated with high-dose diuretics), electrolyte imbalance: lower dose should be considered for patients with a history of hepatic impairment, changes in renal function including renal failure may occur in susceptible individuals. Blood urea and serum creatinine may be increased in patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney, lactation, children NPRA Safety Alert 1. 28 May 2025 Intestinal Angioedema",False
"Levodopa 200 mg, Benserazide 50 mg Tablet",Madopar,Nervous System > Anti-parkinson Drugs,N04BA02977T1001XX,Yes,APPL,B,Parkinson's Disease,None,"Initial: 100/25 mg 1-2 times/day, increase every 3-4 days until therapeutic effect, optimal dosage: 400/100 mg to 800/200 mg/day divided into 4-6 doses. Dose: 200/50 mg used only when maintenance therapy is reached and not to exceed levodopa 1000-1200 mg/benserazide 250-300 mg per day","Anorexia, nausea and vomiting, diarrhoea, insomnia, agitation, cardiac arrhythmias, postural hypotension (rarely labile hypertension), dizziness, tachycardia, arrhythmias, reddish discoloration of urine and other body fluid, rarely hypersensitivity, abnormal involuntary movement. Lost or change of taste. Abnormal involuntary movements. Rarely, skin reactions, haemolytic anaemia, mild, transient leukopenia and thrombocytopenia. Agitation, anxiety, insomnia, hallucination, delusion and temporal disorientation in the elderly","Hypersensitivity to this drug. Patient on MAOIs therapy with decompensated endocrine, renal or hepatic function, cardiac disorders, psychiatric diseases or closed-angle glaucoma. Pregnancy. Patients less than 25 years. Lactation. Combination with MAOIs (except selegiline)","Hypertensive crisis with MAOIs, increased hypotensive effect with antihypertensives, antagonism effect of antipsychotic, reduced absorption by iron, plasma concentration increased by metoclopramide. Tricylic antidepressant, phenothiazines, phenytoin, pyridoxine. Potentiates effects of sympathomimetics. Neuroleptics, opioids, antihypertensives containing reserpine, antacid, protein-rich meal","Open-angle glaucoma, depression, diabetes, severe cardiovascular disease, bronchial asthma, renal, hepatic or endocrine disease, history of psychoses or convulsion. Lactation. Perform liver function and blood count tests during treatment. Discontinue 12-48 hours before surgery requiring general anaesthesia. If patient must undergo surgery without Madopar having been withdrawn, avoid anaesthesia with cyclopropane or halothane",False
Budesonide 160mcg and Formoterol 4.5mcg Inhalation,,Respiratory System > Drugs for Obstructive Airway Diseases,R03AKO7-989-A21-01-XXX,Yes,Government Contract,"A*, A/KK","Prescriber category A/KK: i) Regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - Patients not adequately controlled with inhaled corticosteroids and ""as needed"" inhaled short-acting beta2-agonists. or - Patients already adequately controlled on both inhaled corticosteroids and long- acting beta2-agonists. ii) As a reliever treatment for mild asthma patients who do not adhere to regular inhaled corticosteroid Prescriber category A*: iii) Treatment of COPD patients with a blood eosinophil count of 300 cells/microliter and more iv) Treatment of COPD patients with blood eosinophil count of 100 cells/microliter and more with history of repeated exacerbation despite regular treatment with long-acting bronchodilators.","70 PT (KKTPG, KKTD, KKJ),  60 PT (KKBC, KKB), 40  PT (KKS, KKTS)  (KUOTA)","i) Asthma Maintenance therapy: Adult ≥18 yr 160 mcg to 320 mcg bd. Some patients may require up to a max of 640 mcg bd. Adolescent 12-17 yr 160 mcg to 320 mcg bd. Childn 6-11 yr 160 mcg bd, <6 yr Not recommended. Maintenance & relief Adult and adolescent ≥12 yr 320 mcg/day either as 160 mcg bd or 320 mcg od either morning or evening. For some patients a maintenance dose of 320 mcg bd may be appropriate. Patients should take 160 mcg additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken. Not more than 960 mcg should be taken on any single occasion. A total daily dose of more than 1280 mcg is not normally needed, however a total daily dose of up to 1920 mcg could be used for a limited period. Patients using more than 1280 mcg daily should seek medical advice, should be reassessed & their maintenance therapy reconsidered. ii) Asthma reliever-only therapy: 160 mcg as needed, but no more than 960 mcg to be taken on any single occasion. Children <12 yr: Not recommended iii & iv) COPD: Adult ≥18 yr 320 mcg bd.","Palpitations, candida infections in the oropharynx, headache, tremor, mild irritation in the throat, coughing and hoarseness, tachycardia, nausea, muscle cramps, dizziness, agitation, restlessness, nervousness, sleep disturbances, bruises","Hypersensitivity to budesonide, formoterol or lactose (which contains small amounts of milk protein).","Itraconazole, ritonavir, CYP3A4 inhibitors. β-blockers (including eye drops), potent CYP3A4 inhibitors. Quinidine, disopyramide, procainamide, phenothiazines, antihistamines (terfenadine), MAOIs (furazolidone & procarbazine) & tricyclic antidepressants, anesthetic, digitalis.","Taper dose when discontinuing treatment. Seek medical advice if treatment is ineffective or exceeds highest recommended dose. Maintenance dose should be taken even when asymptomatic. Prophylactic use eg before exercise, has not been studied. Therapy should not be initiated during an exacerbation. Should be discontinued upon paradoxical bronchospasm, with an immediate increase in wheezing after dosing. Potential systemic effects in patients on high doses for prolonged periods eg adrenal suppression, reduced bone mineral density, glaucoma, cataract. Thyrotoxicosis, phaeochromocytoma, diabetes mellitus, untreated hypokalaemia, hypertrophic obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe hypertension, aneurysm, severe cardiovascular disorders. Unstable & acute asthma. Monitor K levels. Pregnancy, lactation. Monitor growth in children & adolescents especially with long-term therapy. Formoterol may induce prolongation of the QTc-interval. Fungal or viral infections in the airways.",True
Zuclopenthixol Decanoate 200 mg/ml Injection,Clopixol Depot,Nervous System > Psycholeptics,N05AF05135P2001XX,Yes,Government Contract,B,"Maintenance treatment of schizophrenia and other psychoses, especially with symptoms such as hallucinations, delusions and thought disturbances along with agitation, restlessness, hostility and aggressiveness in patients not responding to available standard drugs",None,By deep IM injection test dose 100 mg followed after 7 - 28 days by 100 - 200 mg or more followed by 200 - 400 mg at intervals of 2 - 4 weeks adjusted according to response. Maximum 600 mg weekly. Child not recommended,"Extrapyramidal syndrome, drowsines, anticholinergic effect, tachycardia, postural hypotension, dizziness, tardive dyskinesia, urinary retention, disturbed accommodation","Severe central nervous system depression, blood dyscrasias, phaeocromocytoma. Previous hypersensitivity to zuclopenthixol or clopenthixol. Comatose states, acute alcohol, barbiturate and opiate intoxication. Pregnancy","Alcohol, barbiturates and central nervous system depressant, tricyclic antidepressant, metoclopramide - increased effect","Previous hypersensitivity to other neuroleptic agents, particularly thioxanthenes, fluphenazine and perphenazine, Hepatic or renal disease or cardiovascular disease, pregnancy, breastfeeding, epileptic or parkinsonian patients or organic brain syndrome. Patients on long-term therapy should be monitored carefully. May affect ability to drive or operate machinery",False
"Rifampicin 150 mg, Isoniazid 75 mg, Pyrazinamide 400 mg & Ethambutol HCl 275 mg Tablet",Akurit-4,Antiinfectives for Systemic Use > Antimycobacterials,J04AM06-000-T10-01-XXX,Yes,Government Contract,B,"Treatment of both pulmonary and extrapulmonary tuberculosis, in the intensive treatment phase",None,"ADULT: 30 - 37 kg: 2 tablets daily, 38 - 54 kg: 3 tablets daily, 55 - 70 kg: 4 tablets daily, more than 70 kg: 5 tablets daily","Reddish discoloration of body fluids, increased hepatic enzyme levels, gastrointestinal disturbances, tiredness, drowsiness, headache, dizziness, ataxia, leucopenia, eosinophilia, flushing, itching, rash, disturbances in the menstrual cycle, induction of crisis in Addison patients, 'flu-like' symptoms, disturbances of liver function, hepatitis, peripheral neuropathy, agranulocytosis, eosinophilia, thrombocytopenia, allergic reactions, lupus erythematosus-like syndrome, pellagra, gynaecomastia, hyperuricaemia, interstitial nephritis, dysuria, photosensitivity, porphyria, reversible retrobulbar neuritis with a reduction of visual acuity, central scotoma and green-red color blindness, jaundice, peripheral neuritis, confusion, hallucinations, joint pain, fever, malaise, anorexia and abdominal pain NPRA Safety Alert 1. 9 Jan 2025 Ethambutol: Risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)","Combined preparation not suitable for use in children. History of drug-induced hepatitis, acute liver diseases regardless of their origin, peripheral neuritis","Oral contraceptives, hormone replacement therapy, anticoagulants, antidiabetics, antihypertensives, cardiac drugs, antiepileptics, antacids, cimetidine, opioid analgesics, disulfiram, anxiolytics, sedatives, sulfinpyrazone, allopurinol, colchicine, probenecid, corticosteroids, chloramphenicol, ketoconazole, dapsone, methadone, theophylline, cyclosporin A, azathioprine, alcohol","Impaired renal or liver function, diabetes mellitus, chronic alcoholism, undernourished patients and history of gout, convulsive disorders, and acute porphyria. Avoid tyramine and histamine-containing food. May impair ability to drive or operate machinery",False
Lactulose 3.35g/5 ml Liquid,,Alimentary Tract and Metabolism > Drugs for Constipation,A06AD11-000-L50-01-XXX,Yes,Government Contract,C+,i) Constipation ii) Hepatic encephalopathy,None,"i) ADULT 15-45 ml daily in 1-2 divided doses adjusted to patient's need. Maintenance dose: 15-30ml daily in 1-2 divided doses. CHILD 0.5 ml/kg/dose once or twice daily. ii) ADULT: 30-45 ml 2-4 times daily, dose adjusted to produce 2-3 soft stools daily. CHILD: 1 ml/kg/dose 3-4 times daily.","Flatulence, cramps and abdominal discomfort","Galactosaemia, intestinal obstruction",Response may be altered by anti-infective agents,"Diabetics, patients with lactose intolerance, pregnancy, lactation",False
Levodopa 100 mg and Carbidopa 25 mg Tablet,Sinemet,Nervous System > Anti-parkinson Drugs,N04BA02000T1001XX,Yes,APPL,B,Parkinson's disease,None,"Patients not receiving Levodopa before, initially 100 - 125 mg 3 - 4 times daily adjusted according to response. Maintenance: 0.75 - 2 g in divided doses. In patients previously treated with Levodopa the dose should be about 20 - 25% of the dose previously being taken","Central nervous system: Anxiety, confusion, nervousness, mental depression, psychotic symptoms. Anorexia, nausea and vomiting, diarrhoea, insomnia, agitation, postural hypotension, dizziness, chest pain, tachycardia, arrhythmias, reddish discoloration of urine and other body fluid. Dyskinesia, muscle twitching and blepharospasm may be taken as early signs to consider dosage reduction. Gastrointestinal bleeding, development of duodenal ulcer, dark saliva, leukopenia, hemolytic and non-hemolytic anaemia, thrombocytopenia, agranulocytosis, angioedema, urticaria, pruritus, paraesthesia, increased libido, dyspnoea, alopecia, rash, dark sweat, dark urine","Hypersensitivity to this drug. Patient on MAOIs therapy or 2 weeks prior to initiating therapy. May be administered concomitantly with or an MAOI with or selectivity for MAO type B (eg selegiline HCl). Narrow-angle glaucoma with compensated endocrine, renal or hepatic function, cardiac disorders, psychiatric diseases or closed-angle glaucoma, undiagnosed skin lesion, melanoma, pregnancy","Hypertensive crisis with MAOIs, increased hypotensive effect with antihypertensives, antagonism effect of antipsychotic, reduced absorption by iron, plasma concentration increased by metoclopramide. Linezolid, clonidine, anticholinergics, tricylic antidepressant, phenothiazines, phenytoin, papaverine, selegiline and high protein diet","Not recommended for treatment of drug-induced extrapyramidal reactions. The occurrence of dyskinesias in patients previously treated with levodopa alone may require dosage reduction. All patients should be observed carefully for the development of depression with concomitant suicidal tendencies. Cardiovascular disease or pulmonary disease, bronchial asthma. Hepatic impairment, renal impairment, endocrine disease, chronic wide-angle glaucoma. Observe carefully when the dosage is reduced abruptly or discontinued, especially if the patient is receiving neuroleptics. Pregnancy, women of childbearing potential. Not recommended in patients less than 18 years",False
Gliclazide 80 mg Tablet,,Alimentary Tract and Metabolism > Drugs Used In Diabetes,A10BB09000T1001XX,Yes,APPL,B,Diabetes mellitus type 2,None,"Initially 40-80mg daily. A single dose should not exceed 160mg and when higher doses are required, a twice daily split dosage is advised and should be divided. Maximum daily dose: 320mg. For elderly, starting dose should be 40mg twice daily.","Nausea, vomiting, heartburn, anorexia, diarrhoea, metallic taste, increased appetite, weight gain, skin rashes, pruritus, hypoglycemia, hypersensitivity. Infrequently, SIADH","Type 1 diabetes mellitus, pregnancy and lactation, diabetic ketoacidosis, diabetics undergoing surgery, diabetic coma, diabetic precoma, hyperosmolar nonketotic coma, after severe burns or trauma, or during infections, hypersensitivity, severe renal or hepatic insufficiency, treatment with miconazole","Alcohol (causing disulfiram-like reaction) Drugs that potentiate hypoglycaemic effect: Coumarins, sulphonamides, salicylates, phenylbutazone, beta blockers, MAOIs, ketoconazole, miconazole Drugs that diminish hypoglycaemic effect: Thiazide diuretics, corticosteroids and oestrogens","Paediatric, excessive exercise, severe diarrhoea, severe gastroparesis, intestinal obstruction, prolonged vomiting, hyperglycaemia, hyperthyroidism, hypoglycaemia, hypothyroidism, renal impairment, hepatic impairment, intercurrent infections, traumas, shock, after anaesthesia, major surgery",False
Escitalopram 10mg Tablet,Lexapro,Nervous System > Psychoanaleptics,N06AB10-124-T10-01-XXX,Yes,Government Contract,B,i) Major depression ii) Treatment of panic disorder with or without agoraphobia iii) Treatment of social anxiety disorder (social phobia) iv) Treatment of obsessive-compulsive disorder (OCD) v) Treatment of generalised anxiety disorder,None,"i) Initial: 10mg once daily. Increase gradually if necessary up to a maximum of 20mg daily ii) Initial: 5mg daily for the first week and then increase to 10mg daily Increase if necessary up to a maximum of 20mg daily ELDERLY Initial: half the adult dose, lower maximum dose should be considered iii) Usual dose: 10mg once daily Adjust as necessary based on patient response to either 5mg or up to a maximum of 20mg daily iv) & v) Usual dose: 10mg once daily Adjust as necessary based on patient response up to a maximum of 20mg daily Dosing is individualised and according to product insert/ protocol. Should not be used in patients under 18 years old. If, based on clinical need, a decision to treat is nevertheless taken; the patient should be carefully monitored for appearance of suicidal symptoms.","Dizziness, headache, nausea, sweating, somnolence, insomnia, constipation, diarrhoea, increase or decreased appetite, sexual dysfunction, fatigue, pyrexia, sinusitis, yawning, rash, Steven Johnson Syndrome, rhinitis, blurred vision, nasal congestion, prolactinemia, dry mouth, decrease prothrombin, hepatic failure, hypoglycemia, hypokalemia, suicidal ideation, diaphoresis, Syndrome of inappropriate antidiuretic hormone secretion (SIADH), ear ache, urinary tract infection, urinary frequency.",Concurrent use of MAOIs or within 14 days of discontinuing MAOS treatment,"MAOI, selegiline, lithium, tryptophan, agents that may lower seizure threshold, St John's Wort, omeprazole, high doses of cimetidine, drugs metabolised by CYP2D6 and CYP2C19 enzymes, alcohol, aspirin, NSAIDs, warfarin, carbamazepine, ketoconazole, linezolid, tramadol, metoprolol, 5 HT agonist, gingko, lamotrigine","Paradoxical anxiety, seizures, mania, diabetes, suicidal tendencies, hyponatraemia, haemorrhage, electroconvulsive therapy, reversible selective MAO-A inhibitors, serotonin syndrome, St John's Wort, lactation, renal and hepatic function impairment, abnormal bleeding, avoid abrupt discontinuation, may activate hypomania or mania, concomitant use of NSAIDs, work requiring mental alertness.",False
Budesonide 64mcg Nasal Spray,Rhinocort Aqua,Respiratory System > Nasal Preparations,R01AD05-000-A41-03-XXX,Yes,LP,A/KK,"Seasonal allergic, perennial rhinitis and nasal polyposis",None,ADULT and CHILD 6 years and older. Rhinitis : 2 spray into each nostril once daily in the morning or 1 spray into each nostril twice daily. Nasal polyps : 2 spray twice daily,"Nasal irritation, nose bleeding, dryness of throat, epistaxis, pharyngitis, cough, nasal irritation, bronchospasm, cataract, cushing's syndrome, glaucoma, secondary hypocortisolism","Severe nasal infection, recurrent nasal bleeding, hypersensitivity to budesonide products, status asthmaticus or other acute episodes of asthma","Erythromycin, clarithromycin, lansoprazole, amoxicillin, fluvoxamine, itraconazole, ketoconazole, protease inhibitors, voriconazole, cimetidine","Severe fungal and viral nasal infections, chronic use, liver cirrhosis, reduce liver function, pulmonary tuberculosis, glaucoma, adrenal suppression",True
Metformin HCl 500 mg Extended Release Tablet,Diabetmin XR,Alimentary Tract and Metabolism > Drugs Used In Diabetes,A10BA02-110-T50-01-XXX,Yes,APPL,B,Diabetes mellitus who experienced gastrointestinal side effects with normal metformin,"100 PT (KKS), 150 PT (KKBC, KKTS), 200 PT (KKTPG, KKTD, KKJ, KKB) (KUOTA)",500 mg once daily. Maximum dose 2000 mg once daily with evening meal,"Gastrointestinal disorders, taste disturbance/metallic taste. Rarely, decreased vitamin B12 absorption, lactic acidosis, skin reactions, liver function tests abnormalities NPRA Safety Alert 1. 27 Sept 2022 2. 4 Mac 2024 (updated) Vitamin B12 Deficiency","Hypersensitivity, diabetic ketoacidosis, diabetic precoma, renal failure (CrCl < 60ml/min), acute conditions with potential to alter renal function (e.g. dehydration, severe infection, shock), acute or chronic disease which may cause tissue hypoxia (e.g. cardiac or respiratory failure, recent myocardial infarction), hepatic insufficiency, alcohol, lactation","Alcohol, iodinated contrast agents, glucocorticoids, beta-2 agonists, diuretics, ACEIs","Renal failure (risk of lactic acidosis), administration of iodinated contrast agent (discontinue prior to radiologic exam and restart 48 hours afterwards), surgery (discontinue 48 hours prior to surgery and restart 48 hours afterwards), pregnancy NPRA Safety Alert 1. 4 Mac 2024 May reduce vitamin B 12 serum levels. (For full info, please refer package insert/related NPRA Safety Alert)",False
Insulin Aspart 100 IU/ml Injection,Novorapid,Alimentary Tract and Metabolism > Drugs Used In Diabetes,A10AB05000P3001XX,Yes,Government Contract,A/KK,Diabetic Type 1 and 2 in patients that still experienced hypoglycaemia with use of human insulin,Tertakluk kepada arahan surat Ketua Pengarah Kesihatan dengan no. ruj.: KKM.600-34/1/3 Jld.4(21) bertarikh 21 Ogos 2024 dan garis panduan berkaitan yang dikeluarkan dari semasa ke semasa.; 20 PT/KK,Dose to be individualised. The average daily insulin requirement is between 0.5 to 1.0 units/kg body weight,"Transient oedema, local reactions and fat hypertrophy at injection site, hypoglycaemia, hypokalaemia, generalized hypersensitivity","Hypersensitivity to insulin aspart and its components, hypoglycaemia","Oral hypoglycaemic agents, octreotide, MAOIs, alcohol, lithium, non selective beta blocker, ACE inhibitor, salicylates, anabolic steroids, glucocorticoids, oral contraceptives, sulphonamides, disopyramides, diuretics fibrates, fluoxetine, propoxyphene, thyroid hormone, symphatomimetics, danazol, niacin, isonazide, guanethidine, reserpine, clonidine, phenothiazine","Decreased insulin requirements due to hepatic or renal impairment, malabsorption, diarrhoea, nausea/vomiting, hypothyroidism hypokalaemia, stress due to fever, infection, surgery, trauma, systemic allergic reactions",True
Pre/Post Natal Vitamin & Mineral Capsule,-,Alimentary Tract and Metabolism > Vitamins,A11AA03903C1001XX,Yes,LP,C+,Vitamin and mineral supplement for use during pregnancy and lactation,None,1 capsule daily or based on individual requirements,Hypervitaminosis,Hypersensitivity to product components,"Pyridoxine will antagonise the therapeutic effect of Levodopa (should not be administered concurrently), vitamin B6 reduces the plasma levels of phenobarbitone and phenytoin, ascorbic acid increases plasma level of ethinyloestradiol",Severe renal or liver failure,False
Trimetazidine 20 mg Tablet,Vastarel,Cardiovascular System > Cardiac Therapy,C01EB15110T1001XX,No,Government Contract,B,Prophylactic treatment of episodes of angina pectoris,None,20 mg 3 times daily,Gastrointestinal disorders such as nausea and vomiting,Concomitant administration with MAOIs,Not known,"Pregnancy especially first trimester, unstable angina, hypertension, renal or hepatic insufficiency",False
Perindopril 4 mg and Indapamide 1.25 mg Tablet,Coversyl Plus,Cardiovascular System > Agents Acting on the Renin-angiotensin System,C09BA04-900-T10-01-XXX,No,Government Contract,B,"Essential hypertension, for patients whose blood pressure is insufficiently controlled by perindopril alone.",10PT /KK (KUOTA),"One tablet daily, preferably taken in the morning and before a meal.","Headache, asthenia, dizziness, sleep disturbances, cramps, hypotension, rash, gastrointestinal disturbances, slight reversible increase in urea and plasma creatinine, hypokalaemia, hyponatraemia with hypovolaemia, raised uric acid and blood glucose levels NPRA Safety Alert 1. 5 May 2022 Choroidal effusion, acute myopia, acute angle closure glaucoma","Hypersensitivity to other ACE inhibitors or sulphonamides. Bilateral renal artery stenosis or single functioning kidney, severe renal failure (creatinine clearance less than 30 mL/min), dialysis patients, hepatic encephalopathy, severe hepatic impairment, hyperkalaemia or hypokalaemia, untreated decompensated cardiac insufficiency. Previous history of angioneurotic oedema linked to treatment with ACE inhibitor, hereditary or idiopathic angioneurotic oedema. Pregnancy and lactation","Lithium, insulin, sulfonylureas, baclofen, NSAIDs, high dose salicylates, tricyclic antidepressants, neuroleptics, corticosteroids, tetracosactide, potassium-sparing diuretics, potassium salts, potassium-lowering drugs, anaesthesia, allopurinol, immunosuppressant, cardiac glycosides, procainamide and other drugs which cause torsades de pointes, antihypertensive drugs, metformin, calcium salts, ciclosporin, iodinated contrast media","Renal insufficiency especially when associated with systemic autoimmune collagen vascular diseases. Concomitant treatment with immunosuppressant or treatment causing leucopoenia. Marked sodium and water depletion, hypotension, chronic heart failure, cirrhosis with oedema and ascites, ischemic heart disease, cerebral circulatory insufficiency, severe cardiac insufficiency (grade IV) or IDDM patients. Monitor serum potassium regularly. Surgery, elderly, hyperaldosteronism, malnourishment, acute porphyria",False
Rosuvastatin 10 mg Tablet,Crestor,Cardiovascular System > Lipid Modifying Agents,C10AA07390T1002XX,No,LP,A/KK,Dyslipidaemia not responsive to atorvastatin 40mg or equivalent doses of other statins,"30 PT (KKBC, KKTS), 50 PT (KKS), 70 PT (KKTD), 80 PT (KKB), 100 PT (KKJ), 250 PT (KKTPG)  (KUOTA) ","Initially 5-10 mg once daily (5mg in patients with pre-disposing factors to myopathy), increased if necessary at intervals of at least 4 weeks to 20 mg once daily, increased after further 4 weeks to 40 mg daily ONLY in severe hypercholesterolemia with high cardiovascular risk. Patient of Asian origin, patients on concomitant ciclosporin/fibrate and patients with risk factors for myopathy/rhabdomyolysis (including personal/family history of muscular disorders/toxicity), the maximum dose should be 20 mg daily","Pharyngitis, headache, diarrhoea, dyspepsia, nausea, myalgia, asthenia, back pain, flu syndrome, urinary tract infection, rhinitis, sinusitis, altered liver function tests, paraesthesia, abdominal pain, flatulence, constipation and vomiting. Cognitive impairment (e.g. memory loss, forgetfulness, amnesia, memory impairment, confusion). Increase in HbA1c and fasting blood glucose NPRA Safety Alert 1. 27 May 2025 (Statins) Myasthenia Gravis / Ocular Myasthenia",Active liver disease including elevated serum transaminases more than 3 times upper limit of normal. Severe renal impairment (creatinine clearance less than 30 mL/min). Patients with myopathy. Patients receiving concomitant ciclosporin. Pregnancy and lactation,"Warfarin, vitamin K antagonists, ciclosporin, gemfibrozil, lopinavir/ritonavir, antacids (aluminium and magnesium hydroxide), erythromycin, ketoconazole, spirinolactone, cimetidine, oral contraceptives, digoxin, fenofibrate NPRA Safety Alert 1. 19 Feb 2024 (Statins) Interaction with Ticagrelor Leading to Increased Risk of Rhabdomyolysis","Monitor renal and liver function. Predisposing factors for myopathy such as renal impairment, advanced age, hypothyroidism. Acute serious conditions suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis. Concurrent use of fibrates may cause severe myositis and myoglobinuria, concurrent use of other lipid-lowering therapies including gemfibrozil may increase the risk of myopathy NPRA Safety Alert 1. 18 Jul 2023 (Statins) Risk of Inducing or Aggravating Myasthenia Gravis 2. 27 May 2025 (Statins) Myasthenia Gravis / Ocular Myasthenia",True
Influenza Vaccine (Inactivated) Injection,Vaxigrip Tetra,Antiinfectives for Systemic Use > Vaccines,J07BB02963P30XXXX,Yes,Government Contract,B,i) Prophylaxis of influenza for frontliners (KKM staff and essential services personnel). ii) Prophylaxis of influenza in high risk groups. Refer to current recommendation by WHO for selection of product of inactivated influenza vaccines.,B,0.25ml to 1.0ml by IM. Dosing is according to product insert and WHO recommendations.,"Transient thrombocytopenia, transient lymphadenopathy, allergic reactions, neuralgia, paraesthesia, febrile convulsions, neurological disorders (such as encephalomyelitis, Guillain-BarrÈ Syndrome), vasculitis, generalized skin reactions.","Hypersensitivity to any components of the vaccine, eggs, chicken proteins, neomycin, formaldehyde and octocinol 9.",Immunosuppressive drugs.,"Serious acute febrile, bleeding disorders, on anticoagulant therapy, active neurologic disorder, patients known to have experienced Guillain-Barre syndrome within 6 to 8 weeks after a previous influenza vaccination.",False
Insulin Detemir 100 IU/ml Injection in Prefilled syringe/cartridge,Levemir,Alimentary Tract and Metabolism > Drugs Used In Diabetes,A10AE05000P5001XX,Yes,Government Contract,A/KK,"i)Type 1 Diabetes patients on basal bolus regimen, whom experience hypoglycaemia with conventional insulin, to be used in combination with rapid or short-acting insulin. ii)Type 2 Diabetes patients on oral anti-diabetics and basal insulin regimen or basal bolus insulin regimen whom experience hypoglycaemia with conventional basal insulin.","5 PT (KKS, KKTPG, KKJ, KKBC, KKTS), 10 PT (KKTD, KKB) (KUOTA)","Individualized dose given via SC once or twice daily. Initiate at a dose of 10IU or 0.1-0.2IU/kg. For twice daily dosing, the evening dose can be administered either with the evening meal, at bedtime, or 12 hours after the morning dose.","Hypoglycaemia, allergic reactions, lipodystrophy, pruritus, rash, mild injection site reactions, oedema, weight gain.","Hypersensitivity to insulin detemir or any of its excipients, hypoglycemia","Oral antidiabetics, MAOIs, nonselective β-blockers, ACE inhibitors, salicylates, alcohol, thiazides, glucocorticoids, β-sympathomimetics, thyroid & growth hormones, danazol, octreotide/lanreotide.","Monitor glucose levels in elderly and patients with renal or hepatic impairment. Transferring from other insulin types should be done under strict medical supervision. Concomitant illness especially infection usually increase insulin requirement. Do not administer intravenously. Risk of hyper/hypoglycemia during therapy. Pregnancy and lactation, children.",True
Nicotine 10mg/16hr Transdermal Patch,Nicorette Patch,Nervous System > Other Nervous System Drugs,N07BA01000M7005XX,Yes,LP,A/KK,"For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit.",None,The patch should be apply to an intact area of the skin upon waking up in the morning and removed at bedtime. Heavy smoker (those smoking 15 or more cigarettes in a 24-hour period): Step 1: 25mg/16 hours patch and use one patch daily for 8 weeks. Step 2: One 15mg/16hours patch should be daily for 2 weeks Step 3: One 10mg/16 hours patch daily for 2 weeks. Light smokers (those smoking less than 15 cigarettes in a 24-hour period): Step 1: 15mg/16hours patch for 8 weeks Step 2: 10mg/16hours for the final 4 weeks. Combination therapy with the patch (Flexible smoking cessation format) for fast relief of cravings in: i) Highly dependent smokers; or ii) Smokers who experience breakthrough cravings; or iii) Those who have failed single NRT treatment,"Mild skin reactions, erythema, itching, oedema and aphtous ulcers, headache, dizziness, nausea and vomiting, palpitations.",- Hypersensitivity to nicotine or any other product component. - Patients with recent myocardial infarct; unstable or worsening angina pectoris; - Prinzmetal's angina; severe cardiac arrhythmias; acute stroke. - Pregnancy and lactation. - Children below 18 years old.,"- Paracetamol, caffeine, imipramine, oxazepam, pentazocine, propranolol, theophylline, warfarin, oestrogens, lignocaine, phenacetin; may require a decrease in dose at cessation of smoking due to the de-induction of hepatic enzymes on smoking cessation. - Subcutaneous insulin absorption may increase with smoking cessation. - Adrenergic antagonists (eg. prazosin, labetalol); decrease in circulating catecholamines with smoking cessation. - Adrenergic agonists (eg. isoprenaline, phenylephrine); may require an increase in dose at cessation of smoking due to a decrease in circulating catecholamines with smoking cessation. - Other effects, associated with smoking, include reduced analgesic efficacy with propoxyphene, reduced diuretic response to frusemide and reduced rates of ulcer healing with H2-antagonists.","- Patients with chronic generalised dermatological disorders eg, psoriasis, chronic dermatitis or urticaria should not use the patch. - Patients with severe cardiovascular disease (eg, occlusive peripheral arterial disease, cerebrovascular disease, stable angina pectoris and heart failure), vasospasms, uncontrolled hypertension, severe hepatic and/or renal impairment, active duodenal and gastric ulcer. - Patients with diabetes mellitus, hyperthyroidism or pheochromocytoma, since nicotine causes the release of catecholamines from the adrenal medulla",True
Vitamin B Complex Tablet,-,Alimentary Tract and Metabolism > Vitamins,A11EA00901T1001XX,No,APPL,C+,Prophylaxis and treatment of vitamin B deficiency,None,1-2 tablets daily,Skin rashes or itching in allergic persons. Nicotanamide in large doses may cause liver disease and active peptic ulcer.,Sensitivity to thiamine and nicotinamide.Nicotanamide in large doses may cause liver disease and active peptic ulcer. Thiamine: Weniche's encephalopathy.,Alcohol may inhibit absorption of these vitamins,Not for treatment of pernicious anaemia or other megaloblastic anaemias where vitamin B12 is deficient,False
"Ferrous controlled release 525 mg, Vitamin B1, Vitamin B2, Vitamin B6, Vitamin B12, Vitamin C, Niacinamide, Calcium Pantothenate, Folic Acid 800 mcg Tablet",Iberet-Folic-500,Blood and Blood Forming Organs > Antianemic Preparations,B03AE10903T1001XX,Yes,Government Contract,A/KK,"Anemia due to iron deficiency, megaloblastic anemia where there is an associated deficiency of Vitamin C and Vitamin B-complex particularly in pregnancy. In primary health clinic, the indication is restricted to anemia due to iron deficiency in pregnant women ONLY.",None,One tablet daily,"Rare, occasionally with nausea, vomiting, constipation or diarrhea, gastric pain at high doses","Patients with hypersensitivity to any of the ingredients of this drug, patients with thalassemia, sideroblastic anemia, hemochromatosis, and hemosiderosis. Should not be used in paediatric patients and also contraindicated in the rare instance of hypersensitivity to folic acid",Magnesium trisilicate and antacid which contains carbonate will inhibit the absorption of iron. Ferrous sulfate affects tetracycline absorption. Levodopa may produce reversed effect due to pyridoxine. Administration with milk or egg may inhibit the absorption of iron.,Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemia where vitamin B12 is deficient. There is the possibility of dark feces. Not suitable to patients who received repeated blood transfusion or non-iron deficiency anemia. Long-term usage may cause iron accumulation. Use in the elderly: Elderly people who have tendency of vitamin B12 deficiency must have regular monitoring of vitamin B12 serum concentration while taking this drug.,True
Allopurinol 300 mg Tablet,Zyloric,Musculo-skeletal System > Antigout Preparations,M04AA01-000-T10-01XXX,Yes,APPL,A/KK,i) Frequent and disabling attacks of gouty arthritis (2 or more attacks/year). ii) Clinical or radiographic signs of erosive gouty arthritis. iii) The presence of tophaceous deposits. iv) Urate nephropathy. v) Urate nephrolithiasis. vi) Impending cytotoxic chemotherapy or radiotherapy for lymphoma or leukaemia,-,Initial dose: 50-100 mg daily. Maintenance: 300-900mg daily (depending on renal function).,"Skin rash, maculopapular, pruritic, Stevens-Johnson Syndrome, peripheral neuritis, alopecia, GI upset, toxic epidermal necrolysis. Acute attack of gouty arthritis in early stages of therapy. Skin reactions (discontinue immediately at first sign of rash). Very rarely, granulomatous hepatitis. Occasionally; thrombocytopenia, agranulocytosis, & aplastic anaemia in patients with impaired renal function","Hypersensitivity to allopurinol, pregnancy, lactation, acute gout, asymptomatic hyperuricaemia","Oral anticoagulants, azathioprine, antidiabetics, mercaptopurine.Use only quarter of the usual dose of 6-mercaptopurine or azathioprine when given concurrently. Increases plasma half-life of adenine arabinoside. Effects decreased by uricosurics & large doses of salicylates","Renal/hepatic dysfunction, asymptomatic hyperuricaemia, Hypersensitivity and pregnancy",True
Nevirapine 200mg Tablet,,Antiinfectives for Systemic Use > Antivirals for Systemic Use,J05AG01-000-T10-01-XXX,Yes,APPL,A/KK,Treatment of HIV-1 infection in combination with other antiretroviral agents,None,"Combined with other antiretrovirals: 200 mg once daily for the 1st 14 days; up to 200 mg twice daily if rash does not develop. Re-introduce at a lower dose for the 1st 14 days if treatment is interrupted for >7 days,necessitate reintroduction at a lower dose for the first 14 days.","Hepatitis, hepatic failure (life threatening), hepatotoxicity, severe skin reaction, headache, fatique, diarrhoea, nausea, rash","Hypersensitivity to nevirapine or any component of the formulation, breast feeding, severe hepatic impairment","Methadone, rifampicin, ketoconazole, other antivirals such as saquinaxir, indinavir, St. John's wort, warfarin",Pregnancy. Interrupt treatment if severe hepatotoxicity or life-threatening skin reactions develop. Renal or hepatic insufficiency. Monitor liver function periodically. Avoid use in patients with CD4 cell counts more than 250 cells/mm3 in adult women and 400 cells/mm3 in adult men.,True
Zidovudine 300mg & Lamivudine 150mg Tablet,Combivir,Antiinfectives for Systemic Use > Antivirals for Systemic Use,J05AR01-964-T10-01-XXX,Yes,APPL,A/KK,HIV infection in combination with at least one other antiretroviral drug,None,ADULT and CHILD over 12 years: 1 tablet twice daily,"Nausea, vomiting, diarrhoea, abdominal pain, cough; headache, fatigue, insomnia, malaise, fever, rash, alopecia, muscle disorders, peripheral neuropathy, pancreatitis, neutropenia, anaemia, thrombocytopenia and red-cell aplasia, lactic acidosis, raised liver enzymes and serum amylase, somnolence, dizziness, sweating, dyspnoea, dyspepsia, flatulence, bad taste, chest pain, loss of mental acuity, anxiety, urinary frequency, depression, generalised pain, chills, urticaria, pruritus and flu-like syndrome.","Abnormally low neutrophil cell count (less than 0.75 x 109/L) or abnormally low Hb levels (less than 7.5 g/dL). Hypersensitivity to zidovudine. New born infants with hyperbilirubinaemia requiring treatment other than phototherapy, or increased transaminase levels of over five times than the upper limit of normal.","Trimethoprim, phenytoin, paracetamol, aspirin, codeine, morphine, indomethacin, ketoprofen, naproxen, oxazepam, lorazepam, cimetidine, clofibrate, dapsone and isoprinosine, potentially nephrotoxic or myelosuppressive drugs, ribavirin",Advanced cirrhotic liver disease due to chronic hepatitis B infection. Severe hepatic or renal impairment. Monitor haematological parameters. Pregnancy and lactation.,True
Tenofovir Disoproxil Fumarate 300 mg & Emtricitabine 200 mg Tablet,,Antiinfectives for Systemic Use > Antivirals for Systemic Use,J05AR03-964-T10-01-XXX,Yes,APPL,A/KK,i. Treatment of HIV-1 infection in adults in combination with other antiretroviral agents (such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors). ii. Indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.,"Indication (ii): i. To prescribe Emtricitabine/Tenofovir Disoproxil as part of a comprehensive prevention strategy ii. All uninfected individuals must be counselled to strictly adhere to the recommended Emtricitabine/Tenofovir Disoproxil dosing schedule iii. A negative HIV-1 test must be confirmed immediately prior to initiating Emtricitabine/Tenofovir Disoproxil. If clinical symptoms consistent with acute viral infection are present and recent (<1 month) exposures are suspected, starting of PrEP must be delayed for at least one month and HIV-1 status need to be reconfirmed, including acute or primary HIV-1 infection; and iv. To screen HIV-1 infection at least once every 3 months while taking Emtricitabine/Tenofovir Disoproxil for PrEP.",1 tablet once daily.,"Nausea, vomiting, diarrhoea, abdominal pain, dyspepsia, flatulence, pain, hypersensitivity, increased pigmentation, asthenia, osteonecrosis, osteomalacia, metabolic abnormalities (e.g. hyperglycaemia, insulin resistance, hypercholesterolaemia, hypertriglyceridaemia, hyperlactataemia), lipodystrophy, elevated lipase, amylase, creatine kinase or transaminases levels, hyperbilirubinaemia, insomnia, abnormal dreams, neutropenia, anaemia, immune reactivation syndrome, renal impairment, acute renal failure, fanconi syndrome.",Hypersensitivity to tenofovir or emricitabine.,"Increased plasma level of tenofovir and reduced plasma levels of other agent: atazanavir, lopinavir (both have to be co-administered with ritonavir). Increased adverse events of other agent: didanosine. Increased risk of nephrotoxicity when used with other nephrotoxic agents (e.g. aminoglycosides, vancomycin, etc). Increased plasma level when used with other agents excreted renally by active tubular secretion (e.g. probenecid).","Liver impairment; caution in Hepatitis B virus (HBV) coinfection, may result in severe and acute exacerbation or flare up of hepatitis on discontinuation of treatment. Renal impairment; dosing adjustment required in CrCl < 50ml/min, not recommended if CrCl < 30ml/min. Avoid co-administration of nephrotoxic agents. Lactation, avoid breast feeding. Avoid co-administration of lamivudine.",True
Vildagliptin 50mg Tablet,,Alimentary Tract and Metabolism > Drugs Used In Diabetes,A10BH02-000-T10-01-XXX,Yes,Government Contract,A/KK,FUKKM restriction: As add-on therapy for patient who failed therapy and/or contraindicated/unable to tolerate metformin and/or sulphonylurea. i) As second line therapy in type 2 diabetes patients inadequately controlled on maximal tolerated dose of metformin monotherapy and high risk of hypoglycaemia; ii) As second line therapy in type 2 diabetes patients inadequately controlled on maximal tolerated dose of sulphonylurea and intolerant/contraindicated for metformin therapy; iii) As third line therapy in type 2 diabetes patients inadequately controlled with dual OAD combination therapy with sulphonylurea and metformin; iv) As a monotherapy in type 2 diabetes mellitus patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance; v) An adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus: As a dual therapy in combination with insulin in patients with insufficient glycaemic control. Insulin dose and regimen should be optimized before addition of vildagliptin.,"120 PT (KKS, KKBC, KKB, KKTS) 240 PT (KKTPG, KKTD, KKJ) (KUOTA)","ADULT over 18 years: 50mg bd when combine with metformin, 50 mg od when combine with sulphonylurea","Tremor, dizziness, headache, nausea, asthenia, hypoglycaemia, weight increase, oedema peripheral, hyperhidrosis, decreased blood glucose, headache, chills, gastro-oesophageal reflux disease.",Hypersensitivity to vildagliptin or to any of the excipients.,"Low potential for interactions with co-administered medicinal products. Since vildagliptin is not a cytochrome P (CYP) 450 enzyme substrate and dose not inhibit or induced CYP 450 enzymes, it is not likely to interact with active substances that are substrate, inhibitors or inducers of these enzymes. Hypoglycaemic effect of vildagliptin may be reduced by certain active substances including thiazides, corticosteroids, thyroid products, sympathomimetics.","Vildagliptin is not a substitute for insulin in insulin-requiring patients. Vildagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Renal Impairment. Hepatic impairment. Liver enzyme monitoring. Cardiac failure. Skin disorders. Pancreatitis. Hypoglycaemia. Patients receiving vildagliptin in combination with a sulphonylurea may be at risk of hypoglycaemia. Pregnancy, lactation.",True
Nicotine 2mg Gum,"Nicorette, Niquitin",Nervous System > Other Nervous System Drugs,N07BA01000M9901XX,Yes,LP,A/KK,"For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit.",None,"Smokes ≤ 20 sticks/day, chew 2mg gum. Smokes ≥ 20 sticks/day,chew 4 mg gum. (MAX 24 pieces /day for up to 12 week.)","ADR Common: - CNS: Headache, dizziness. - GI: Hiccups, gastric systems eg, nausea, vomiting, indigestion, heartburn. Local: Increased salivation, irritation or sore mouth or throat, jaw muscle ache, the gum may stick to and in the rare cases damage dentures and dental appliances. Less Common: - Cardiovascular: Palpitations. - Skin: Erythema, urticaria. Rare: - Cardiovascular: Cardiac arrhythmias (eg, atrial fibrillation). Others: Allergic reactions.","- Hypersensitivity to nicotine or any other product component, hypersensitivity to menthol (inhalation). - Pregnancy & lactation. - Children<18 year.","- Acetaminophen, caffeine, imipramine, oxazepam, pentazocine, propranolol, theophylline. - Smoking tends to increase metabolism and may lower blood levels of these drugs or others. - Smoking cessation, with or without nicotine medication, may reverse these effects. - Food ;Effective absorption of nicotine gum depends on mildly alkaline saliva. Coffee, cola, and other drinks or food may reduce salivary pH and should probably be avoided 15 min before and during chewing of gum.","Active peptic ulcer diseases, angina, CHD. Oesophagitis, temporomandibular joint disease.",True
Bisoprolol Fumarate 2.5 mg Tablet,Bisocor 2.5,Cardiovascular System > Beta Blocking Agents,C07AB07-000-T10-01-XXX,Yes,APPL,B,i) Hypertension ii)Coronary heart disease (angina pectoris) iii) Treatment of stable congestive cardiac failure in addition to ACEI's and diuretics,None,"1.25 mg once daily, gradually titrate to maximum tolerable dose (i) & (ii): Max: 20mg/ day (iii): Max 10mg/ day","Arrythmia, bradycardia, chest pain, oedema, hypotension, dizziness, headache, fatique, diarrhoea, nausea, impotency, cough, rhinitis","Hypersensitivity, cardiac failure, pulmonary oedema, pregnancy, severe asthma or severe chronic obstructive pulmonary disease, hypotension","Prazosin, digoxin, amiodarone, ACEI, antidiabetic agent, calcitriol, cholestyramine, clonidine","Avoid abrupt withdrawal; gradual withdrawal over a period of 1 to 2 weeks is recommended. Bronchospastic disease, congestive heart failure, diabetes mellitus, hyperthyroidism/thyrotoxicosis. Peripheral vascular and renal disease",False
Rifampicin 150mg & Isoniazid 75mg tablet,,Antiinfectives for Systemic Use > Antibacterials for Systemic Use,J04AM02-000-T10-01-XXX,Yes,LP,B,For pulmonary tuberculosis in which organisms are susceptible in continuation phase treatment for 4 months,None,"30-37kg: 2 tablets once daily, 38-54kg: 3 tablets once daily, 55-70kg: 4 tablets once daily, Above 70kg: 5 tabs once daily","Rifampicin: Headache, muscular weakness, gastrointestinal disturbances, hepatitis, thrombocytopenia, transient leukopenia, elevations in serum BUN and uric acid, allergic reactions. Isoniazid: Peripheral neuropathy, convulsion, optic neuritis, elevated serum transaminases, jaundice, hepatitis, agranulocytosis, aplastic anemia, thrombocytopenia, hypersensitivity reactions.","Patients with previous hypersensitivity reaction to any of the rifamycins or to isoniazid including drug-induced hepatitis. Patients with previous isoniazid-associated hepatic injury; severe adverse reactions to isoniazid, such as fever, chills and arthritis; acute liver disease of any etiology","Rifampicin: May reduce the activity of anticoagulant, methadone, corticosteroids, digitoxin, oral contraceptives, oral hypoglycaemics, quinidine, disopyramide, dapsone. Isoniazid: Decreases excretion of phenytoin and increases its effect.","Risk of liver dysfunction. Liver function test should be performed prior to therapy and periodically during treatment. Hypersensitivity reaction; Not for intermittent therapy; staining of contact lenses; red-orange coloured urine, feces, sputum, saliva and sweat occurs; reliability of oral contracpetives affected; pregnancy, lactation; severe renal dysfunction",False
Iron (III)-hydroxide polymaltose complex (IPC) 100mg iron and 0.35mg folic acid chewable tablet,Maltofer® Fol,Blood and Blood Forming Organs > Antianemic Preparations,B03AD04-250-T20-01-XXX,No,Government Contract,A/KK,Treatment of iron deficiency without anaemia and iron deficiency anaemia,"10 PT (KKKEBUN, KKKD), 20 PT (KKS, KKTS), 25 PT (KKTPG, KKBC), 40 PT (KKJ, KKTD, KKB) (KUOTA)",Dosage and duration of therapy are dependent upon the extent of iron deficiency. Manifest iron deficiency: 1 chewable tablet two to three times daily until a normalization of the hemoglobin value is achieved. Afterwards the therapy should be continued with 1 chewable tablet daily at least until the end of pregnancy to replenish the iron stores. Latent iron deficiency and prevention of iron and folic acid deficiency: 1 chewable tablet daily,"Constipation, diarrhea, nausea, abdominal pain, gastric disorders, indigestion (dyspepsia), vomiting, rash (urticarial, exanthema, pruritis) A dark colouration of the stool due to iron elimination is of no clinical significance","Iron overload (e.g haemochromatosis, haemosiderosis) or disturbances in iron utilization (e.g lead anaemia, sidero-achrestic anaemia, thalassemia) and anaemia not caused by iron deficiency (e.g haemolytic anaemia). Known intolerance of any of the ingredients","Until now interactions have not been observed. Since the iron is complex-bound, ionic interactions with food components (phytin, oxalates, tannin etc) and concomitant administration of medicaments (tetracyclines, antacids) are unlikely to occur. The haemoccult test (selective for Hb) for the detection of occult blood is not impaired and therefore there is no need to interrupt iron therapy","Notice to diabetics: 0.03 bread units per chewable tablets. In cases of anaemia due to infections or malignancy, the substituted iron is stored in the reticulo-endothelial system, from which it is mobilized and utilized only after curing the primary disease.",True
Fenofibrate 145mg tablet,Lipanthyl Penta 145mg Film Coated Tablet,Cardiovascular System > Lipid Modifying Agents,C10AB05-000-T10-02-XXX,Yes,Government Contract,A/KK,"1) As second line therapy after failed gemfibrozil in patients: a) Hypercholesterolemia and hypertriglyceridemia alone or combined [type IIa,IIb,III and V dysplipidemias] in patients unresponsive to dietary and other non-pharmacological measures especially when there is evidence of associated risk factors b) Treatment of secondary hyperlipoproteinemias if hyperlipoprotenemia persists despite effective treatment of underlying disease c) Dyslipidemia in Type 2 Diabetes Mellitus 2) Diabetic retinopathy - indicated for the reduction in the progression of diabetic retinopathy in patients with type 2 diabetes and existing diabetic retinopathy.","For indication (2): For mild to moderate non-proliferative diabetic retinopathy only.; 20 PT/KK (KKS, KKB), 30 PT/KK (KKJ, KKBC), 40 PT/KK (KKTS), 50 PT/KK (KKTPG, KKTD) (KUOTA)","145mg once daily, with or without food","Gastrointestinal disorders, moderately elevated serum transaminase levels.","Gallbladder disease, history of hypersensitivity to fenofibrate, including severe skin rashes, hypersensitivity to fenofibric acid, the active metabolite of fenofibrate, liver disease, active, including primary biliary cirrhosis and unexplained persistent liver function abnormality, nursing mothers, renal impairment","Oral anticoagulants, cyclosporin, HMG-CoA reductase inhibitors & other fibrates.",Reduce dose in renal impairment. Monitor transaminase & creatinine levels every 3 months at the initiation of treatment. Discontinue if AST & ALT levels more than 3 times/upper limit of normal. Pancreatitis. Hypoalbuminemia. Patients with predisposing factors for myopathy/rhabdomyolysis.,True
Terazosin HCl 1 mg Tablet,Hytrin,Genito Urinary System and Sex Hormones > Urologicals,G04CA03110T1001XX,No,LP,A/KK,i) Treatment of Benign Prostatic Hyperplasia ii) Hypertension,None,i) Initial dose: 1 mg at bedtime. Maintenance dose: 5-10mg once daily ii) Initial dose: 1mg at bedtime. Maintenance dose: 1-5mg once daily. Max: 20-40mg/day,"Tachycardia, dizziness, syncope, headache and asthenia, nasal congestion, drowsiness, nausea, peripheral edema, postural hypotension.",Hypersensitivity to terazosin products or other quinazolines,"In patients currently on beta blockers, the first dose response (marked initial drop in blood pressure, particularly on standing) to an alpha-1 adrenergic blocking drug may be exaggerated. Concomitant therapy with ibuprofen and antihypertensive agents has been reported to result in increases in blood pressure and interference with blood pressure control","Carcinoma of the prostate and benign prostatic hyperplasia may cause the same symptoms. Prostate cancer should be ruled out prior to treatment. Dizziness, lightheadedness, orthostatic hypotension, syncope (first-dose effect). Patients advised to avoid driving or doing hazardous tasks for the first 12 hours after the initial dose or when dose is increased.",True
Atorvastatin 40 mg Tablet,Storvas C 40mg Tablet,Cardiovascular System > Lipid Modifying Agents,C10AA05-000-T10-01-XXX,Yes,Government Contract,B,i) Hypercholesterolaemia ii) Prevention of cardiovascular disease,None,i) & ii) 10 mg once daily. Maximum: 80 mg daily,"Gastrointestinal disturbances, headache, myalgia, asthenia, insomnia, angioneurotic oedema, muscle cramps, myostitis, myopathy, cholestatic jaundice, peripheral neuropathy, pruritus. Cognitive impairment (e.g. memory loss, forgetfulness, amnesia, memory impairment, confusion), increase in HbA1c and fasting blood glucose. NPRA Safety Alert 1. 27 May 2025 Myasthenia Gravis / Ocular Myasthenia","Liver disease, hypersensitivity to atorvastatin, pregnancy or lactation","Risk of myopathy increased with concurrent administration of cyclosporin, fibric acid derivatives, erythromycin, niacin or azole antifungals. Decreased atorvastatin plasma concentration with oral antacid suspensions containing magnesium and aluminium hydroxides and colestipol NPRA Safety Alert 1. 19 Feb 2024 Interaction with Ticagrelor Leading to Increased Risk of Rhabdomyolysis","Heavy alcohol use, history of liver disease. Discontinue therapy if serum transaminase levels rise to 3 times upper limit of normal and are persistent. This class of drug has been known to cause myopathy and renal failure due to rhabdomyolysis. Concomitant administration of fibrates, niacin, cyclosporin or erythromycin may increase the risk of myopathy NPRA Safety Alert 1. 18 Jul 2023 Risk of Inducing or Aggravating Myasthenia Gravis 2. 27 May 2025 Myasthenia Gravis / Ocular Myasthenia",False
Itraconazole 100 mg Capsule,,Antiinfectives for Systemic Use > Antimycotics for Systemic Use,J02AC02-000-C10-01-CXX,Yes,LP,A/KK,i) Dermatomycosis including pityriasis versicolor ii) Oral candidiasis iii) Palmar tinea manus and plantar tinea pedis iv) Fingernail onychomycosis v) Toenail onychomycosis vi) Vulvovaginal candidiasis,None,i) 200 mg once daily for 7 days ii) 100 mg daily for 15 days iii) 200 mg twice daily for 7 days iv) 200mg twice daily for 1 week per month for 2 months v) 200 mg twice daily for 1 week per month for 3 months vi)200 mg morning and evening for 1 day or 200 mg once daily for 3 days,"Rash, hypokalemia, diarrhoea, nausea and vomiting, Stevens-Johnson syndrome, neutropenic disorder, hepatotoxicity, anaphylaxis",Hypersensitivity to azole antifungals; pregnancy and lactation; hepatic disease.,"Rifampicin& phenytoin reduce oral bioavailability of itraconazole. CYP3A4 metabolized substrates that can prolong the QT-interval e.g; astemizole, cisapride, quinidine, terfenadine, HMG-CoA reductase inhibiotrs, triazolam, oral midazolam, ergot alkalaoids, warfarin, digoxin, cyclosporin, oral contraceptives.","Lactation, history of liver or renal disease, children, decreased gastric acidity. Patients with risk factors for congestive heart failure such as ischaemic and valvular cardiac disease",True
Indacaterol Maleate 110mcg & Glycopyrronium Bromide 50mcg inhalation powder hard capsules,,Respiratory System > Drugs for Obstructive Airway Diseases,R03AL04-989-C11-01-XXX,No,LP,A/KK,As a once-daily maintenance bronchodilator treatment to relieve symptoms and reduce exacerbations in adult patients with chronic obstructive pulmonary disease (COPD).,"Patients with inhaler coordination problem. (Only applies to Primary Care settings); 5 PT (KKBC, KKTD), 3PT (KKS, KKTPG,KKJ, KKB, KKTS)  (KUOTA)",One capsule inhalation daily.,"- Very common (≥1/10): Upper respiratory tract infection - Common (≥ 1/100 to < 1/10): Nasopharyngitis, urinary tract infection, sinusitis, rhinitis, dizziness, headache, cough, oropharyngeal pain, dyspepsia, dental caries, gastroenteritis, musculoskeletal pain, pyrexia, chest pain - Uncommon (≥ 1/1000 to < 1/100): Hypersensitivity, angioedema, diabetes, insomnia, paraesthesia, glaucoma, cardiac disorders, paradoxical bronchospasm, epistaxis, dry mouth, pruritus, myalgia, pain in extremity, muscle spasm, bladder obstruction and urinary retention, peripheral oedema, fatigue","Hypersensitivity to the active substances, to lactose or to any of the other excipients.","Concomitant use not recommended: Beta-adrenergic blockers, anticholinergics, sympathomimetic agents. Caution required with concomitant use: Hypokalaemic treatment. To be taken into account with concomitant use: Drugs that inhibit CYP3A4 and P-glycoprotein will increase serum Indacaterol; organic cation transport such as cimetidine will increase serum Glycopyrronium.","- Not indicated for the initial treatment of acute episodes of bronchospasm, asthma, paradoxical bronchospasm. - Use with caution in patients with narrow angle glaucoma and urinary retention, severe renal impairment and end stage renal disease, patient with history of cardiovascular disease, hypokalaemia, hyperglycaemia, convulsive disorders, thyrotoxicosis, unsually responsive to beta2-adrenergic agonists, rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose - galactose malabsorption",True
Pneumococcal polysaccharide conjugate vaccine (adsorbed) 13-valent injection,Prevenar 13,Antiinfectives for Systemic Use > Vaccines,J07AL01-000-P30-02-XXX,Yes,Government Contract,"A*, C+","1. Active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F (including invasive disease, pneumonia and acute otitis media) in infants, children and adolescents from 2 months to 17 years of age: - PRESCRIBER CATEGORY C+: National Immunisation Programme (NIP) - PRESCRIBER CATEGORY A*: Immunisation other than NIP 2. Active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in adults aged 18 years and older. - PRESCRIBER CATEGORY A*","INDICATION (1): i. Immunisation for newborn cohort eligible for National Immunisation Programme (NIP) (Prescriber Category: C+) ii. Paediatric population without history of vaccination or not eligible for NIP, who have associated risk in IPD with following conditions (Prescriber Category: A*): a) Infants/children from 2 months of age with one of the following conditions: • Functional or anatomical asplenia; • Cochlear implant; • Congenital immunodeficiency; • Haematopoietic and solid organ transplant; • Cerebrospinal fluid leakage b) High risk infants/children from 2 months old with one of the following conditions: • Immunosuppression (including asymptomatic HIV) • Nephrotic syndrome • Chronic lung or heart disease (adapted from Paediatric Protocols for Malaysia Hospital, 3rd Edition) • Chronic liver disease INDICATION (2) (Prescriber Category: A*): i. Adult population aged 18 years and above with associated risk in IPD with following conditions: a) Functional or anatomical asplenia; b) Cochlear implant; c) Congenital immune-deficiency; d) Haematopoietic and solid organ transplant. ii. Adult population aged 60 years and above with associated risk in IPD with following conditions: a) Chronic lung diseases, including chronic obstructive pulmonary disease (COPD), emphysema & asthma (requiring frequent hospital visit & use of multiple medications); b) Chronic liver disease including cirrhosis, biliary atresia, chronic hepatitis; c) Chronic cardiac disease, including congestive heart failure, congenital heart disease, and cardiomyopathies.","For indication 1(i): 2-dose primary series (2+1): A series consisting of 3 doses, each of 0.5 ml may be given. Dosing is according to Immunisation Schedule under NIP. For other indications: ADULT: to be administered as a single dose to adults 18 years and older including those previously vaccinated with a pneumococcal polysaccharide vaccine. The need for re-vaccination with a subsequent dose of PCV13 has not been established. INFANT: Infants aged 2-6 months: i) Three-dose primary series: The recommended immunisation series consists of four doses, each of 0.5 mL. The primary infant series consists of three doses, with the first dose usually given at 2 months of age and with an interval of at least 1 month between doses. The first dose may be given as early as six weeks of age. The fourth (booster) dose is recommended between 12-15 months of age, or ii) Two-dose primary series: A series consisting of three doses, each of 0.5 mL may be considered. The first dose may be given from the age of 2 months, with a second dose 2 months later. The third (booster) dose is recommended between 11-15 months of age. Preterm infants (<37 weeks gestation): The recommended immunisation series consists of four doses, each of 0.5 mL. The primary infant series consists of three doses, with the first dose given at 2 months of age and with an interval of at least 1 month between doses. The first dose may be given as early as six weeks of age. The fourth (booster) dose is recommended between 11 and 15 months of age. Unvaccinated infants and children ≥ 7 months of age Infants aged 7-11 months: Two doses, each of 0.5 ml, with an interval of at least 1 month between doses. A third dose is recommended in the second year of life. CHILDREN: Children aged 12-23 months: Two doses, each of 0.5 ml, with an interval of at least 2 months between doses. Children and adolescents aged 2 years to 17 years: One single dose of 0.5 ml. Young Children (12-59 months) completely immunized with PCV (7 valent): One dose of 0.5 mL of Pneumococcal polysaccharide conjugate vaccine (adsorbed), 13-valent to elicit immune responses to the 6 additional serotypes. This dose of PCV 13 should be administered at least 8 weeks after the final dose of Prevenar (7 valent) Children 5-17 years: One single dose of 0.5 ml if they have been previously vaccinated with one or more doses of Pneumococcal polysaccharide conjugate vaccine (adsorbed). This dose should be administered at least 8 weeks after the final dose of PCV (7-valent).","• Gastrointestinal disorders: Very common: Decreased appetite; Common: Vomiting; diarrhea • Skin and subcutaneous tissue disorders:Common: Rash • General disorders and administration site conditions: Very common: Pyrexia; irritability; any vaccination-site erythema, induration/swelling or pain/tenderness; somnolence; poor quality sleep. • Vaccination-site erythema or induration/swelling (after the booster dose and in older children [age 2 to 5 years]): Common: Pyrexia > 39°C; Vaccination-site movement impairment (due to pain); vaccination-site erythema or induration/swelling (after infant series). • Blood and lymphatic system disorders: Lymphadenopathy (localised to the region of the vaccination site). • Immune system disorders: Anaphylactic/anaphylactoid reaction including shock; angioedema. • Skin and subcutaneous tissue disorders: Erythema multiforme. • General disorders and administration site conditions: Vaccination-site urticaria; vaccination-site dermatitis; vaccination-site pruritus; flushing. • Additional information in special populations: Apnoea in very premature infants (≤28 weeks of gestation). Children and adolescents aged 6 to 17 years of age • Nervous system disorders: Common: Headaches • Gastrointestinal disorders: Very common: Decreased appetite; Common: Vomiting; diarrhoea. • Skin and subcutaneous tissue disorders: Common: Rash; urticaria or urticaria-like rash. • General disorders and administration site conditions: Very common: Irritability; any vaccination-site erythema; induration/swelling or pain/tenderness; somnolence; poor quality sleep; vaccination-site tenderness (including impaired movement); Common: Pyrexia. Adults ≥18 years and the elderly • Metabolism and nutrition disorders: Very common: Decreased appetite. • Nervous system disorders: Very common: Headaches. • Gastrointestinal disorders: Very common: Diarrhoea; vomiting (in adults aged 18 to 49 years); Common: Vomiting (in adults aged 50 years and over). • Skin and subcutaneous tissue disorders: Very common: Rash. • General disorders and administration site conditions: Very common: Chills; fatigue; vaccination site erythema; vaccination site indurations/swelling; vaccination site pain/tenderness; limitation of arm movement; Common: Pyrexia (very common in adults aged 18 to 29 years). • Musculoskeletal and connective tissue disorders: Very common: Arthralgia; myalgia.","Hypersensitivity to the active substances, to any of the excipients. The administration of PCV 13 should be postponed in subjects suffering from acute, severe febrile illness. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination.",Children and adolescents 6-17 years of age and adults 18-49 years of age: No data are currently available regarding concomitant use with other vaccines. Adults aged 50 years and older: PCV 13 may be administered concomitantly with the seasonal trivalent inactivated influenza vaccine (TIV). Concomitant use with other vaccines has not been investigated. Different injectable vaccines should always be given at different injection sites. Concomitant administration of PCV 13 and 23-valent polysaccharide vaccine has not been studied.,"PCV 13 must not be administered intravascularly. Appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine. This vaccine should not be given as an intramuscular injection to individuals with thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection, but may be given subcutaneously if the potential benefit clearly outweighs the risk. PCV 13 will only protect against Streptococcus pneumoniae serotypes included in the vaccine, and will not protect against other microorganisms that cause invasive disease, pneumonia, or otitis media. As with any vaccine, PCV 13 may not protect all individuals receiving the vaccine from pneumococcal disease. Individuals with impaired immune responsiveness. Safety and immunogenicity data are available for a limited number of individuals with sickle cell disease, HIV infection, or with a haematopoietic stem cell transplant. Safety and immunogenicity data for PCV 13 are not available for individuals in other specific immuno-compromised groups (e.g., malignancy or nephrotic syndrome) and vaccination should be considered on an individual basis.",True
Empagliflozin 10mg tablet,Jardiance,Alimentary Tract and Metabolism > Drugs Used In Diabetes,A10BK03-000-T32-01-XXX,Yes,LP,A/KK,"Indication 1: Indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as: Add-on combination therapy: In combination with other glucose–lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. Indication 2: Indicated in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular disease (CVD) to reduce the risk of cardiovascular (CV) death: As an adjunct to diet, exercise and standard of care, to reduce the risk of cardiovascular (CV) death. Indication 3: Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV).",Indication 1: Patients with HbA1c between 6.5%-10.0% while on single / combination anti-diabetic therapy. Indication 2: Patients with HbA1c not more than 10.0% while on adequate trial of metformin. Indication 3: i. Treatment to be initiated in hospital setting before continuation of treatment for stable patients by Family Medicine Specialist (FMS) in the primary care setting. ii. All patients must be counselled regarding risk of euglycemic ketoacidosis before initiation of treatment; 30 PT /KK (KUOTA),"Indication 1 & 2: - Starting dose is 10 mg empagliflozin once daily for monotherapy and add-on combination therapy with other glucose-lowering medicinal products including insulin. - In patients tolerating empagliflozin 10 mg once daily and need tighter glycaemic control, the dose can be increased to 25 mg once daily. - The maximum daily dose is 25 mg. Indication 3: 10mg once daily","Hypoglycaemia (when used with SU or insulin), volume depletion, vaginal moniliasis, vulvovaginitis, balanitis and other genital infection, urinary tract infection (including pyelonephritis and urosepsis), thirst, constipation, pruritus (generalised), allergic skin reactions (rash, urticaria), increase urination, serum lipids increased.","Hypersensitivity to the active substance or to any of the excipients listed; For type 2 diabetes mellitus indication only - patient with severe renal impairment (eGFR < 30 ml/min/1.73m2 ), end-stage renal disease and patients on dialysis. For heart failure: For treatment of heart failure in patients with or without type 2 diabetes mellitus, empagliflozin 10 mg is not recommended for use in patients with eGFR < 20 ml/min/1.73 m2","Diuretics, insulin and insulin secretagogues, lithium, interference with 1, 5-anhydroglucitol (1,5-AG) assay NPRA Safety Alert 1. 28 May 2024 Interaction with Lithium (for Therapeutic Use) Leading to Decreased Serum Lithium Concentration","Should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Use with cautions in patients with renal impairment, hepatic injury, pregnancy & lactation, ketoacidosis, necrotizing fasciitis of the perineum (Fournier’s gangrene), elderly patients, complicated urinary tract infections, patients at risk for volume depletion, lower limb amputations, abnormal urine laboratory assessment, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption. NPRA Safety Alert 1. 20 June 2022: Risk of Tubulointerstitial Nephritis",True
Dapagliflozin 10mg Tablet,,Alimentary Tract and Metabolism > Drugs Used In Diabetes,A10BX09-999-T32-01-XXX,Yes,LP,A/KK,"Indication 1: Dapagliflozin is indicated for use as an add-on combination therapy in combination with other glucose-lowering medicinal products including insulin, to improve glycemic control in adult patients with type 2 diabetes mellitus when these, together with diet and exercise, do not provide adequate glycaemic control. Indication 2: Dapagliflozin is indicated to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). Indication 3: To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class ll-lV) with reduced ejection fraction. Indication 4: For cardiorenal protection in adult patients with chronic kidney disease, with or without Type 2 Diabetes Mellitus, with eGFR≥25mL/min/1.73m2 and urine albumin creatinine ratio (UACR) ≥200-5,000mg/m2 (or the equivalent in uPRC/u-dipstick) receiving stable treatment with ACEi or ARB (unless they are contraindicated or not tolerated).","Indication 1: Patients with HbA1c between 6.5%-10.0% while on single / combination anti-diabetic therapy. Indication 2: Patients with HbA1c not more than 10.0% while on adequate trial of metformin. Indication 3: Treatment to be initiated in hospital setting before continuation of treatment for stable patients by Family Medicine Specialist (FMS) in the primary care setting; All patients must be counselled regarding risk of euglycemic ketoacidosis before initiation of treatment. Indication 4: In adult patients with underlying Type 2 Diabetes Mellitus, to be used only if HbA1c level <10%. All patients must be counselled regarding risk of euglycemic ketoacidosis before initiation of treatment.; 50 PT (KKS), 
70 PT (KKBC,KKB,KKTS) 
100 PT (KKTPG,KKJ,KKTD)",10 mg once daily,"Hypoglycaemia (when used with sulphonylureas or insulin), vulvovaginitis, balanitis and related genital infections, urinary tract infection, dizziness, rash, back pain, dysuria, polyuria, haematocrit increased, creatinine renal clearance decreased during initial treatment and dyslipidaemia",Hypersensitivity to the active substance or to any of the listed excipients,"Diuretics, insulin and insulin secretagogues, lithium and , interference with 1,5-anhydroglucitol (1,5-AG) assay NPRA Safety Alert 1. 28 May 2024 Interaction with Lithium (for Therapeutic Use) Leading to Decreased Serum Lithium Concentration","Renal impairment, hepatic impairment, risk for volume depletion and/or hypotension, diabetic ketoacidosis, necrotising fasciitis of the perineum (Fournier's gangrene), urinary tract infections, elderly (≥ 65 years) cardiac failure, chronic kidney disease, risks for lower limb amputations, abnormal urine laboratory assessment, pregnancy, lactation, patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.",True
Perindopril 10mg and Indapamide 2.5mg film coated tablet,,Cardiovascular System > Agents Acting on the Renin-angiotensin System,C09BA04-900-T10-03-XXX,No,LP,A/KK,"As substitution therapy for treatment of essential hypertension, in patients already controlled with perindopril and indapamide given concurrently at the same dose level.","20 PT (KKS), 30 PT (KKTPG, KKTD, KKB, KKJ, KKBC, KKTS) (KUOTA)",1 tablet daily,"Headache, asthenia, dizziness, sleep disturbances, cramps, hypotension, rash, gastrointestinal disturbances, slight reversible increase in urea and plasma creatinine, hypokalaemia, hyponatraemia with hypovolaemia, raised uric acid and blood glucose levels NPRA Safety Alert 1. 5 May 2022 Choroidal effusion, acute myopia, acute angle closure glaucoma","Hypersensitivity to other ACE inhibitors or sulphonamides. Bilateral renal artery stenosis or single functioning kidney, severe renal failure (creatinine clearance less than 30 mL/min), dialysis patients, hepatic encephalopathy, severe hepatic impairment, hyperkalaemia or hypokalaemia, untreated decompensated cardiac insufficiency. Previous history of angioneurotic oedema linked to treatment with ACE inhibitor, hereditary or idiopathic angioneurotic oedema. Pregnancy and lactation","Lithium, insulin, sulfonylureas, baclofen, NSAIDs, high dose salicylates, tricyclic antidepressants, neuroleptics, corticosteroids, tetracosactide, potassium-sparing diuretics, potassium salts, potassium-lowering drugs, anaesthesia, allopurinol, immunosuppressant, cardiac glycosides, procainamide and other drugs which cause torsades de pointes, antihypertensive drugs, metformin, calcium salts, ciclosporin, iodinated contrast media","Renal insufficiency especially when associated with systemic autoimmune collagen vascular diseases. Concomitant treatment with immunosuppressant or treatment causing leucopoenia. Marked sodium and water depletion, hypotension, chronic heart failure, cirrhosis with oedema and ascites, ischemic heart disease, cerebral circulatory insufficiency, severe cardiac insufficiency (grade IV) or IDDM patients. Monitor serum potassium regularly. Surgery, elderly, hyperaldosteronism, malnourishment, acute porphyria",True
Acetylsalicylic Acid 75mg Dispersible Tablet,,Nervous System > Analgesics,N02BA01-000-T40-02-XXX,Yes,LP,C,Initial treatment of cardiovascular disorders such as angina pectoris and myocardial infarction and for the prevention of cardiovascular events in patients at risk. Other such uses include the treatment and prevention of cerebrovascular disorders such as stroke,None,Dose to be individualised. 150mg to be taken daily. Use in children under 16 years old is not recommended,"Gastric haemorrhage, hypersensitivity, thrombocytopenia,GI disturbances; prolonged bleeding time, rhinitis, urticaria and epigastric discomfort; angioedema, salicylism, tinnitus; bronchospasm","Gastric and duodenal ulcers, haemorrhagic diathesis, hypersensitivity to aspirin or other NSAIDs, children under 12 years old. Hypersensitivity (attacks of asthma, angioedema, urticaria or rhinitis), pregnancy (third trimester), patients with haemophilia or haemorrhagic disorders, gout, severe renal or hepatic impairment, lactation","Acetazolamide, Dipyridamol: salicylate toxicity (vomiting, tachycardia, hyperpnea, mental confusion) or acetazolamide toxicity (fatigue, lethargy, somnolence, confusion, hyperchloremic metabolic acidosis). Alendronate : GI distress. Antacids, calcium. Alcohol, corticosteroids, phenylbutazone and oxyphenbutazone may increase risk of GI ulceration. Aspirin increases phenytoin levels. May antagonize actions of uricosurics and spironolactone.","Renal disorders, G6PD deficiency, pregnancy, patients with flu, chicken pox or haemorrhagic fever. History of peptic ulcer or those prone to dyspepsia and those with gastric mucosal lesion, asthma or allergic disorders, dehydrated patients, uncontrolled hypertension, impaired renal or hepatic function, elderly",False
